AUTHOR INDEX

Abbasi, F., 235, 457, 843, 1355
Abdel-Wahab, Y.H.A., 514
Abdelgadir, M., 304
Abdesselam, S.A., 1093
Abdou, M.O., 1148
Abe, Y., 932, 1548
Abfalter, E., 599
Abraham, I., 1274
Abrams, S., 127
Abu Basha, E.A., 1184
Acevedo, E.O., 657
Ackermans, M.T., 57
Adachi, J., 737
Adachi, M., 716
Adeli, K., 334, 409
Agardh, C.-D., 267, 1279
Agardh, E., 1279
Agewall, S., 750
Aguilar-Salinas, C.A., 44, 218, 560
Ahmed, S., 97
Ahrén, B., 12, 304
Akcay, T., 1360
Alademir, Z., 1360
Alasmi, M., 25
Aliabadi, N., 260
Aljada, A., 487
Allen, R.H., 981
Allred, J., 1471
Al-Makdissy, N., 1261
Aloia, J.F., 180
Amante, A., 1
Ambrosio, M.R., 387, 1363
An, P., 360
Andersen, R.E., 1528
Anderson, P., 121
Anderton, K., 847
Anello, M., 1340
Anile, C., 616
Anthony, M.S., 523
Antonini, R., 1298
Apperson-Hansen, C., 432
Arakawa, Y., 575
Arany, E.J., 765
Araújo-Vilar, D., 1047
Arca, M., 1298
Archuletta, R., 274
Ardigo, D., 1022
Ares, M.P.S., 327
Arisaka, O., 1377
Aro, A., 1253
Arrowsmith, F., 1569
Arteaga, E., 1410
Arunabh, S., 180
Asagami, T., 843
Asano, A., 1017
Aso, Y., 471
Assem, H.M., 292, 1148
Assian, E., 487
Assimacopoulos-Jeannet, F., 549
Ater, J.L., 1381
Auwerx, J., 664
Averbukh, Z., 1392
Avery, N.G., 864
Ayotte, P., 482

Bachórzewska-Gajewska, H., 733
Bagby, G.J., 1061
Baker, B., 949
Baldelli, R., 387
Barakat, H.A., 211, 1514
Barban, A., 1463
Barbas, C., 1444
Barbosa, J., 144
Barbul, A., 1269
Bard, M., 380
Barilli, A.L., 1022
Barini, A., 137
Barnett, C.R., 514
Baroni, M.C., 1022
Baroni, M.G., 1298
Barrett, P.H.R., 1041, 1206
Barrett-Connor, E., 356
Bartfay, E., 645
Bartfay, W.J., 645
Bartlett, S.J., 1528
Basaglia, N., 1363
Basson, M.D., 1525
Bauer, G., 1274
Baur, L., 1569
Bayley, T.M., 25
Baynes, J.W., 645
Bazot, D., 906
Becker, D.J., 248
Becker, R., 796
Beckett, T., 1397
Bedini, J., 372
Begtrup, K., 896
Beindorff, M.E., 206
Bell-Farrow, A.D., 1223
Benavides, A., 925
Bennett, A., 847
Bergamini, E., 110
Berglund, L., 941
Bergmann, S., 743
Berlan, M., 1291
Berman, D.M., 853
Berman, S., 1392
Bermudo, F., 423
Berne, C., 304, 941
Berthiaume, N., 595
Bertsch, T., 492
Bessesen, D.H., 787
Bhargava, N., 1458
Bianchi, A., 616
Bieg, S., 569
Bieglmayer, C., 34
Bilz, S., 754
Birmingham, C.L., 1427
Biro, F.M., 432
Bixler, E.O., 887
Björn, F., 750
Björntorp, P., 642
Bloesch, D., 754
Bloom, S.R., 195
Bobbioni-Harsch, E., 549
Boemi, M., 297
Boldrini, P., 1363
Bombara, M., 110
Bonaccorsi, G., 1463
Bond, M.G., 52
Bondanelli, M., 387, 1363
Bonner, A.B., 1562
Borecki, I.B., 360
Borgiani, P., 419
Borgonha, S., 1143
Born, J., 531, 1370
Borst, S.E., 1061
Bottini, E., 1
Bottini, N., 419
Bouchard, C., 360, 451, 642
Bower, J.F., 211, 1514
Bressler, P., 1111
Brito, M.N., 343, 1501
Brito, S.M.R.C., 343
Brito, S.R.C., 1501
Broadhead, R.L., 1418
Brock, B., 671
Broedl, U., 189
Brown, J., 260
Brown, M.D., 1402
Bruckert, E., 1071
Bruzzo, F., 819
Brynes, A.E., 195
Bryson, J., 518
Bunyard, L.B., 853
Burattini, R., 297
Burge, M.R., 761
Busconi, L., 105
Bustos, P., 1410
Buzzetti, R., 419
Byun, Y., 477

Cabezas-Cerrato, J., 1047
Calvo, C., 1410
Camozzi, D., 105
Campagna, F., 1298
Campbell, W.W., 989
Camps, J., 609
Cañete, R., 423
Cardona, F., 429
Carpenter, K., 366
Carter, L., 1171
Castracane, V.D., 657
Castro, G., 1410
Caterson, I., 518
Cefalu, W.T., 1223
Celentano, E., 52
Ceresini, G., 691
Cerri, G.G., 1034
Cesarman, G., 44
Cester, N., 605
Cha, S., 1191
Chadha, P.L., 876
Chan, C.B., 708
Chan, D.C., 1041, 1206
Chan, E., 1120

Chang, H.-D., 1423
Chang, K.-C., 622
Chang, T.-C., 769
Chapman, I., 949
Chapman, M.J., 1071
Charles, M.A., 1120
Chausse, A.-A., 175
Chavira-López, I.J., 44
Chen, C.-H., 255
Chen, J., 1439
Chen, J.-F., 255
Chen, M., 1439
Chen, M.M., 1427
Chen, S.-S., 274
Cheng, J., 438
Cherrington, A.D., 1324
Cheung, J., 1458
Cheung, R.C., 334, 409
Chevrier, J., 482
Chien, W.-Y., 255
Chiu, C.-Y., 394
Chiu, K.C., 115
Cho, K.Y., 998
Choi, C.S., 838
Choi, S.B., 38
Choi, Y.O., 912
Christiansen, C., 69
Christodoulou, J., 366
Chrousos, G.P., 887
Chu, J.W., 255
Chuang, L.-M., 115
Chung, Y.E., 838
Ciaraldi, T.P., 1171
Clarkson, T.B., 523
Clore, J.N., 1471
Clot, J.-P., 175
Cobelli, C., 1582
Cohen, M., 1392
Cohen, M.P., 901
Collins, P., 847
Colvin, P.L., 1053
Conde-Knape, K., 500
Conget, I., 372
Connelly, P.W., 919, 1596
Consoli, A., 1111
Cooke, J.P., 843
Coppola, C.P., 1525
Corcione, L., 691
Corcoran, J., 25
Cornier, M.-A., 787
Costa, A., 372
Coste, T., 284
Couret, I., 958
Covetti, G., 52
Coyne, D.W., 206
Craig, B.W., 271
Crampes, F., 1291
Crandall, S.C., 876
Cravello, L., 105
Crawford, J.T., 1065
Cucinelli, F., 137
Curzi, M.C., 605

Dahlmans, V.E.H., 695
Daida, H., 1081
Dalgaard, M., 896
Damian, M.S., 796
Dandona, P., 487
Darmaun, D., 5, 628
Davies, K.M., 935
Davis, A.O., 169
Davy, B., 1478
Davy, K., 1478
DeFronzo, R.A., 1111
De Glisezinski, I., 1291
Degli Uberti, E.C., 387, 1363
De Jong, S.A., 1306
Delannoy, P., 906
Delbachian, I., 1261
Deleon, M.J., 376
DelPrato, S., 1111
Del Ricon Jarero, J.P., 218
Delsignore, R., 1022
De Marinis, L., 616
De Michele, M., 52
Dengel, D.R., 1402
Dennis, K.E., 853
Denyer, G., 518
Derfler, K., 976
De Roos, N.M., 1534
Deschamps, J.-Y., 628
Deshaies, Y., 211
DeSouza, C., 783
Després, J.-P., 482
De Vries, W.R., 1093
Dewailly, E., 482
Dichtl, W., 327
Dicker-Brown, A., 65, 783
Diglio, C.A., 380
Dincer, Y., 1360
DiPaola, L.M., 432
Di Pietro, C., 1340
Djurhuus, M.S., 1331
Doga, M., 387
Dohm, G.L., 460
Doi, K., 544
Donegà, P., 1463
Donmoyer, C.M., 274
Donner, M., 1261
Donohue, T.M., 97
Dopp, J.M., 1506
Dostou, J., 1494
Drouin, P., 1261
Dufayet De La Tour, D., 284
Dumon, H., 628
Dunlap, J.A., 225
Dunning, B.E., 1324
Durán-Sandoval, D., 1410
Durand, R.J., 657
Durando, B., 1065
Dzienis-Strączkowska, S., 75
Dziura, J., 1522

Ebenbichler, C., 599
Ebihara, S., 575
Edwards, C.M., 195
Edwards, I.J., 1223
Egashira, T., 1161
Ejiofor, J., 274
El Alaily, R.K., 292
Elbagir, M., 304
Eleid, N., 1065
Elian, K.M., 881
El Matary, W., 292
Eltom, M., 304
Endert, E., 57
Eng, H.-L., 255
Erbey, J.R., 248
Erickson, K.L., 1104
Eriksson, P., 327
Esteva de Antonio, I., 429
Eto, M., 964
Evans, J., 127
Evans, M.L., 1522
Evans, W.J., 989
Eydoux, N., 807

Fan, X., 1522
Fanghänel-Salmón, G., 44
Fassbender, K., 492
Faulkner, D., 919, 1596
Fehm, H.L., 531, 1370
Feitosa, M.F., 360
Felber, J.-P., 549
Fellin, R., 1463
Fernandes, J.K., 1381
Fernandez, M.L., 500
Ferrari, E., 105
Ferré, N., 609
Ferrell, R.E., 774, 853
Feuerman, M., 180
Fick, C.A., 271
Fierabracci, V., 110
Fiestras-Janeiro, G., 1047
Fineman, M.S., 636, 657
Fioravanti, M., 105
Fiquet, C., 819
Flatt, P.R., 514
Fogelman, I., 1458
Föger, B., 599
Fonseca, V.A., 65, 783
Fontaine, K.R., 1528
Fontaine, R.N., 724
Forrest, K.Y.Z., 248
Fradin, S., 1088
Franceschetti, P., 387, 1363
Franckowiak, S.C., 1528
Franco, A., 560
Franco, M., 443
Frohlich, J.J., 1427
Frost, G.S., 195
Fruchart, J.C., 1410
Fruehwald-Schultes, B., 531
Fujita, T., 737
Fujiwara, T., 350
Fujiwara, Y., 471
Fukuchi, M., 1317
Fukumitsu, N., 814
Fukushima, M., 539, 544, 1578
Fukuzawa, Y., 792
Fumelli, D., 297
Fumelli, P., 297
Fustuccia, W.T.L., 1501

Gagnon, J., 360
Galen, F.-X., 175
Gallegos-Martínez, J., 44
Gannon, M.C., 1027
Gänzer, H., 599
García-Estévez, D.A., 1047
Garofalo, M.A.R., 343, 1501
Gascón, F., 423
Gasparini, P., 1022
Gayles, E.C., 787
Gentilella, R., 616
George, D., 127
Gerich, J.E., 1128, 1494
Ghanim, H., 487
Ghatei, M.A., 195
Giachelli, C.M., 327
Giampietro, A., 616
Gimpel, T., 657
Gin, H., 1484
Giordano, M., 1111
Giorgini, A., 419
Giral, P., 1071
Girona, J., 609
Giustina, A., 387, 616
Glass, L., 1111
Gloria-Bottini, F., 1, 419
Glueck, C.J., 724
Goetz, F.C., 144
Golay, A., 549
Goldammer, A., 976
Goldberg, A.P., 774, 853, 1053
Goldfine, I.D., 465
Gómez, A.L., 864
Gómez, F., 609
Gómez-Díaz, R.A., 44
Gómez-Foix, A.M., 121
Gómez-Pérez, F.J., 44, 218, 560
Gómez-Valadés, A.G., 121
Gómez-Zumaquero, J.M., 429
Gottwald, B.M., 1519
Goyke, E., 1605
Grechi, G., 605
Green, A., 1514
Gregersen, G., 1180
Gregersen, S., 155, 671
Grinspoon, S., 260, 1143
Grugni, G., 1011
Grunder, L., 1211
Guillén, L.E., 44
Guillén-Pineda, L.E., 218
Guo, ZK., 1198
Guzzaloni, G., 1011

Haas, M.J., 376
Habicht, F., 549
Hada, T., 438, 893, 1317
Hadigan, C., 260, 1143
Hagberg, J.M., 774, 1053
Hagopian, W., 144
Halpern, A., 1034
Hama, K., 539
Hamanaka, D., 544
Hammond, J., 366
Hampson, G., 1458
Hamsten, A., 327
Hanada, H., 1247
Hanefeld, M., 743
Hannan, P., 144
Hansen, B.C., 465
Hao, E., 1514
Hara, T., 792
Harada, J., 814
Harada, N., 1230
Hashimoto, T., 163
Hashimoto, T., 184
Hassan, I., 582
Hatae, Y., 544
Hatano, T., 814
Hatsumi, C., 1081
Havekes, L.M., 695
Havel, P.J., 12, 1104
Hayakawa, N., 871
Hayashi, K., 1553
Hayashi, R., 539
Haymond, M.W., 127, 827
Heaney, R.P., 935
Heffner, M., 1065
Heinz, G., 976
Hejnova, J., 1291
Henkel, E., 743
Henriksen, E.J., 1065
Henriksen, J.E., 1331
Henry, R.R., 1171
Heras, M., 609
Hermansen, K., 155, 671, 896
Herrera, E., 1444
Herrmann, W., 1235
Hesketh, J.E., 1285
Hickner, R.C., 460, 1514
Higuchi, S., 1135
Hill, D.J., 765
Himeno, Y., 1230
Hirako, M., 1285
Hirano, M., 1562
Hirano, T., 716
Hirao, K., 932
Hirose, H., 314, 1407
Ho, R.C., 1478
Hoffer, L.J., 399, 881
Hoffman, R.P., 1506, 1582
Holmdahl, L., 267
Holst, J.J., 1180
Homma, K., 1553
Hong, S.K., 838
Hopkins, W.G., 678
Hoppichler, F., 1274
Horani, M.H., 376
Horikami, K., 932
Hörl, W.H., 976
Hornstra, G., 695
Horowitz, M., 949
Hosoda, T., 1241
Houmard, J.A., 460
Howard, T.K., 206
Hsieh, C.-J., 255
Hsu, W.H., 1184
Hu, R., 1439
Huang, W.-S., 1423
Hud, E., 901
Huesca-Gómez, C., 443
Hul, G.B., 1003
Humbert, B., 628

Ichikawa, K., 1135
Ide, T., 1191
Igarashi, H., 814
Igualá, I., 372
Iida, M., 1135
Iino, K., 1135
Ikeda, T., 1324
Ikewaki, K., 1348
Ilkova, H., 1360
Imamura, H., 1313
Imbeault, P., 482
Imthurn, B., 1216
Inoue, S., 716
Intrieri, M., 52
Inukai, T., 471
Isenović, E., 380
Ishii, T., 314
Ishimura, N., 702
Israelsson, B., 1279
Ito, S., 1452
Itoh, M., 871, 1230
Iwamoto, Y., 20
Iwasaki, M., 1348
Iwase, K., 871
Iwase, M., 1135
Izzo, S., 691

Jackson, C.-J.C., 919
Jacob, R.J., 1522
Jacobs, D.R., Jr, 144
Jämsä, T., 92
Jang, Y.J., 912
Jannot, M.F., 284
Jansen, M., 976
Jap, T.-S., 394
Jaroß, W., 743
Jauhiainen, M., 1410
Jellema, W.T., 57
Jenkins, D.J.A., 919, 1596
Jensen, M.D., 1198
Jenssen, T., 1128
Jiménez-Chillarón, J.C., 121
Joanisse, D.R., 451
Johnson, L.G., 657
Jones, P.J.H., 25, 652
Jones, S.A., 1027
Jong, M.C., 695
Jong-Yeon, K., 460
Jönson, A.N., 327
Josse, R.G., 1596
Joven, J., 609
Jovinge, S., 327

Ka, T., 438, 1317
Kabir, M., 819
Kageyama, A., 716
Kageyama, H., 716
Kai, Y., 1247
Kajioka, T., 149

Kaku, K., 964
Kakumu, S., 792
Kales, A., 887
Kanatsuka, A., 1161
Kanauchi, M., 184
Kanazawa, S., 1377
Kanda, T., 1553
Kang, J.-S., 589
Kanno, H., 1377
Kano, K., 1377
Karvonen, H.M., 1253
Kaser, S., 599
Katan, M.B., 1534
Kato, S., 1230
Kato, T., 871
Katsuda, Y., 1017
Kawai, T., 314
Kawamura, W., 575
Kawashita, N.H., 343, 1501
Kawata, M., 544
Keebler, M., 783
Keller, P.J., 1216
Keller, U., 754
Kelley, P.C., 318
Kendall, C.W.C., 919, 1596
Kennedy, R., 65
Kern, P.A., 65
Kern, W., 531, 1370
Kesala, R.L., 1120
Kettelhut, I.C., 343, 1501
Kibenge, M.T., 708
Kiess, W., 1389
Kikuchi, M., 575
Kim, C., 912
Kim, C.-H., 838
Kim, D.-J., 833
Kim, D.-K., 998
Kim, D.-S., 589
Kim, J.Y., 838
Kim, K.-W., 833
Kim, S.H., 477
Kim, S.-H., 833
Kim, S.Y., 477
Kim, T.-W., 589
Kim, Y.I., 838
Kinalska, I., 75, 733
Kirchmair, R., 599
Kishimoto, H., 539
Kishimoto, K., 814
Kitada, C., 1241
Kitahara, Y., 1452
Kizhner, T., 1538
Klein, M.J., 1381
Klein, S., 169
Klitgaard, N.A.H., 1331
Knapp, J.P., 1235
Knuuttila, M.L.E., 92
Kobayashi, K-i., 403
Kobayashi, T., 871, 1230
Koda, J.E., 636
Koehler, C., 743
Koizumi, J., 1017
Kojima, M., 1377
Kokkotou, E., 1489
Koll, M., 97
Kolterman, O.G., 636
Koppeschaar, H.P.F., 1093
Korach, M., 307
Korczynska, J., 1605
Kotake, M., 871
Koumbridis, G., 1596
Kowalska, I., 75, 733
Kraemer, R.R., 657
Kraemer, W.J., 864
Kraus, J.P., 981
Kraus-Friedmann, N., 79
Krempf, M., 5
Krug-Wispe, S., 25
Kruskall, L.J., 989
Kühl, S., 492
Kuller, L.H., 1573
Kumagai, H., 1553
Kumagai, S., 1247
Kuo, M.-C., 255
Kuo, S.-W., 1423
Kuribayashi, T., 1377
Kuroe, A., 1578
Kushiro, M., 1191
Kusunoki, M., 792
Kuttesch, J.F., 1381
Kwon, H.J., 477

Laager, R., 754
Laclau, M., 318
Lacy, D.B., 274
Lain, K.Y., 1433
Lambert, K., 807
Lamendola, C., 843, 1355
Landt, M., 206
Lang, J.E., 724
Lanzone, A., 137
Laposata, M., 260
Lapsley, K.G., 1596
Larkin, K.M., 206
Laube, H., 796
Laughlin, M.H., 1587
Layton, C., 1065
Lear, S.A., 1427
Leary, E., 1355
LeCesne, C., 1065
Lechleitner, M., 1274
Leclercq, P., 307
Lee, K.-S., 477, 622
Lee, K.-U., 838
Lee, M.-K., 833, 998
Lee, M.S., 838
Lee, M.-S., 1423
Lee, M.-S., 833
Leem, C.H., 912
Lehotay, D.C., 645
Leite, C.C., 1034
Leiter, L.A., 1596
Lemmerer, M., 1235
Leon, A.S., 360
Leoni, F., 137
Lernmark, Å., 569
Leroux, J.-L., 958
Leverve, X., 307
Lewczuk, P., 75
Li, F., 1439
Li, J., 1471
Lidfeldt, J., 267
Lim, K.I., 271
Lin, C.-C., 622
Lin, H.-M., 887
Lin, M., 1120
Lindenthal, B., 492
Ling, A., 1569
Linn, T., 796
Liou, C.-W., 255
Liu, P.P., 645
Liu, R.-T., 255
Lizzio, M.N., 1340
Llobera, M., 925
López, A., 44
López-Tejero, M.D., 925
Lopuhaä, C.E., 57
Löster, H., 1389
Louca, J., 260
Love, D.M., 864
Lowell, J.A., 206
Lu, Y.-C., 255
Luc, G., 443
Lucarelli, P., 1, 419
Luef, G., 1274
Lütjohann, D., 492
Lykins, D.L., 1433

Ma, R., 180
Maas, H.C.M., 1093
Mabuchi, H., 1017
McCay, J., 274
MacDonald, K., 1514
MacDonald, M.J., 318
McGill, J.B., 169
McGuiness, O.P., 274
Machado, U.F., 1501
McLaughlin, T., 843, 1355
McNamara, D.B., 783
Madsbad, S., 896
Maffei, P., 387
Maggio, M., 691
Maggs, D.G., 636
Magot, T., 5
Magri, F., 105
Mahoudeau, J., 1088
Maïmoun, L., 958
Maira, G., 616
Maitimu, I., 1093
Majercik, M., 1291
Majors, A.K., 1433
Manary, M.J., 1418
Mancini, A., 616
Mancuso, S., 137
Mangaloglu, L., 409
Mano, T., 1230
Mantle, D., 97
Mantzos, E.I., 1489
Marafelia, P., 1489
Maranhão, R.C., 1097
Marcheselli, F., 1384
Marchie, A., 1596

Margutti, A., 1363
Maria, A.T., 1298
Mariano-Goulart, D., 958
Marie, P.J., 906
Marion-Latard, F., 1291
Martin, C., 175
Martin, C.R., 1562
Martin, P., III, 761
Martinez, D.S., 115
Martínez, S., 1444
Martos, R., 423
Marumoto, K., 539
Masiello, P., 110
Massironi, P., 1022
Massó, F., 443
Matsubara, K., 314
Matsuda, D., 1034
Matsuda, M., 1111
Matsui, K., 1161
Matsumoto, K., 244, 932, 1548
Matsumoto, S., 471
Matsumura, R., 201
Matsushita, K., 539
Matthews, K.A., 1573
Mattila, P.T., 92
Maturana, M.A., 238
Maugeais, C., 5
Maugère, P., 5
Mauras, N., 127
Mauriège, P., 482
Mazzanti, L., 605
Mazzilli, G., 1011
Mecocci, P., 691
Medina, E.A., 1104
Meininger, G., 260
Melby, C.L., 1478
Meloni, G.F., 419
Mensink, R.P., 695
Mercier, J., 807
Merki-Feld, G.S., 1216
Meyer, C., 1494
Micallef, J.-P., 958
Migliorini, R.H., 343, 1501
Mikkola, T.S., 523
Milhavet, O., 807
Milov, D., 127
Min, K.-M., 998
Min, Y.-K., 833
Mine, T., 1452
Misawa, Y., 201
Mito, N., 1241
Mitsugi, Y., 1081
Miura, K., 1452
Miyake, S., 244, 932, 1548
Miyamoto, N., 1313
Miyashita, K., 1407
Miyashita, Y., 201
Miyata, T., 792
Mochizuki, K., 1348
Mochizuki, S., 1348
Modai, D., 1392
Mogensen, A.M., 1180
Mogensen, J.H., 671
Mohamed, S.M., 1148
Mohideen, P., 1171
Mokuno, H., 1081
Mokuno, T., 871
Mollica, G., 1463
Montali, A., 1298
Montaño, L.F., 443
Mooney, M.H., 514
Mooradian, A.D., 376
Moore, M.C., 1324
Morabito, F., 1011
Morales, R., 423
Morello, R., 1088
Moretti, N., 605
Morganti, S., 691
Mori, T.A., 1041
Mori, Y., 814
Morita, T., 575
Moriwaki, Y., 438, 893, 1317
Morley, J.E., 554
Moro, D., 1011
Moroni, F., 1384
Morris, H., 949
Morrison, J.A., 432
Motomiya, K., 184
Moura, M.A.F., 343, 1501
Mouritzen, U., 69
Moustafa, T.M., 1148
Movsesyan, L., 69
Mudaliar, S., 1171
Mudd, S.H., 981
Müller, D.M., 1389
Munger, R., 549
Muniyappa, R., 380
Murano, T., 201
Murase, Y., 1017
Murray, E.J.B., 1153
Murray, S.S., 1153
Murthy, S.N., 783
Mussner, M.J., 189
Muurling, M., 695
Muzzoni, B., 105

Nagai, Y., 403
Nagasaka, A., 871, 1230
Nagasaka, S., 539, 544, 1578
Nagata, M., 871
Nakada, J., 814
Nakahara, T., 1562
Nakai, Y., 539, 544, 1578
Nakamura, H., 244
Nakamura, T., 792
Nakaya, Y., 702, 792
Namba, Y., 716
Nanetti, L., 605
Nardi, A., 34
Nasr, I.S., 292
Natalucci, S., 297
Nawata, H., 163
Neal, D.W., 1324
Negishi, M., 1377
Nerbrand, C., 267
Newgard, C.B., 121
Nguyen, P., 628
Nicklas, B.J., 853
Nieweglowski, T., 1605
Nilsson, J., 327
Nin, K., 1578
Nishide, R., 1348
Nishikai, K., 1407
Nishikawa, T., 350
Nishikura, K., 1377
Nitta, A., 1377
Nivet-Antoine, V., 175
Nohara, E., 403
Nolan, A., 801
Novelli, M., 110
Nozaki, O., 1161
Ntanios, F.Y., 652
Numata, M., 1377
Nuotio, I., 664
Nuttall, F.Q., 1027
Nyberg, P., 267

Ogawa, H., 792
Ogihara, N., 575
Oguma, Y., 314
Ogura, M., 1578
Oh, J.-Y., 356
Ohanna, F., 958
O'Harte, F.P.M., 514
Ohdo, S., 1135
Ohmura, H., 1081
Okamoto, M., 575
Okazaki, Y., 314
O'Keefe, M., 1065
Okubo, K., 1553
Okuda, Y., 575
Okumura, T., 539, 544, 1578
Olaiz, G., 560
Oliveira, M.R.M., 1097
Oliveriusova, J., 981
Olson, J.C., 248
Oltmanns, K.M., 531, 1370
Om, A.-S., 589
Omar, M., 292
Omori, Y., 20
Omura, M., 350
Opolon, P., 1071
Oppert, J.-M., 819
Orchard, T.J., 248
Ortmeyer, H.K., 465
Osaka, T., 716
Osman-Dualeh, M., 1093
Otto, C., 189
Ouguerram, K., 5
Owens, D., 847
Ozaki, H., 201

Pabst, W., 796
Pachinger, O., 327
Paice, A.G., 1285
Palmer, J., 144
Palmer, T.N., 97
Pan, J., 1120
Panico, S., 52
Pansini, F., 1463
Papanicolaou, D.A., 887
Parhofer, K.G., 189

Park, C.S., 912
Park, G.-S., 998
Park, I.-K., 589
Park, J.Y., 838
Park, S., 38
Park, S.W., 998
Parker, T.L., 919, 1596
Parris, W., 334
Passaro, A., 1463
Patanè, G., 1340
Patrick, P., 554
Patsch, J.R., 599
Pearce, G.L., 1166
Pedersen, S.B., 155
Peinado-Onsurbe, J., 925
Pellechia, J., 1587
Pender, C., 465
Pérez-Méndez, O., 443
Perng, H.-W., 1423
Perri, C., 137
Pérronet, F., 307
Perry, H.M., III, 554
Peruchon, E., 958
Peters, A., 531, 1370
Peters, T.J., 97, 737, 1285
Petrella, E., 657
Pfeifer, M., 211
Phares, D.A., 774, 1053
Phillips, B.G., 1506
Phillips, C., 847
Phuyal, J., 518
Pieri, C., 1384
Pijl, H., 695
Piro, S., 1340
Poehlman, E.T., 322, 801
Poirier, L.A., 783
Pontrelli, L., 334, 409
Popa, E., 1494
Pories, W., 1514
Posadas-Romero, C., 443
Pousse, P., 1088
Poussier, P., 569
Powers, R.W., 1433
Poynard, T., 1071
Pozzilli, P., 419
Prats, E., 609
Preedy, V.R., 97, 737, 1285, 1562
Préfaut, C., 807
Prentki, M., 110
Privette, J., 1514
Prokop, J., 733
Prolo, P., 887
Purrello, F., 1340
Purrello, M., 1340
Py, G., 807

Quilliot, D., 1261
Quintó, L., 372
Qureshi, T., 876

Rabe, J., 260, 1143
Rabemanantsoa, C., 1484
Rabini, R.A., 605
Rabuazzo, A.M., 1340
Raccah, D., 284
Racette, S.B., 169
Radominski, R., 1034
Raeini-Sarjaz, M., 652
Rafferty, K., 935
Räikkönen, K., 1573
Rainwater, D.L., 508
Ramanathan, S., 569
Rankinen, T., 451
Rao, D.C., 360
Rapoport, M., 1392
Rassam, A.G., 761
Ratziu, V., 1071
Rawson, E.S., 801
Reaven, G.M., 235, 255, 457, 843, 1022, 1355
Rebecchi, I., 691
Recchioni, R., 1384
Rector, R.S., 1587
Redgrave, T.G., 1041
Rehman, N., 1171
Reynolds, T.H., IV, 1402
Reznik, Y., 1088
Ribalta, J., 609
Ricart-Jané, D., 925
Ricci, G., 1298
Rice, T., 360
Richter, T., 1389
Rigalleau, V., 1484
Rigler, B., 1235
Rini, A., 127
Ritsch, A., 599
Rivière, D., 1291
Rizk, M.M., 292
Rizkalla, S.W., 819
Roberts, J.M., 1433
Robinson, J., 1065
Rodríguez-Sureda, V., 925
Roel, J., 144
Rojas, R., 560
Rojo-Martínez, G., 429
Romijn, J.A., 57
Rooney, K., 518, 1569
Rosenberg, R., 1392
Rosmond, R., 360, 642
Rossi, M., 958
Rowlands, D.S., 678
Rubba, P., 52
Rudinsky, S., 1065
Ruiz de Adana, M.S., 429
Rull, J.A., 218, 560
Rutkowski, B., 1605
Ruz, F.J., 423
Ryu, H.J., 912

Saavedra-González, Á., 1047
Saberi, M., 859
Sacchetti, L., 52
Saccucci, P., 1
Saeed, A., 1027
Said, S.T., 65
Saito, I., 1407
Saito, M., 964
Sakaguchi, K., 539
Sakai, M., 539, 544, 1578
Sakai, T., 575
Sakakibara, F., 792
Sako, Y., 163
Salinas-Orozco, S., 44
Salminen, I., 1253
Samsioe, G., 267
Sánchez-Reyes, L., 44
San Miguel, G.I., 582
Saris, W.H., 1003
Sarkkinen, E.S., 1253
Sartori, E., 1022
Saruta, T., 314, 1407, 1553
Sasaki, H., 1247
Sasano, H., 350
Sato, K., 1241
Sato, Y., 149
Sauerwein, H.P., 57
Sawano, M., 1081
Schachter, N.S., 500
Schade, D.S., 761
Scheek, L.M., 1534
Scheett, T.P., 864
Schers, T.J., 1093
Scherstén, B., 267
Schocken, D.D., 582
Schouten, E.G., 1534
Schultes, B., 1370
Schulze, K., 1410
Schwandt, P., 189
Scott, M.F., 1324
Seed, P.T., 1458
Seim, H., 1389
Seino, Y., 1578
Seitz, H.K., 97
Semmelrock, H.J., 1235
Seo, I.A., 833
Sepulveda, J., 560
Sera, Y., 244, 932, 1548
Shahparaki, A., 1211
Sharman, M.J., 864
Shea, E., 901
Shearman, C.W., 901
Shen, L.Z., 636
Shenoy, S., 206
Sherwin, R.S., 1522
Shimokata, H., 149
Shinohara, K., 1191
Shirai, K., 201
Shirali, S., 1562
Shirota, T., 1313
Shuldiner, A.R., 801
Sicard, G.A., 206
Sicolo, N., 387
Siegert, G., 743
Sieve-Smith, L., 724
Silver, K., 801
Sim, K.G., 366
Simanowski, U.A., 97
Simó, J.M., 609
Simonson, W., 569
Sims, C.J., 1433
Singh, M.K., 859
Sinkey, C.A., 1506

Sites, C.K., 322
Skinner, J.S., 360
Slama, G., 819
Smith, T.L., 859
Sochaski, M.A., 645
Soendergaard, K., 896
Soghier, L.M., 1148
Solerte, S.B., 691
Soliman, A.T., 292
Song, M.S., 998
Sonoki, K., 1135
Sopke, S., 531
Soranna, L., 137
Soriguer, F.J., 429
Sorisky, A., 1211
Sowers, J.R., 380
Sprangers, F., 57
Sprecher, D.L., 432, 1166
Spritzer, P.M., 238
Stabler, S.P., 981
Stadil, F., 1180
Stanger, O., 1235
Stanhope, K.L., 1104
St. Clair, P.W., 523
Steegborn, C., 981
Stelmanska, E., 1605
Stępień, A., 75, 733
Stich, V., 1291
Stillman, J., 1471
Strączkowski, M., 75, 733
Strobel, S.A., 636
Stroick, M., 492
Strum, W., 599
Stuelinger, M., 843
Stulnig, T., 976
Sturek, M.S., 1587
Sucajtys, E., 1605
Sudhop, T., 1519
Sueioshi, M., 201
Suga, T., 792
Sugiyama, T., 201
Suljkovicova, H., 1291
Sumida, K.D., 876
Sun, G., 451
Sun, G.Y., 1587
Sunehag, A.L., 827
Supiano, M.A., 1402
Sutherland, W.H.F., 1306
Svanberg, M.J., 92
Svendsen, O.L., 69
Swierczynski, J., 1605
Synovitz, L.B., 657
Szelachowska, M., 733
Szolkiewicz, M., 1605

Taborsky, G.J., Jr, 12
Tada, N., 1348
Taghibiglou, C., 409
Tajiri, Y., 163
Takahashi, A., 702
Takahashi, S., 438, 893, 1317
Takahashi, Y., 1191
Takamatsu, I., 1553
Takamura, T., 403
Takei, I., 314
Takemura, Y., 471
Takesue, K., 1452
Takiguchi, K., 575
Takishita, E., 702
Takizawa, T., 20
Tamburrano, G., 387
Tamez, R., 44
Tanenberg, R.J., 211
Tang, J., 1439
Tang, R., 52
Taniguchi, A., 539, 544, 1578
Taniyama, M., 314, 1407
Tankó, L.B., 69
Tantry, U., 1269
Tapola, N.S., 1253
Taskinen, M.-R., 664
Tatematsu, S., 1553
Tayama, K., 471
Tchernof, A., 322, 1397
Telemaque-Potts, S., 121
Temelkova-Kurktschiev, T., 743
Teno, S., 20
Teramura, S., 539
Terry, J.G., 1223
Teshima, K., 1313
Thomas, T.R., 1587
Thompson, A., 765
Thompson, C., 518, 1569
Thorkelson, T., 25
Thornton, F.J., 1269
Thorpe, S.R., 645
Thuesen-Olesen, B., 1279
Tinahones, F.J., 429
Tischler, M.E., 1065
Toft, I., 1128
Tokuyama, H., 1553
Tokuyama, K., 539, 544
Tokuyama, Y., 1161
Tominaga, T., 932, 1548
Tomita, M., 314, 1407
Tomkin, G.H., 847
Torres-Acosta, E.M., 44
Toschek, B., 531
Toth, M.J., 322, 1397
Towner, P., 1285
Townsend, R.R., 779
Trankjaer, A., 1180
Tranquilli, L.A., 605
Trautwein, E.A., 1596
Tremblay, A., 482
Trevino, B., 859
Trinka, E., 1274
Tritos, N.A., 1489
Tsai, Y.-F., 769
Tsang, R.C., 25
Tsao, P.S., 843
Tso, Y.-C., 394
Tsui, J.K.C., 970
Tsuji, M., 716
Tsujimura, T., 871
Tsutsumi, K., 792
Tsutsumi, Z., 438, 893, 1317
Tsuzuku, S., 149
Tu, K.N., 1153
Tung, S.-C., 255
Turkalj, I., 754
Turpin, G., 1071

Uchida, R., 575
Uchida, Y., 1452
Uchimura, H., 1562
Uchimura, K., 871
Uchiyama, M., 814
Udupi, V., 1514
Ueki, Y., 244, 932, 1548
Ueno, Y., 737
Uezono, K., 1247
Ukkola, O., 451, 642
Ulloa, N., 1410
Umeda, F., 163
Unterberger, I., 1274
Uto, Y., 20
Uusitupa, M.I.J., 1253

Vaaler, S., 896
Vague, P., 284
Vaja, S., 1458
Valenti, G., 691
Valle, D., 616
Valle, M., 423
Valles, V., 560
Van, J.T., 1120
Van Aggel-Leijssen, D.P., 1003
Van Baak, M.A., 1003
Van der Zee, J.S., 57
Van Iderstine, S.C., 409
Van Lieshout, J.J., 57
Vanstone, C.A., 652
Van Tol, A., 1534
Vassilopoulou-Sellin, R., 1381
Vázquez-Chávez, C., 44
Vega-López, S., 500
Vela-Bueno, A., 887
Verna, R., 1298
Vesely, D.L., 582
Vetrugno, E., 1022
Vgontzas, A.N., 887
Vicini, P., 1582
Vidal, H., 664, 819
Vidal-Quintanar, R.-L., 500
Vidgen, E., 919, 1596
Vierhapper, H., 34
Vigna, G.B., 1463
Vignati, G., 105
Vigneri, R., 1340
Viikari, J., 664
Vittorini, S., 110
Volek, J.S., 864
Volgger, B., 599
Von Bergmann, K., 189, 492, 1519
Voshol, P.J., 695
Vozzo, R., 949

Wada, R., 1452
Wagner, C., 981
Wahl, M.C., 981
Wajchenberg, B.L., 1034

Walker, R.J., 1306
Walsh, M.F., 380
Wang, C.-Y., 769
Wang, J., 508
Wang, P., 724
Wang, P.-W., 255
Wang, S.-T., 255
Wang, X.L., 508
Ward, J., 1569
Watanabe, T., 539, 1578
Watanabe, Y., 1081
Watts, G.F., 1041, 1206
Weinstein, R.B., 1065
Weissgarten, J., 1392
Welch, S., 127
Welle, S., 1494
Werman, M.J., 1538
Weyer, C., 636
White, D., 1471
White, D., 847
Wilcken, B., 366
Williams, K., 248
Williams, S.M., 1306
Wilmore, J.H., 360
Wiltschnig, S., 976
Wilund, K.R., 774, 1053
Wishart, J.M., 949
Witte, M.B., 1269
Wittert, G.A., 949
Woerle, H.J., 1494
Wollesen, F., 941
Wong, N.C.W., 376
Wong, N.L.M., 970
Wright, D.C., 271
Wu, Y.-C., 394
Wursch, P., 819

Xiao, J., 155

Yagi, K., 1017
Yagihashi, S., 1452
Yamada, Y., 1578
Yamadori, N., 1578
Yamaguchi, H., 1081
Yamaguchi, J., 575
Yamaguchi, K., 350
Yamamoto, K., 1230
Yamamoto, T., 438, 893, 1317
Yamamoto, Y., 314, 1407
Yamanouchi, K., 544
Yamashita, H., 403
Yamazaki, N., 871, 1230
Yanada, S., 814
Yang, K., 765
Yang, S.-P., 1423
Yang, Y., 1439
Yarasheski, K.E., 1418
Yaspelkis, B.B., III, 859
Yayashi, Y., 575
Yibchok-anun, S., 1184
Yin, J., 1439
Ylitalo, K., 664
Yoo, S.J., 477
Yoon, C., 115
Yorek, M.A., 225
Yoshida, S., 201
Yoshihiro, A., 814
Yoshii, S., 544, 1578
Yoshikawa, H., 163
Yoshinari, M., 1135
Yoshioka, I., 539
Young, K.L., 1153
Young, V., 1143
Youngren, J.F., 465
Younsi, M., 1261

Zanca, R., 1463
Zander, M., 896
Zarrilli, F., 52
Zatelli, M.C., 1363
Zavaroni, I., 1022
Zhao, H., 779
Zhong, W.-B., 769
Ziegler, O., 1261
Zinker, B.A., 595
Zoumakis, M., 887
Zuppi, P., 616

SUBJECT INDEX

AAs, *see* Amino acids
Ab(s), *see* Antibodies
Abdominal adipose tissue (AT)
  fasting insulin level, plasma pollutant level, weight loss and, 484
  in older hypertensive women engaged in aerobic exercise, 1004
  see also Abdominal adipose tissue, subcutaneous
Abdominal adipose tissue (AT), subcutaneous
  fasting insulin level, plasma pollutant level, weight loss and, 484
  in middle-age, premenopausal, and early postmenopausal women, 324, 325
  in NIDDM, TZD effects on, 171
Abdominal subcutaneous preadipocyte differentiation, omental preadipocyte differentiation compared with, 1211-1215
Absorptiometry, dual-energy x-ray, bone loss evaluation in SCI with bone biochemical markers and, 958-963
Acetoacetate, *see* Plasma acetoacetate
N-Acetyl-L-cysteine (NAC), mitochondrial depolarization in hyperglycemia-induced apoptosis of HAECs prevented with, 1384-1388
Acquired immunodeficiency syndrome, *see* HIV infection
Acromegaly, *see* Growth hormone in acromegaly
ACTH (adrenocorticotropic hormone), *see* Corticotropin
Acute alcohol intake, effects of, on skeletal muscle lysosomal, cytoplasmic, and proteosomal protease activities, 97-104
Acute effects of insulin-induced hypoglycemia on pituitary-thyroid axis, 1370-1374
Acute infection, urea production and leucine oxidation in malnourished children with and without, 1418-1422
Acute lipotoxicity, effects of, on IR, HK1, CPT1, and GLUT2 gene expression in INS-1 cells, 155-162
Acylation-stimulating protein (ASP) in FCHL, PPARγ, HSL, and C3 expression in AT and, 667, 668
Acylcarnitine, fibroblast, in respiratory chain defects and mitochondrial fatty acid β-oxidation disorders, compared, 366-371
Acyltransferase, *see* Lecithin:cholesterol acyltransferase
Adaptation
  BBB, to elevated brain glucose levels in DM with chronic hyperglycemia, 1522-1524
  to high-protein diet, *see* High-protein diet, adaptation to, BAT and
Adenine, beer effects on, 1321
Adenine dinucleotide, *see* Nicotinamide adenine dinucleotide
Adenoma
  aldosterone-producing, unilateral hyperaldosteronemia compared with, 350-355
  pituitary, GH deficiency in, detected with PD/GHRH stimulation test, 34-37
Adenosine, beer effects on, 1321
Adenosine monophosphate, *see* cAMP; cAMP agonists
Adenosine triphosphatase, *see* Na^+/K^+ ATPase
S-Adenosylmethionine (SAM) and *S*-adenosylhomocysteine (SAH), hepatic and RBC, CS-045 effects on CβS and MTHFR in Hcy metabolism, plasma Hcy and, 783-786
Adhesion molecule-1
  soluble intercellular, levels and relationship of, to insulin resistance and TNF-α activity in obesity, 75-78
  vascular, *see* Vascular cell adhesion molecule-1
Adipocytes, inhibition of LPL in, by TCDD, 65-68
Adiponectin, *see* Serum adiponectin in Japanese subjects
Adipose tissue (AT)
  brown, *see* High-protein diet, adaptation to, BAT and

Adipose tissue (AT) (*Continued*)
exercise and, *see* Adipose tissue in exercising subjects
fasting insulin level, plasma pollutant level, weight loss and, 484
in FCHL, PPARγ, and C3 expression in, 664-670
in HIV-infected subjects, *see* Adipose tissue in HIV-infected subjects
HSL mRNA in, *see* Hormone-sensitive lipase mRNA in AT
lipolytic function of, race and differences in, 1514-1516
in middle-age and premenopausal women, 324, 325
in non-obese subjects, *see* Adipose tissue in non-obese subjects
in obesity, IR autophosphorylation and, 467
in postmenopausal women, *see* Adipose tissue in postmenopausal women
taurine synthesis in, cysteine dioxygenase and cysteine sulfinic acid decarboxylase mRNA and, 1191-1197
vitamin E uptake by white, around parturition and during lactation not dependent on LPL activity, 1444-1451
see also Adipocytes; Adipose tissue distribution; Fat-free mass; Fat mass
Adipose tissue (AT) distribution
FFAs associated with AT redistribution in insulin response to glucose in HIV infection, 260-266
in NIDDM, *see* Adipose tissue distribution in NIDDM
role of ERT and, in corticotropin and cortisol response to CRH in postmenopausal women, 137-143
see also Regional adipose tissue
Adipose tissue (AT) distribution in NIDDM
in Japanese men, pioglitazone effects on metabolic parameters, serum adiponectin and, 314-317
monosaccharide ingestion and, 950
soluble serum E-selectin correlated with obesity but not with, 932-934
Adipose tissue (AT) in exercising subjects
effects of MCFA and LCFA oxidation on, 461
endurance exercise effects in sedentary subjects, 1056
high-fat or high-CHO diet effects on lipolysis in, 1291-1297
in older men engaged in lower versus whole body resistive exercise, 992
in older women, *see* Adipose tissue in exercising women, older
Adipose tissue (AT) in exercising women, older
engaged in lower versus whole body resistive exercise, 992
hypertensive women, and effects of aerobic exercise on insulin sensitivity, 1004
Adipose tissue (AT) in HIV-infected subjects
antiprotease therapy and, 308
FFAs associated with AT redistribution in insulin response to glucose in HIV infection, 260-266
lipolysis of, in HIV-infected men on antiretroviral therapy, 1145
Adipose tissue (AT) in non-obese subjects
non-obese men, apo B-100 kinetics and AT compartments in, 1206-1210
non-obese young women, weight cycling effects on, 150, 151
Adipose tissue (AT) in postmenopausal women
in early postmenopausal women, 324, 325
on ERT, plasma CE transfer and, 601
ADMA (asymmetric dimethylarginine), metformin effects on, in NIDDM, 843-846
Adolescents
early, determination of insulin sensitivity and glucose effectiveness in, with one- and two-compartment–labeled minimal model, 1582-1586
serum T associated with lower HDL-C in 10- to 15-year-old males, apo A-I and A-II concentrations and, 432-437
ADR, *see entries beginning with terms*: Adrenergic receptor
Adrenal androgens, circulating E_2 and concentrations of, in men on glucocorticoids, steroid-induced osteoporosis and, 1458-1462
Adrenal hyperplasia
congenital, longitudinal metabolic process of bone growth in NESS and, 1377-1380
unilateral and primary, unilateral hyperaldosteronemia compared with, 350-355
Adrenal-pituitary axis, hypothalamic,in postmenopausal women, ERT effects on, 137-143
Adrenal venous sampling in detection of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, 350-355
Adrenaline, *see* Epinephrine
α (alpha)- and β (beta)-Adrenergic inhibition, effects of, on muscle glucose uptake and blood flow, 1505-1513
β_2 ($beta_2$)-Adrenergic receptor (ADRB2) gene polymorphism in obese Korean NIDDM subjects, 833-837
β_3 ($beta_3$)-Adrenergic receptor (ADRB3) gene polymorphism
lipid phenotypic expression in FCHL and, 1298-1305
Trp64Arg β_3-, effects of, on weight loss, body composition, or energy expenditure in obese postmenopausal women, 801-805
Adrenoceptor (adrenergic receptor), *see* β_2-Adrenergic receptor gene polymorphism; β_3-Adrenergic receptor gene polymorphism
Adrenocortical micronodules, multiple, unilateral hyperaldosteronemia due to, adrenal venous sampling in detection of, 350-355
Adrenocorticotropic hormone, *see* Corticotropin
Adverse effects
of short-term metformin therapy, 532
of TSH, 693
Aerobic exercise
by older hypertensive women, plasma TNF-α levels and effects of, on insulin sensitivity, 1402-1406
weight loss and physiologic changes after CHO-restricted diet and structured lifestyle activity or, 1528-1533
African Americans, *see* Race and ethnicity
Age
of acromegalic subjects, 617, 618
age- and sex-specific plasma Hcy correlation with MDA, 1433-1438
and apo A-I and B distribution in urban Mexican population, 563-565
of CAD men, 734
of chronic AITD subjects, 1490
of CPEO subjects, 797
diet and, *see* Age, diet and
and effects of oral contraceptives, 1217
and effects of Pro12Ala polymorphism of PPARγ2 gene on serum adiponectin, 1408
of epileptic patients, 1275
of ESRD subjects, 882
exercise and, *see* Age of exercising subjects
of FCHL subjects, *see* Age of FCHL subjects
of Graves' disease subjects, 770
of head trauma subjects, 1364
of HIV-infected subjects, *see* Age of HIV-infected subjects
of hypercholesterolemic subjects, *see* Age of hypercholesterolemic subjects
of IBD children on chronic glucocorticoid therapy, 128
of IDDM subjects, *see* Age of IDDM subjects
and insulin regulation of FFAs, 780
of insulin-resistant subjects, *see* Age of insulin-resistant subjects
of late-onset DM subjects, 1162, 1163
of MAT I/III deficiency subjects, 983

Age (*Continued*)
of MCS patients, 424, 425
of men on glucocorticoid therapy, adrenal androgen concentrations and circulating E_2 in, 1459
of methionine-induced hyperhomocysteinemic subjects, 1237
microalbuminuria and insulin metabolism in 58-year-old men, 750-753
of MS subjects, *see* Age of MS subjects
of NIDDM relatives, and [^{3}H]ouabain binding capacity in SM, 1332
of NIDDM subjects, *see* Age of NIDDM subjects
of non-obese subjects, *see* Age of non-obese subjects
of normotensive nondiabetic subjects, carotid artery intima-media thickening and, 256, 257
of obese subjects, *see* Age of obese subjects
of OSAS subjects, 623
of pituitary adenoma subjects, 35
of postmenopausal women, *see* Age of postmenopausal women
and PP TG, NEFA, and/or incretin response to sucrose in men at risk for CHD, 195-200
of premenopausal women, plasma glycerol and, 324
as risk factor, *see* Age, as risk factor
and risk for NIDDM, *see* Age of subjects at-risk for NIDDM
of sarcopenic women, 70
of SCI subjects, 960
serum T association with lower HDL-C in 10- to 15-year-old male adolescents, 432-437
and TBP in women, 181, 182
of unilateral hyperaldosteronemia, 351
of unilateral nephrectomy subjects, 207
WC and metabolic risk factors and, 1428, 1429
see also Aging effects *and entries beginning with terms*: Middle-age, Older, Young
Age, diet effects and
age of infant and diet effects on total plasma C and LDL-C, 29
fiber and multivitamin effects on LDLs and, 1168
FM increase in overfed young men, 452
in hypercholesterolemic early postmenopausal women, diet effects compared with simvastatin, ETP, and/or estrogen-progestogen replacement therapy effects in, 1464
in malnourished children with and without acute infection, 1419
oral L-carnitine supplementation effects on LCFA oxidation, 1390
Age, as risk factor
for CAD, 1082, 1085
for CV disease, 1035, 1038, 1072, 1073
for metabolic syndrome in women, 1574
Age of endurance exercise subjects
and cortisol response to exercise, 362
of insulin-resistant obese NIDDM men, 1249, 1250
in sedentary subjects, endurance exercise effects on, 1056
Age of exercising men
of obese insulin-resistant NIDDM engaged in endurance exercise, 1249, 1250
of obese weight-reduced men engaged in long-term low-intensity exercise and, 1005
of older men engaged in lower versus whole body resistive exercise, 992
Age of exercising subjects
and changes in HDL-C subfractions, 776
and effects of high-fat or high-CHO diet on lipolysis in AT, 1292
endurance exercise, *see* Age of endurance exercise subjects
and oxidation of MCFAs and LCFAs in skeletal muscle, 461
see also Age of exercising men; Age of exercising women, older
Age of exercising women, older
engaged in lower versus whole body resistive exercise, 992
hypertensive women engaged in aerobic exercise, 1404
Age of FCHL subjects
and kindreds, plasma lipid- and apo B–based diagnostic criteria and, 221
lipid phenotypic expression and, 1299
and PPARγ, HSL, and C3 expression in AT, 666, 667
Age of HIV-infected subjects
on antiprotease therapy, 308
on antiretroviral therapy, 1145, 1146
and FFA in HIV lipodystrophy, 262-264
Age of hypercholesterolemic subjects
and effects of α-linoleic acid–rich *Camelina sativa* oil, 1254
of heterozygous and homozygous FH subjects, 977
Age of IDDM subjects
age of IDDM onset correlated with cytosolic low-molecular-weight protein tyrosine phosphatase, 419-422
with insulin resistance, atherosclerosis and, 942, 944-946
LEAD and, 250, 251
Na^+/K^+ ATPase regulation and, 284
and oxidative stress effects on RBC glutathione pathways, 1361
on PP biphasic insulin aspart therapy, 897
PP hyperglucagonemia and, 637
serum leptin concentration and, 293, 295
Age of insulin-resistant subjects
atherosclerosis and, 942, 944-946
obese pubertal and prepubertal children, 1012
see also Age of NIDDM subjects, insulin-resistant
Age of MS subjects
and effects of MS and hormonal status on bone density, 268
in older subjects, VDR polymorphism and, 357
serum ceruloplasmin and, 839-841
Age of NIDDM men
Japanese men, pioglitazone effects and, 315
low-glycemic index breakfast effects and, 820
Age of NIDDM subjects
apo E gene polymorphism-dependent effects of BMI, fasting TGs and, on PP lipemia, 1088-1092
beta-cell function and, 145
with combined dyslipidemia, 1356
400 or 600 mg/d CS-045 effects and, 46
FPG and PP plasma glucose concentrations and, 457
and glucagon dose-response curve for hepatic glucose production, 1112
and glycemic control with alpha-glucosidase inhibitor and sulfonylurea drug, 1549, 1550
insulin and IGF-1 action in SM and, 1172
insulin-resistant, *see* Age of NIDDM subjects, insulin-resistant
ischemic stroke and, 245, 246
of Japanese NIDDM subjects, *see* Age of NIDDM subjects, Japanese
leptin concentrations and, 305
Na^+/K^+ ATPase regulation and, 284
nateglinide effects on glucose tolerance and, 21
obese, *see* Age of NIDDM subjects, obese
with remnant-like Lp particles, 966
and response to monosaccharide ingestion, 950
see also Age of NIDDM men
Age of NIDDM subjects, insulin-resistant
atherosclerosis and, 942, 944-946
obese men, 1249, 1250
Age of NIDDM subjects, Japanese
with carotid artery IMT, 540, 541

Age of NIDDM subjects, Japanese (*Continued*)
of Japanese men, pioglitazone effects and, 315
see also Age of NIDDM subjects, Japanese non-obese insulin-resistant
Age of NIDDM subjects, Japanese non-obese insulin-resistant
CRP and, 1579
regional AT relationship to serum TGs and, 545
Age of NIDDM subjects, obese
hypofibrinolysis and coagulation and, 472, 474
of insulin-resistant obese men, BP response to exercise and, 1249, 1250
of Korean subjects, ADRB2 gene polymorphism and, 834-836
and progressively defective insulin action on GS, 550
soluble serum E-selectin and, 933
Age of non-obese subjects
with CAD, insulin secretion and, 185
non-obese men, kinetics of apo B-100, AT compartments and, 1207
see also Age of NIDDM subjects, non-obese insulin-resistant; Age of non-obese women
Age of non-obese women
PP TG response to fat-containing meal and, 213, 214
weight cycling effects and, 150
Age of obese men
engaged in long-term low-intensity exercise, 1005
of insulin-resistant obese NIDDM men, blood pressure response to exercise and, 1249, 1250
Age of obese subjects
with CAD, insulin secretion and, 185
of hypothalamic subjects, 1382
ICAM-1 levels and, 76, 77
of insulin-resistant obese pubertal and prepubertal children, 1012
with NIDDM, *see* Age of NIDDM subjects, obese
and PP TG response to fat-containing meal, 213, 214
with visceral obesity, 1043, 1045
weight loss and physiologic changes after CHO-restricted diet and structured aerobic exercise or lifestyle activity, 1529
see also Age of obese men; Age of obese women
Age of obese women
and lipolytic function of AT, race and, 1515
of nondiabetic hyperinsulinemic women, 1263
of normolipidemic women on energy-restricted diet, 1099
see also Age of obese women, postmenopausal
Age of obese women, postmenopausal
and apo E genotype effects on diet-induced changes in HDL-C, 855
race and, and effects of Trp64Arg β_3-adrenoceptor gene polymorphism, 803
Age of postmenopausal women
early postmenopausal women, plasma glycerol and, 324
on ERT, *see* Age of postmenopausal women on ERT
hyperinsulinemic women, 239, 241
obese, *see* Age of obese women, postmenopausal
Age of postmenopausal women on ERT
atherothrombosis, thrombophilia and, 727, 728
of hypercholesterolemic early postmenopausal women, and effects of ETP, simvastatin, estrogen-progestogen replacement therapy, and/or diet, 1464
plasma CE transfer and, 601
on sequential estrogen-progestin replacement therapy, 1411
Age of subjects at-risk for NIDDM
high risk, 745-747
uric acid syndrome and, 373, 374
Aging effects
on thyroid function, 105-109
see also Aging effects on SM; Older subjects
Aging effects on SM
effects of TNF neutralization on aging-induced impaired insulin responsiveness in, 1061-1064
on muscle mass in women, 935-939
AIDS (acquired immunodeficiency syndrome), *see* HIV infection
AITD (autoimmune thyroiditis), chronic, serum MCP-1 in, 1489-1493
ALA (α-lipoic acid), effects of, on NF-κB activation and monocyte adhesion by D-glucose or L-fucose, 230
Alanine (Ala)
blood, portal glucose incretin effect and concentrations of, 1324, 1325
effects of Pro12Ala polymorphism of PPARγ2 gene on serum adiponectin in Japanese subjects, 1407-1409
in infected chronic TPN subjects, 280, 281
in NIDDM, insulin replacement effects on, 1496
L-NMMA effects on concentrations of, 62
Alanine aminotransferase (ALT)
CV disease risk factors associated with elevated, in hyperlipidemia, 1071-1076
in MCS, 424-426
in parenchymal liver cirrhosis, 611
Albumin
in elderly male subjects, effects of Ca-deficient diet on, 1232
glycated, *see* Glycated albumin in DM
in parenchymal liver cirrhosis, 611
serum, *see* Serum albumin
and thyroid function in elderly subjects, 106
see also Albuminuria
Albuminuria (proteinuria)
in IDDM and NIDDM with insulin resistance and atherosclerosis, 942
in LPG, 202
troglitazone and pioglitazone effects on, in STZ-DM, 403-408
see also Microalbuminuria
Alcohol
in *Camelina sativa* oil–containing diet, 1256
in CHO-restricted diet, 866
in dietary portfolio of vegetable proteins, fiber, and plant sterols, 1597
in high- and low-isoflavone soy diet, 920
in phytosterol-enriched margarine, 191
see also Alcohol intake
Alcohol intake
by men on glucocorticoids, SIOP and, 1459
and metabolic syndrome in women, 1574
as risk factor for CHD, 196
as risk factor for CV disease, 1072, 1073
see also Alcohol intake, effects of, on SM
Alcohol intake, effects of, on SM
and cardiac muscle, *c-myc* mRNA and protein increase as, 1285-1290
see also Chronic alcohol intake, effects of, on SM
Aldehydes, plasma, chronic iron overload effects on, 647
Aldosterone
angiotensin II effects on, 894
in treadmill-exercising men, 1424
Aldosterone-producing adenoma (APA), unilateral hyperaldosteronemia compared with, 350-355
Alkaline phosphatase (ALP)
effects of Ca-deficient diet on, in elderly male subjects, 1232

Alkaline phosphatase (ALP) (*Continued*)
GH therapy effects on, in IBD children, 131
in parenchymal liver cirrhosis, 611
serum, in SCI, bone loss and, 961
Allele distribution and frequency
of CETP D442G, 396
of *LMNA* gene, 1019, 1020
Alloxan-induced diabetes mellitus (DM)
glucagon responses to hypoglycemia, neuroglycopenia, arginine, and carbachol in, 12-19
hepatic or intestinal microsomal triglyceride transfer protein and PP dyslipidemia in, 847-852
ALP, *see* Alkaline phosphatase
Alpha (α)-adrenergic inhibition, effects of, on muscle glucose uptake, blood flow and, 1505-1513
Alpha (α)-carotene (vitamin A), plant sterol effects on, 653-655
Alpha (α)-cryptoxanthin, serum, plant sterol effects on, 653, 655
5Alpha-dihydrotestosterone (5α-DHT), effects of, on apo A-I mRNA, 376-379
Alpha (α)-glucosidase inhibitor, effects of sulfonylurea drug with, on duration of glycemic control in NIDDM, 1548-1552
Alpha (α)-linoleic acid–rich *Camelina sativa* oil, effects of, on serum fatty acid composition and serum lipids in hypercholesterolemia, 1253-1260
Alpha (α)-lipoic acid (ALA), effects of, NF-κB activation and monocyte adhesion by D-glucose or L-fucose, 230
Alpha-lipoprotein, *see* High-density lipoprotein(s)
17-Alpha-methyltestosterone (17αMTT), effects of, on apo A-I gene expression, 376-379
Alpha-tocopherol, *see* Vitamin E
ALT, *see* Alanine aminotransferase
Amino acids (AAs)
plasma, GH therapy effects on, in IBD children on chronic glucocorticoid therapy, 130
see also specific amino acids
L-Amino acids in protein-free diets, 570
Aminotransferases, *see* Alanine aminotransferase; Aspartate aminotransferase
AMP (adenosine monophosphate), *see* cAMP; cAMP agonists
Amylin, plasma, effects of intermittent exercise at different intensities on, 657-663
Amyloid A, serum, high- and low-isoflavone soy diet effects on, 921
Ancestry, European and/or Chinese, and relationship between WC and metabolic risk factors, 1427-1432
Androgens
adrenal, circulating E_2 and concentrations of, in men on glucocorticoids, steroid-induced osteoporosis and, 1458-1462
effects of, on apolipoprotein A-I mRNA, 376-379
in hyperinsulinemic perimenopausal and postmenopausal women, 238-243
see also specific androgenic hormones
Androstenedione
in postmenopausal women, ACTH and cortisol response to CRH and, 139, 140
serum, in men on glucocorticoids, SIOP and, 1460
ANF (atrial natriuretic factor) in CHF, 582-588
Angiography of circulating E-selectin, VCAM-1, and ICAM-1 in men with CAD and disturbed CHO metabolism, 733-736
Angiotensin II
effects of, on urinary excretion of purine bases and oxypurinol, 893-895
plasma, in cardiomyopathy, 971
ANPs (atrial natriuretic peptides) in CHF, 582-588
Antibodies (Abs)
anticardiolipin, in IDDM children, 1148-1152
anti-oxidized LDL, C levels and, 429-431
Anticardiolipin antibodies (Abs) in IDDM children, 1148-1152
Antioxidative enzymes
renal and retinal, in DM, quantitative competitive PCR measuring, 1279-1284
see also specific antioxidant enzymes
Anti-oxidized low-density lipoprotein (LDL) antibodies (Abs), C levels and, 429-431
Antiprotease therapy, metabolic response to glucose in HIV infection before and after, 307-313
Antiretroviral therapy, lipolysis in HIV-infected men on, 1143-1147
Antithrombin III (ATIII) in hypercholesterolemic early postmenopausal women, effects of ETP, diet, simvastatin, and/or estrogen-progestogen replacement therapy on, 1468
Aortic endothelial cells, *see* Human aortic endothelial cells
APA (aldosterone-producing adenoma), unilateral hyperaldosteronemia compared with, 350-355
Apheresis, LDL, atorvastatin in homozygous and heterozygous familial hypercholesterolemia treated with, 976-980
Apnea syndrome, obstructive sleep, effects of laser-assisted uvuloplasty on sleep energy expenditure in, 622-627
Apo(s), *see specific apolipoproteins*
Apolipoprotein A (apo A) in NIDDM men, effects of low-glycemic index breakfast with soluble fiber on, 823
Apolipoprotein A-I (apo A-I)
chronic hyperthyroidism effects on kinetics of, 443-450
concentrations of, and serum T association with lower HDL-C in 10- to 15-year-old male adolescents, race and, 432-437
distribution of, in urban Mexican population, 560-568
in hypercholesterolemia, effects of dietary portfolio of vegetable proteins, fiber, and plant sterols on, 1599, 1601, 1602
in IDDM, LEAD and, 250, 251
in LPG, 202
in MCS, 425, 426
in NIDDM, *see* Apolipoprotein A-I in NIDDM
in normolipidemic obese women on energy-restricted diet, 1099
and risk of CAD, 1082
see also Apolipoprotein A-I, postmenopausal ERT effects on; Apolipoprotein A-I gene expression
Apolipoprotein A-I (apo A-I), postmenopausal ERT effects on
of estrogen-progestogen therapy, ETP, diet, and/or simvastatin in hypercholesterolemic early postmenopausal women, 1465
plasma CE transfer and, 601
of sequential postmenopausal estrogen-progestin therapy effects on, 1412
of tibolone and/or CEEs on, 526
Apolipoprotein A-I (apo A-I) gene expression in HepG2 cell line, DHEA effects on, 376-379
Apolipoprotein A-I (apo A-I) in NIDDM
with apo E gene polymorphism, 1089
cilostazol effects on, 1350, 1351
Apolipoprotein A-II (apo A-II)
chronic hyperthyroidism effects on, 445
concentrations of, and serum T association with lower HDL-C in 10- to 15-year-old male adolescents, race and, 432-437
in LPG, 202
Apolipoprotein B (apo B)
atorvastatin effects on, *see* Apolipoprotein B, atorvastatin effects on
diet effects on, *see* Apolipoprotein B, diet effects on
distribution of, in urban Mexican population, 560-568
in FCHL, *see* Apolipoprotein B in FCHL

Apolipoprotein B (apo B) (*Continued*)
in hypercholesterolemia, effects of dietary portfolio of vegetable proteins, fiber, and plant sterols on, 1599, 1601, 1602
in LPG, 202
in NIDDM, *see* Apolipoprotein B in NIDDM
plasma, *see* Plasma apolipoprotein B
postmenopausal ERT and, *see* Apolipoprotein B, postmenopausal ERT effects on
and risk of CAD, 1082
Apolipoprotein B (apo B), atorvastatin effects on
in dyslipidemia combined with impaired fasting glucose, 336, 338
in fructose-induced insulin resistance, atorvastatin effects on, 413-414
Apolipoprotein B (apo B), diet effects on
energy-restricted diet effects in normolipidemic obese women, 1099
fiber and multivitamin effects, 1168
phytosterol-enriched margarine effects, 191
psyllium effects on, sex and hormonal status and, 502
Apolipoprotein B (apo B), postmenopausal ERT effects on
of estrogen-progestogen therapy in hypercholesterolemic early postmenopausal women, 1465
plasma, tibolone and/or CEEs on, 526
plasma CE transfer and, 601
of sequential postmenopausal estrogen-progestin therapy, 1412
Apolipoprotein B (apo B) in FCHL
diagnostic criteria for FCHL in kindreds of FCHL subjects based on plasma lipids and, 218-224
PL gene polymorphism and, 1302, 1303
and PPARγ, HSL, and C3 expression in AT, 666-668
Apolipoprotein B (apo B) in NIDDM
with apo E gene polymorphism, 1089
cilostazol effects on, 1350, 1351
in dyslipidemic NIDDM, atorvastatin effects on, 336, 338
400 or 600 mg/d CS-045 effects on, 47, 48
in NIDDM men, effects of low-glycemic index breakfast with soluble fiber on, 823
Apolipoprotein B:AI (apo B:AI) in NIDDM with apo E gene polymorphism, 1089
Apolipoprotein B-48 (apo B-48) in alloxan-induced DM, hepatic or intestinal MTP effects on PP dyslipidemia and, 849, 850
Apolipoprotein B-100 (apo B-100)
in alloxan-induced DM, hepatic or intestinal MTP effects on PP dyslipidemia and, 849, 850
kinetics of, in visceral obesity, plasma apo C-III and, 1041-1046
in non-obese men, AT compartments and, 1206-1210
Apolipoprotein C-II (apo C-II)
in LPG, 202
in NIDDM, cilostazol effects on, 1350, 1351
Apolipoprotein C-III (apo C-III)
in LPG, 202
in NIDDM, cilostazol effects on, 1350, 1351
plasma, *see* Plasma apolipoprotein C-III
Apolipoprotein E (apo E)
in LPG, 202
in NIDDM, cilostazol effects on, 1350, 1351
see also Apolipoprotein E gene; Apolipoprotein E genotype; Plasma apolipoprotein E
Apolipoprotein E (apo E) gene
Arg^{25}→Cys mutation of, TG-rich Lp and HUVEC interaction with, in Lp glomerulopathy, 201-205
polymorphism of, in NIDDM, effects of age, BMI, and fasting TGs on PP lipemia on, 1088-1092
Apolipoprotein E (apo E) genotype, effects of, on diet-induced changes in HDL-C in obese postmenopausal women, 853-858
Apolipoprotein E2 (apo E2) genotype, remnant-like Lp particles in NIDDM with, 964-969
Apolipoprotein E3/3 (apo E3/3) genotype, remnant-like Lp particles in NIDDM with, 964-969
Apoptosis
mitochondrial depolarization in hyperglycemia-induced HAEC, NAC prevention of, 1384-1388
pancreatic islet, induced by chronic exposure to FFAs or high glucose, 1340-1347
PBMC, in chronic hemodialysis patients, effects of Zn metabolism, on proliferation and, 1392-1396
Appendicular lean tissue mass (LTM_A), and prevalence of sarcopenia in women, 69-74
Appetite, response of, to fructose and glucose in NIDDM, 949-957
Aquaporin 2 (AQP2), enalapril effects on inner medullary collecting duct AVP V_2 and, in cardiomyopathy, 970-975
Arg, *see* Arginine
Arg^{25}→Cys mutation, apoE gene, TG-rich Lp and HUVEC interaction with, in Lp glomerulopathy, 201-205
Argininase, and L-arginine supplementation effects on diabetic wound healing, 1269-1273
Arginine (Arg)
glucagon responses to neuroglycopenia, carbachol, hypoglycemia and, in alloxan-induced DM, 12-19
see also Arg^{25}→Cys mutation; L-Arginine; Arginine-vasopressin; Arginine-vasopressin V_2; Dimethylarginine; Trp64Arg β_3-adrenoceptor gene polymorphism
L-Arginine (Arg)
effects of supplementation with, on diabetic wound healing, 1269-1273
see also Nω-Nitro-L-arginine; N^{ω}-Nitro-L-arginine methyl ester
Arginine-vasopressin (AVP), glucose dependent on insulin and glucagon release induced by, 1184-1190
Arginine-vasopressin (AVP) V_2, effects of enalapril on inner medullary collecting duct aquaporin 2 and, in cardiomyopathy, 970-975
Arterial disease of lower extremities in IDDM, glycemia or estimated glucose disposal rate as predictors of, 248-254
Arterial proteoglycans, effects of glipizide GITS/metformin on interaction between plasma LDLs and, in NIDDM, 1223-1229
Ascorbic acid, *see* Vitamin C
ASP (acylation-stimulating protein) in FCHL, PPARγ, HSL, and C3 expression in AT and, 667, 668
Aspartate aminotransferase (AST)
CV disease risk factors associated with elevated, in hyperlipidemia, 1071-1076
in MCS, 424
AST, *see* Aspartate aminotransferase
Asthma, effects of obesity on ovalbumin-specific immune response to, 1241-1246
Asymmetric dimethylarginine (ADMA) in NIDDM, metformin effects on, 843-846
AT, *see* Adipose tissue
Atherogenic lipids, extended-release niacin therapy of Lp(a) and, in IDDM and NIDDM, 1120-1127
Atherosclerosis
in IDDM and NIDDM, insulin resistance and, 941-948
preclinical carotid artery, in women, impaired glucose homeostasis and, 52-56
Atherothrombosis, thrombophilia, and postmenopausal ERT, 724-732

Atorvastatin
effects of, on hepatic VLDL production in fructose-induced insulin resistance, 409-418
see also Atorvastatin, LDL and
Atorvastatin, LDL and
effects of, on LDL particles in dyslipidemia with impaired fasting glucose or NIDDM, 334-342
in homozygous and heterozygous familial hypercholesterolemia treated with LDL apheresis, 976-980
ATP1-A1 polymorphism, and Na^+/K^+ ATPase regulation in IDDM and NIDDM, 284-289
ATPase (adenosine triphosphatase), *see* Na^+/K^+ ATPase
Atrial natriuretic factor (ANF) in CHF, 582-588
Atrial natriuretic peptides (ANPs) in CHF, 582-588
ATIII (antithrombin III) in hypercholesterolemic early postmenopausal women, effects of ETP, diet, simvastatin, and/or estrogen-progestogen replacement therapy on, 1468
Autoimmune thyroiditis (AITD), chronic, serum MCP-1 in, 1489-1493
Autophosphorylation of IR in obesity with insulin resistance, plasma cell membrane glycoprotein and, 465-470
Δ (delta)-5-Avenasterol, *see* Delta-5-avenasterol
AVP, *see* Arginine-vasopressin; Arginine-vasopressin V_2
Azotemia, and thyroid function in elderly subjects, 106

Balloon injury, effects of neointimal formation inhibition by troglitazone on blood flow after, 998-1002
Basal glucose transport in high-fat diet, effects of chronic leptin treatment on, 859-863
Basal metabolic rate (BMR) in OSAS, 623-625
BAT (brown adipose tissue), *see* High-protein diet, adaptation to, BAT and
BBB (blood-brain barrier), adaptation of, to elevated brain glucose levels in DM with chronic hyperglycemia, 1522-1524
Beer, effects of, on plasma uridine and purine bases, 1317-1323
Berberine, effects of, on hyperglycemia, 1439-1443
Beta (β)-adrenergic inhibition, effects of, on muscle glucose uptake and blood flow, 1505-1513
$Beta_2$ (β_2)-adrenergic receptor ($ADR\beta_2$) gene polymorphism in obese Korean NIDDM subjects, 350-355
Beta (β)-carotene (vitamin A), serum, plant sterol effects on, 653, 655
Beta (β) cells, 110-120
contribution of insulin sensitivity and function of, to plasma glucose and insulin concentrations during OGTT, 115-120
function of, in late-onset DM Japanese subjects carrying homozygous *NeuroD1* and *Pax4* mutations, 1161-1165
glycolysis-derived NADH oxidation and, 318-321
GR of, in non-obese diabetic subjects during postnatal development, 765-768
HOMA insulin resistance index and function of, in obese pubertal and prepubertal children, 1011-1016
lipotoxicity effects on, *see* Beta cells, lipotoxicity effects on
in NIDDM, declining function of, 144-148
see also Insulin release and secretion
Beta (β) cells, lipotoxicity effects on, 155-168
acute and/or chronic lipotoxicity effects on gene expression and, 155-162
and biotin effects on glucotoxicity or lipotoxicity, 163-168
Beta (β)-cryptoxanthin, plant sterol effects on, 653, 655
Beta-estradiol, *see* β-Estradiol in postmenopausal women
Beta (β)-hydroxyacyl-CoA dehydrogenase (β-HADH), effects of ovariectomy and estradiol replacement therapy on SM GS, PFK, CS and, 1397-1401
Beta (β)-hydroxy-5-androsten-17-one (dehydroepiandrostenedione) in postmenopausal women, ACTH and cortisol response to CRH and, 139, 140
Beta-hydroxybutyrate, *see* Plasma β-hydroxybutyrate
Beta-lipoprotein, *see* Low-density lipoprotein(s)
Beta (β)-oxidation disorders of mitochondrial fatty acid, similarities between fibroblast acylcarnitine in RC defects and, 366-371
Beta-tocopherol, *see* Vitamin E
BGLIIA*2/BGLIIB*1 haplotype, GH, in glucose-intolerant NIDDM children with GH deficit-related growth retardation, 1-4
Bilirubin in parenchymal liver cirrhosis, 611
Binding proteins
cellular A11-*trans*-retinoic acid, RA catabolism and, 478
see also Fatty acid binding protein-2 gene polymorphism; Insulin-like growth factor-binding protein 3
Biochemical effects
of long-term fructose intake on renal histology, 1538-1547
see also specific biochemical substances
Biomarkers
dual-energy x-ray absorptiometry and, in evaluation of bone loss in SCI, 958-966
inflammatory, effects of low- and high-isoflavone soy diet on, in middle-age men and women, 919-924
Biomechanical properties of bone, dietary xylitol effects on, in elderly subjects, 92-96
Biotin
in alcohol-containing diet, 1563
effects of, on glucotoxicity or lipotoxicity in beta-cells, 163-168
Biphasic insulin aspart, PP, for IDDM, 896-900
Black Americans, *see* Race and ethnicity
Blood alanine (Al), portal glucose incretin effect on, 1324, 1325
Blood-brain barrier (BBB), adaptation of, to elevated brain glucose levels in DM with chronic hyperglycemia, 1522-1524
Blood flow
AT, high-fat or high-CHO diet effects on, during exercise, 1294, 1295
effects of neointimal formation inhibition by troglitazone on, after balloon injury, 998-1002
muscle, effects of α- and β-adrenergic inhibition on muscle glucose uptake and, 1505-1513
Blood glucose
Cr picolinate supplementation effects on, 590
in IDDM, *see* Blood glucose in IDDM
immobilization stress effects on, 927
in NIDDM, *see* Blood glucose in NIDDM
in STZ-DM, *see* Blood glucose in STZ-DM
see also Fasting blood glucose; Hyperglycemia; Hypoglycemia
Blood glucose in IDDM
age of IDDM onset and, 420
see also Fasting blood glucose in IDDM
Blood glucose in NIDDM
glucose ingestion and, 951
in non-obese NIDDM subjects, NG and glibenclamide effects on diabetic neuropathy and, 1452-1457
Blood glucose in STZ-DM
pioglitazone and troglitazone effects on, 405
SM lactate transport and, 809
Blood glycerol, portal glucose incretin effect on, 1324, 1325
Blood glycine, portal glucose incretin effect on, 1324, 1325
Blood insulin
in STZ-DM subjects, SM lactate transport and, 809
see also Hyperinsulinemia

Blood lactate
in endurance exercise, effects of high-fat and high-carbohydrate diets on, compared, 683-686
portal glucose incretin effect on, 1324, 1325
Blood mononuclear cells, peripheral, Zn metabolism effects on apoptosis and proliferation of, in chronic hemodialysis patients, 1392-1396
Blood pressure (BP)
angiotensin II effects on, 894
anti-oxidized LDL antibody effects on, 430
and apo A-I and B distribution in urban Mexican population, 563-565
in carotid artery atherosclerosis, 53
diet effects on, *see* Blood pressure, diet effects on
effects of oral contraceptives on, 1217
in epilepsy, 1275
hormonal status, metabolic syndrome and, 268, 269
in hypercholesterolemia, effects of dietary portfolio of vegetable proteins, fiber, and plant sterols on, 1599
in IDDM, *see* Blood pressure in IDDM
in MCS, 424-426
in microalbuminuric men, insulin metabolism and, 751, 752
in MS, *see* Blood pressure in MS
in NIDDM, *see* Blood pressure in NIDDM
in non-obese subjects, *see* Blood pressure in non-obese subjects
pioglitazone and troglitazone effects on, *see* Blood pressure, TZD effects on
in postmenopausal women, *see* Blood pressure in postmenopausal women
and renal microvascular response in obesity, 1555
as risk factor for metabolic syndrome in women, 1574
and risk factors for CV disease, 1036, 1038, 1072, 1073
in unilateral hyperaldosteronemia, 351, 353
and uric acid syndrome in subjects at risk for NIDDM, 373, 374
in visceral obesity, 1043
WC and metabolic risk factors and, 1428, 1429
see also Hypertension; Normotensive subjects
Blood pressure (BP), diet effects on
fiber and multivitamin effects, 1168
in hypercholesterolemia, effects of α-linoleic acid–rich *Camelina sativa* oil on, 1254
in infected subjects on chronic TPN, 276
Blood pressure (BP), TZD effects on
pioglitazone effects in Japanese NIDDM men, 351
pioglitazone and troglitazone effects in STZ-DM, 405
Blood pressure (BP) in IDDM
with insulin resistance and atherosclerosis, 942, 944, 945
LEAD and, 250, 251
Blood pressure (BP) in Japanese NIDDM subjects
with carotid artery IMT, 540, 541
in Japanese men, pioglitazone effects on, 315
Blood pressure (BP) in MS
in older MS subjects, VDR polymorphism and, 357, 358
serum ceruloplasmin and, 839, 840
Blood pressure (BP) in NIDDM
chronic L-NAME effects on, 703-704
with insulin resistance, *see* Blood pressure in NIDDM with insulin resistance
and ischemic stroke, 245, 246
in Japanese NIDDM subjects, *see* Blood pressure in Japanese NIDDM subjects
in Korean obese subjects, ADRB2 gene polymorphism and, 834-836
leptin concentrations and, 305
Blood pressure (BP) in NIDDM (*Continued*)
and metformin effects on asymmetric ADMA, 844
Blood pressure (BP) in NIDDM with insulin resistance
and atherosclerosis, 942, 944, 945
and BP response to exercise by obese insulin-resistant NIDDM men, 1247-1252
Blood pressure (BP) in non-obese subjects
with CAD, insulin secretion and, 185
non-obese men, short-term metformin therapy effects on, 532, 533
young women, weight cycling effects on, 151
Blood pressure (BP) in postmenopausal women
in hyperinsulinemic women, 239
see also Blood pressure in postmenopausal women on ERT
Blood pressure (BP) in postmenopausal women on ERT
atherothrombosis, thrombophilia and, 727, 728
plasma CE transfer and, 601
Blood serine (Ser), portal glucose incretin effect on, 1324, 1325
Blood threonine (Thr), portal glucose incretin effect on, 1324, 1325
Blood urea nitrogen (BUN) in LPG, 202
Blood vessels
dilators of, in CHF, 582-588
exposed to L-NAME, relaxation of, 383
see also specific blood vessels
BM 15.766, effects of, on hepatic and testicular neutral sterols, 492-499
BMD, *see* Bone mineral density
BMI, *see* Body mass and body mass index
BMR (basal metabolic rate) in OSAS, 623-625
BNP (brain natriuretic peptides), circulating, in treadmill-exercising men, 1423-1426
Body Ca (calcium), total, in women, ethnic variations in, 181
Body composition
and bone loss in spinal cord injury, 959-960
and effects of TNF neutralization on insulin responsiveness in SM, 1062
and hormonal responses to CHO-restricted diet, 864-870
of obese postmenopausal women, effects of Trp64Arg β_3-adrenoceptor gene polymorphism on, race and, 801-805
of older hypertensive women, aerobic exercise effects on, 1403
see also Adipose tissue; Fat-free mass; Fat mass
Body fat, *see* Adipose tissue
Body K (potassium), total, in women, ethnic variations in, 181
Body mass and body mass index (BMI)
and adrenal androgen concentrations and circulating E_2 in men on glucocorticoid therapy, 1459
of aging women, muscle mass and, 936
and apo A-I and B distribution in urban Mexican population, 563-565
of CAD men, 734
and carotid artery atherosclerosis in women, 53
of cigarette-smoking women, 1314
cilostazol effects on, 1350
of CPEO subjects, 797
diet and, *see* Body mass and body mass index, diet effects on
and effects of oral contraceptives, 1217
and effects of Pro12Ala polymorphism of PPARγ2 gene on serum adiponectin in Japanese subjects, 1408
of epileptic subjects, 1275, 1276
exercise and, *see* Body mass and body mass index of exercising subjects
fasting insulin level, plasma pollutant level, weight loss and, 484
of FCHL subjects, *see* Body mass and body mass index of FCHL subjects

Body mass and body mass index (BMI) (*Continued*)
of FH subjects, effects of α-linoleic acid–rich *Camelina sativa* oil and, 1254
of head trauma subjects, 1364
of HIV-infected subjects, *see* Body mass and body mass index of HIV-infected subjects
of HTN subjects, glucose metabolism-insulin release interaction and, 299
of IDDM subjects, *see* Body mass and body mass index of IDDM subjects
and influence of hormonal status and metabolic syndrome on bone density, 268, 269
insulin regulation of FFAs and, 780
of Japanese subjects with late-onset DM, 1162, 1163
of MCS subjects, 424-426
of microalbuminuric men, insulin metabolism and, 751, 752
of middle-age and premenopausal women, plasma glycerol and, 324
of MS subjects, *see* Body mass and body mass index of MS subjects
of NIDDM subjects, *see* Body mass and body mass index of NIDDM subjects
of NIDDM subjects' relatives, 1332
of non-obese subjects, *see* Body mass and body mass index of non-obese subjects
of normotensive nondiabetic subjects, carotid artery intima-media thickening and, 256, 257
of obese subjects, *see* Body mass and body mass index of obese subjects
of older subjects, *see* Body mass and body mass index of older subjects
of OSAS subjects, 623
ovariectomy and estradiol replacement therapy effects on SM enzymes and, 1399
of pituitary adenoma subjects, 35
and plasma leptin after unilateral nephrectomy, 207
of postmenopausal women, *see* Body mass and body mass index of postmenopausal women
as risk factor, *see* Body mass and body mass index, as risk factor
and risk for NIDDM, *see* Body mass and body mass index of subjects at-risk for NIDDM
and sarcopenia, 70
of SCI subjects, 960
sex- and age-specific plasma Hcy correlation with MDA and, 1434
of 10- to 15-year-old male adolescents, serum T association with lower HDL-C and, 433, 434
WC and metabolic risk factors and, 1428, 1429
see also Fat-free mass; Fat mass

Body mass and body mass index (BMI), diet effects on
effects of low-glycemic index breakfast with fiber in NIDDM men, 820
oral L-carnitine supplementation effects, 1390
in overfed young men, 452-454

Body mass and body mass index (BMI), as risk factor
for CAD, 1082, 1085
for CHD, 196
for CV disease, 1035, 1038, 1072, 1073

Body mass and body mass index (BMI) in endurance exercise
cortisol response to exercise and, 362
of obese NIDDM men, BP response to exercise and, 1249, 1250

Body mass and body mass index (BMI) of exercising subjects
effects of high-fat or high-CHO diet on lipolysis in AT and, 1292

Body mass and body mass index (BMI) of exercising subjects (*Continued*)
long-term effects of low-intensity exercise on BMI in obese weight-reduced men, 1005
of obese women, weight loss and physiologic changes after CHO-restricted diet and structured aerobic exercise or lifestyle activity, 1529
of older hypertensive women engaged in aerobic exercise, 1404
oxidation of MCFAs and LCFAs in skeletal muscle and, 461
see also Body mass and body mass index in endurance exercise

Body mass and body mass index (BMI) of FCHL subjects
lipid phenotypic expression and, 1299
PPARγ, HSL, and C3 expression in AT, 666-668

Body mass and body mass index (BMI) of HIV-infected subjects
antiprotease therapy and, 308
on antiretroviral therapy, 1145, 1146
AT redistribution and, 263, 264

Body mass and body mass index (BMI) of IDDM subjects
of IDDM children, relationship of, to serum leptin concentration, 292-296
Na^+/K^+ ATPase regulation and, 284

Body mass and body mass index (BMI) of MS subjects
older subjects, VDR polymorphism and, 357
serum ceruloplasmin and, 839-841

Body mass and body mass index (BMI) of NIDDM men
effects of low-glycemic index breakfast with soluble fiber and, 820
Japanese men, pioglitazone effects on, 315
of obese NIDDM men engaged in endurance exercise, 1249, 1250

Body mass and body mass index (BMI) of NIDDM subjects
beta-cell function and, 145
and duration of glycemic control with alpha-glucosidase inhibitor and sulfonylurea drug, 1549, 1550
effects of age, fasting TGs and, on PP lipemia dependent on apo E gene polymorphism in NIDDM, 1088-1092
FPG and PP plasma glucose concentrations and, 457
and glucagon dose-response curve for hepatic glucose production, 1112
insulin and IGF-1 action in SM and, 1172
with insulin resistance and atherosclerosis, 942, 945
ischemic stroke and, 245
leptin concentrations and, 305
Na^+/K^+ ATPase regulation and, 284
and nateglinide effects on glucose tolerance, 21
older, VDR polymorphism and, 357
with remnant-like Lp particles, 966
response to monosaccharide ingestion and, 950
see also Body mass and body mass index of NIDDM men; Body mass and body mass index of NIDDM subjects, Japanese; Body mass and body mass index of NIDDM subjects, obese; Body mass and body mass index of NIDDM subjects, TZD effects on

Body mass and body mass index (BMI) of NIDDM subjects, Japanese
Japanese men, pioglitazone effects on, 315
non-obese insulin-resistant subjects, 1579
obese, with carotid artery IMT, 540, 541

Body mass and body mass index (BMI) of NIDDM subjects, obese
hypofibrinolysis and coagulation and, 472
in Japanese subjects with carotid artery IMT, 540, 541
Korean subjects, ADRB2 gene polymorphism and, 834-836
and progressive defect of insulin action on GS, 550
soluble serum E-selectin and, 933

Body mass and body mass index (BMI) of NIDDM subjects, TZD effects on
hypoglycemic and nonhypoglycemic effects of 400 or 600 mg/d CS-045, 46, 47
pioglitazone effects on, in Japanese men, 315
and TZD effects on FA flux, 171
Body mass and body mass index (BMI) of non-obese subjects
with CAD, insulin secretion and, 185
Japanese insulin-resistant subjects, 1579
of non-obese men, AT compartments and kinetics of apo B-100 and, 1207
see also Body mass and body mass index of non-obese women
Body mass and body mass index (BMI) of non-obese women
and PP TG response to fat-containing meal, 213, 214
young women, weight cycling effects on, 150
Body mass and body mass index (BMI) of obese men
long-term effects of low-intensity exercise by weight-reduced obese men on, 1005
of NIDDM men engaged in endurance exercise, 1249, 1250
nondiabetic obese men, 1480
Body mass and body mass index (BMI) of obese postmenopausal women
and apo E genotype effects on diet-induced changes in HDL-C, 855
Trp64Arg β_3-adrenoceptor gene polymorphism and, 803
Body mass and body mass index (BMI) of obese subjects
with CAD, insulin secretion and, 185
ICAM-1 levels and, 76, 77
of insulin-resistant obese pubertal and prepubertal children, 1012
with NIDDM, *see* Body mass and body mass index of NIDDM subjects, obese
polymorphism of exon 3 of POMC gene and, 643
see also Body mass and body mass index of obese men; Body mass and body mass index of obese women
Body mass and body mass index (BMI) of obese women
lipolytic function of AT and, race and, 1515
nondiabetic hyperinsulinemic, 1263
normolipidemic, on energy-restricted diet, 1099
weight loss by, and physiologic changes after CHO-restricted diet and structured aerobic exercise or lifestyle activity, 1529
see also Body mass and body mass index of obese postmenopausal women
Body mass and body mass index (BMI) of older subjects
and centenarians, thyroid function and, 106
with MS, VDR polymorphism and, 357
Body mass and body mass index (BMI) of postmenopausal women
and ACTH and cortisol response to CRH, 139, 140
early postmenopausal women, plasma glycerol and, 324
of hypercholesterolemic early postmenopausal women, effects of ETP, diet, simvastatin, and/or estrogen-progestogen replacement therapy on, 1464
hyperinsulinemic women, 239, 241
obese, *see* Body mass and body mass index of obese postmenopausal women
on sequential estrogen-progestogen replacement therapy, 1411
Body mass and body mass index (BMI) of subjects at-risk for NIDDM
high risk for NIDDM, 745-747
uric acid syndrome and, 373, 374
Body phosphorus (P), total, in women, ethnic variations in, 180-183
Body weight (BW)
of alloxan-induced DM subjects, PP dyslipidemia and, 849
of cardiomyopathic subjects, enalapril effects and, 971
of chronic AITD subjects, 1490
Body weight (BW) (*Continued*)
and chronic hyperthyroidism effects on HDL structure and apo A-I kinetics, 445
chronic iron overload effects on, 647
diet effects on, *see* Body weight, diet effects on
exercise and, *see* Body weight, exercise effects on
and FM increase in overfed young men, 452-454
of HIV-infected men on antiretroviral therapy, 1145
and influence of hormonal status and metabolic syndrome on bone density, 268, 269
of MCS subjects, 424
of NIDDM subjects, *see* Body weight of NIDDM subjects
of nondiabetics, chronic L-NAME effects on, 703
normal, *see* Non-obese subjects
of pancreatectomized subjects, FXTN effects on, 40
of postmenopausal women, *see* Body weight of postmenopausal women
and PP TG, NEFA, and/or incretin response to sucrose by men at risk for CHD, 195-200
and sarcopenia, 70
of SCI subjects, 960
of STZ-DM subjects, *see* Body weight of STZ-DM subjects
and TBP in women, 181, 182
of 10- to 15-year-old male adolescents, serum T association with lower HDL-C and, 433, 434
TNF-α effects on, 1105
and troglitazone inhibition of neointimal formation after balloon injury, 999; *see also* Body weight of NIDDM subjects, CS-045 effects on
see also Body weight cycling; Non-obese subjects; Obesity
Body weight (BW), diet effects on
apo E genotype effects on diet-induced changes obese women, 855
effects of dietary portfolio of vegetable proteins, fiber, and plant sterols, 1599
effects of high-fat and high-CHO diet on lipolysis in AT in exercising subjects, 1292
of hyperlipidemic subjects, HF diet effects on, 1145
and intentional weight cycling by young women on energy-restricted diet, 149-154
loss of, *see* Men, obese, weight loss by; Women, obese, weight loss by
of malnourished children with and without acute infection, 1419
see also Body weight, diet effects on, in NIDDM; Body weight, supplementation effects on
Body weight (BW), diet effects on, in NIDDM
in NIDDM men, effects of low-glycemic index breakfast with soluble fiber, 820
response to monosaccharide ingestion and, 950
Body weight (BW), exercise effects on
CETP genotype and, 776
endurance exercise effects in sedentary subjects, 1056
of exercising subjects, effects of high-fat and high-CHO diet on lipolysis in AT and, 1292
long-term effects of low-intensity exercise in obese weight-reduced men, 1005
of lower versus whole body resistive exercise in older men and women, 992
Body weight (BW), supplementation effects on
of Cr picolinate in dexamethasone-treated subjects, 589-594
of creatine, 519
of oral L-carnitine, 1390
of vitamin C, 515

Body weight (BW) cycling, effects of, on non-obese young women, 149-154
Body weight (BW) of NIDDM men
effects of low-glycemic index breakfast with soluble fiber on, 820, 822
Japanese NIDDM men, pioglitazone effects on, 315
Body weight (BW) of NIDDM subjects
chronic L-NAME effects on, 703
with combined dyslipidemia, 1356
CS-045 and, *see* Body weight of NIDDM subjects, CS-045 effects on
effects of GK gene transfer to SM on, 122-123
and metformin effects on asymmetric ADMA, 844
and progressive defect of insulin action on GS, 550
see also Body weight, diet effects on, in NIDDM; Body weight of NIDDM men
Body weight (BW) of NIDDM subjects, CS-045 effects on
hypoglycemic and nonhypoglycemic effects of 400 or 600 mg/d CS-045, 46
on lipid kinetics, 171
Body weight (BW) of postmenopausal women
obese women, and apo E genotype effects on diet-induced changes in HDL-C, 855
see also Body weight of postmenopausal women of ERT
Body weight (BW) of postmenopausal women of ERT
plasma CE transfer and, 601
on sequential estrogen-progestin replacement therapy on, 1411
Body weight (BW) of STZ-DM subjects
pioglitazone and troglitazone effects on, 405
SM lactate transport and, 809
Bone(s)
dietary xylitol effects on biomechanical properties of, in elderly subjects, 92-96
of IBD children on chronic glucocorticoid therapy, GH therapy effects on, 130, 131
longitudinal metabolic process of bone growth in CAH and NESS, 1377-1380
scintigraphy of, in prostate cancer, urinary levels of type I collagen-cross-linked N telopeptide correlated with results of, 814-818
see also Bone loss; Bone mass; Bone mineral density *and element*: Osteo-
Bone biochemical markers with dual-energy x-ray absorptiometry for bone loss evaluation in SCI, 958-963
Bone loss
in SCI, bone biochemical markers and dual-energy x-ray absorptiometry for evaluation of, 958-963
vertebral, effects of long-term strontium ranelate therapy on, 906-911
Bone mass, vertebral, effects of long-term therapy with strontium ranelate on, 906-911
Bone mineral density (BMD)
and bone loss in spinal cord injury, 958-963
calcium-deficient diet effects on, in elderly male subjects, 1230-1234
in hypothalamic obesity, 1382
influence of hormonal status and metabolic syndrome on, 267-270
in men on glucocorticoids, 1459
Bone resorption, *see* Bone loss
Bound leptin, and plasma leptin after unilateral nephrectomy, 207
BP, *see* Blood pressure
Brain
BBB adaptation to elevated levels of glucose in, in DM with chronic hyperglycemia, 1522-1524
Brain (*Continued*)
gender-dependent chronic alcohol intake effects on c-Fos and HSP70 gene expression in different regions of, 1562-1568
Brain glucose, elevated levels of, in DM with chronic hyperglycemia, BBB adaptation to, 1522-1524
Brain natriuretic peptides (BNP), circulating, in treadmill-exercising men, 1423-1426
Brassicasterol
effects of, on serum fat-soluble vitamins and carotenoids, 653
in phytosterol-enriched margarine, 190
8-Br-cGMP (8-bromo-cyclic guanosine monophosphate), effects of, on ClO^--exposed hepatocytes, 175-179
Breakfast, low-glycemic index, with soluble fiber in NIDDM men, 819-826
8-Bromo-cyclic guanosine monophosphate (8-Br-cGMP), effects of, on ClO^--exposed hepatocytes, 175-179
Brown adipose tissue, *see* High-protein diet, adaptation to, BAT and
BUN (blood urea nitrogen) in LPG, 202
BW, *see* Body weight

C, *see* Cholesterol
C3 (complement 3), expression of HSL, PPARγ and, in AT of FCHL subjects, 664-670
Ca and Ca^{2+} (calcium)
in alcohol-containing diet, 1563
chelated intracellular, HF diet and effects of, on insulin sensitivity, 912-918
effects of GH therapy of IBD children on chronic glucocorticoid therapy on kinetics of, 130, 131
homeostasis of, in spinal cord injury, 960, 961
lung cancer-associated hypercalcemia, PTH and PTHrp in, 871-875
metabolism of, in men on glucocorticoids, SIOP and, 1459-1460
total body, in women, ethnic variations in, 181
see also Ca-deficient diet; Ca signaling
Ca (calcium)-deficient diet, effects of, on BMD and estrogen in elderly male subjects, 1230-1234
Ca (calcium) signaling in cytoskeleton, gluconeogenesis and, 80-81, 83
CAD, *see* Coronary artery disease
CAH (congenital adrenal hyperplasia), longitudinal metabolic process of bone growth in NESS and, 1377-1380
Calciferol, *see* Vitamin D; Vitamin D receptor polymorphism
Calcitonin, serum, in lung cancer associated with hypercalcemia, 872
Calcium, *see* Ca
Calories
in breast milk and formula, 27
contained in fiber and multivitamin therapy, 1169
see also Calorimetry; Diet; Thermic effect of a meal *and entries beginning with term*: Energy
Calorimetry, indirect, of progressively defective insulin action on GS in NIDDM with obesity, 550
Camelina sativa oil, effects of α-linoleic acid–rich, on serum fatty acid composition and serum lipids in hypercholesterolemia, 1253-1260
cAMP (cyclic adenosine monophosphate), serum and urinary, in lung cancer associated with hypercalcemia, 872
cAMP (cyclic adenosine monophosphate) agonists, DMP effects on insulin release in response to nutrient secretagogues and, 110-114
Campestanol in phytosterol-enriched margarine, 190, 191
Campesterol
effects of, on serum fat-soluble vitamins and carotenoids, 653
hepatic and testicular, simvastatin, pravastatin, and BM 15.766 effects on, 494-496

Campesterol (*Continued*)
in phytosterol-enriched margarine, 190-192
serum, as potential risk factor for CHD, 1519-1521
Captopril, effects of, on unilateral hyperaldosteronemia, 350-355
Carbachol, glucagon responses to hypoglycemia, arginine, neuroglycopenia and, in alloxan-induced DM, 12-19
Carbohydrate(s) (CHO)
normoglycemia effects on oxidation of, in NIDDM, 1484-1488
see also Carbohydrate(s), intake of; Carbohydrate metabolism *and specific carbohydrates*
Carbohydrate(s) (CHO), intake of
with alcohol-containing diet, 1563
and apo E genotype effects on diet-induced changes in HDL-C in obese postmenopausal women, 855
with breast milk and formula, 27
with *Camelina sativa* oil–containing diet, 1256
with dietary portfolio of vegetable proteins, fiber, and phytosterols, 1597
with fiber and multivitamins, 1169
with HF diet, 709
with high- and low-isoflavone soy diet, 920
by normolipidemic obese women on energy-restricted diet, 1099
by older men and women engaged in lower versus whole body resistive exercise, 990
phytosterol-enriched margarine and, 191
and risk factor for CHD, 196
see also Carbohydrate-restricted diet; High-fat diet, effects of high-CHO or, exercise and
Carbohydrate (CHO) metabolism
angiography of circulating E-selectin, VCAM-1, and ICAM-1 in men with CAD and disturbed, 733-736
GH therapy effects on, in IBD children on chronic glucocorticoid therapy, 130-131
Carbohydrate (CHO)-restricted diet
body composition and hormonal responses to, 864-870
with structured aerobic exercise or lifestyle activity, weight loss and physiologic changes after, 1528-1533
Cardiac muscle, alcohol intake and *c-myc* mRNA increase in, 1285-1290
Cardiomyopathy, enalapril effects on IMCD aquaporin 2 and AVP V_2 in, 970-975
Cardiovascular disease, *see* Risk factors for CV disease
Cardiovascular fitness, and exercise, muscle lipid oxidation and, 462
Cardiovascular syndrome, metabolic, in obese prepubertal children, fasting insulin in, 423-428
Cardiovascular system, *see entries beginning with terms*: Aortic, Arterial, Coronary, Heart, Vascular, Venous *element*: Card- *specific blood vessels and conditions*
L-Carnitine, effects of oral supplementation with, on LCFA oxidation, 1389-1391
Carnitine palmitoyl transferase-1 (CPT-1) expression in INS-1 cells, effects of acute and/or chronic lipotoxicity on, 155-162
α (alpha)- and β (beta)-Carotene, plant sterol effects on, 653, 655
Carotenoids, serum, effects of plant sterols on, 652-656
Carotid artery intima-media thickening (IMT)
LDL-C and insulin resistance effects on, in normotensive nondiabetic subjects, 255-259
preclinical carotid artery sclerosis in women and, 52-56
see also Carotid artery intima-media thickening in NIDDM
Carotid artery intima-media thickening (IMT) in NIDDM
correlation between ischemic stroke and, 244-247
ultrasound of, in Japanese NIDDM subjects, 539-543
Casein
in HF diet, 918
Casein (*Continued*)
in protein-free diets, 570
Catalase, retinal and renal, in DM, measurement of, 1279-1284
Catecholamines
glucose-induced stimulation of, 761-764
see also Epinephrine; Norepinephrine
Caucasian population, *see* Race and ethnicity
CβS, *see* Cystathionine-β-synthase
CE, *see* Cholesteryl ester(s)
CEEs (conjugated equine estrogens), *see* Estrogen-progestin replacement therapy, postmenopausal, effects of, on C efflux potential; Estrogen-progestogen replacement therapy, postmenopausal
Cell adhesion
monocyte, to EC monolayers, effects of L-fucose and D-glucose concentrations on activation of nuclear factor-κB and, 225-234
see also Intercellular adhesion molecule-1; Vascular cell adhesion molecule-1
Cell differentiation, preabdominal subcutaneous preadipocyte, omental differentiation compared with, 1211-1215
Cell membrane
cholesterol release from, to PP plasma in mild hypercholesterolemia, olive and safflower oil effects on, 1306-1312
see also entries beginning with terms: Erythrocyte membrane
Cell proliferation
in head and neck squamous cell carcinoma, retinoic acid 4-hydroxylase-mediated RA catabolism and, 477-481
PBMC apoptosis and, in chronic hemodialysis patients, Zn metabolism effects on, 1392-1396
Cellular A11-*trans*-retinoic acid binding proteins (CRABPs), RA catabolism and, 478
Centenarians, thyroid function in, 105-109
Ceruloplasmin, serum, in MS, 838-842
CETP, *see* Cholesteryl ester transfer protein
c-Fos gene expression, gender-dependent chronic alcohol intake effects on HSP70 and, in different brain regions, 1562-1568
cGMP (cyclic guanosine monophosphate), 8-bromo-Br, effects of, on hepatocytes submitted to ClO^--induced stress, 175-179
CHD (coronary heart disease), *see* Risk factors for CHD
ChE (cholinesterase) in MCS, 424, 425
Chelated intracellular Ca^{2+} (calcium), effects of HF diet and, on insulin sensitivity, 912-918
Chemoattractant protein-1, *see* Monocyte chemoattractant protein-1; Monocyte chemoattractant protein-1 mRNA
CHF (congestive heart failure), ANPs in, 582-588
Childhood
fetal nutrition and muscle oxygen supply in, 1569-1572
see also Children
Children
IBD, on chronic glucocorticoid therapy, GH therapy effects on, 127-135
IDDM, *see* Children, IDDM
long-term effects of dietary C level on synthesis and concentrations of circulating cholesterol in infants, 25-33
malnourished, with and without acute infection, urea production and leucine oxidation in, 1418-1422
prepubertal, *see* Prepubertal children
obese, *see* Obese children
see also Growth and development; Growth retardation
Children, IDDM
anticardiolipin antibodies in, 1148-1152

Children, IDDM (*Continued*)
relationship between insulin dose and serum leptin concentrations in, 292-296
Chinese ancestry, and relationship between WC and metabolic risk factors, 1427-1432
CHO(s), *see* Carbohydrate(s)
Cholestanol
hepatic and testicular, simvastatin, pravastatin, and BM 15.766 effects on, 494-496
in phytosterol-enriched margarine, 191
Cholesterol (C)
in alloxan-induced DM, hepatic or intestinal MTP effects on PP dyslipidemia and, 849, 850
anti-oxidized LDL antibodies and levels of, 429-431
apo A-I and B distribution and, in urban Mexican population, 563-565
C efflux potential of, *see* Estrogen-progestin replacement therapy, postmenopausal, effects of, on C efflux potential
CETP genotype and exercise effects on, 776
in CPEO, 797
dietary, *see* Dietary cholesterol intake
effects of, on serum fat-soluble vitamins and carotenoids, 653
hepatic and testicular, simvastatin, pravastatin, and BM 15.766 effects on, 494, 495
in HTN, glucose metabolism-insulin release and, 299
in hyperlipidemic subjects on HF diet, effects of exercise on, 1592
and lipolysis in HIV-infected men on antiretroviral therapy, 1145
in microalbuminuric men, insulin metabolism and, 751, 752
in NIDDM, *see* Cholesterol in NIDDM
in non-obese men, AT compartments and kinetics of apo B-100 and, 1207, 1208
in normotensive nondiabetic subjects, carotid artery IMT and, 256, 257
in obesity, *see* Cholesterol in obesity
in parenchymal liver cirrhosis, 611, 612
plasma, *see* Plasma cholesterol
in postmenopausal women, *see* Cholesterol in postmenopausal women
and risk factors for CV disease, 1038, 1072, 1073
serum, *see* Serum cholesterol
total, *see* Total cholesterol
and uric acid syndrome in subjects at risk for NIDDM, 373, 374
see also Dehydrocholesterol; High-density lipoprotein-cholesterol; Hypercholesterolemia; Intermediate-density lipoprotein-cholesterol; Lecithin:cholesterol acyltransferase; Low-density lipoprotein-cholesterol; Very-low-density lipoprotein-cholesterol
Cholesterol (C) in NIDDM
400 or 600 mg/d CS-045 effects on, 47, 48
in postmenopausal women, and apo E genotype effects on diet-induced changes in, 855
and PP lipemia, apo E gene polymorphism-dependent effects of age, BMI and fasting TGs on, 1089
and risk factors for CHD, 196
see also Cholesterol in NIDDM men
Cholesterol (C) in NIDDM men
effects of low-glycemic index breakfast with soluble fiber on, 820
in obese Swedish men, polymorphism of exon 3 of POMC gene and, 643
Cholesterol (C) in obesity
in NIDDM Swedish men with polymorphism of exon 3 of POMC gene and, 643
in postmenopausal obese women, and apo E genotype effects on diet-induced changes in, 855
Cholesterol (C) in postmenopausal women
on ERT, atherothrombosis, thrombophilia and, 727, 728
in obese women, and apo E genotype effects on diet-induced changes in, 855
see also Estrogen-progestin replacement therapy, postmenopausal, effects of, on C efflux potential
Cholesterol acyltransferase, *see* Lecithin:cholesterol acyltransferase
Cholesteryl ester(s) (CEs)
effects of postmenopausal sequential estrogen-progestin replacement therapy effects on, 1413
in NIDDM, RLp effects on synthesis of, in macrophages, 966
plasma, ERT enhancing transfer of, 599-304
psyllium effects on, sex and hormonal status and, 503, 504
Cholesteryl ester transfer protein (CETP)
in NIDDM men, effects of low-glycemic index breakfast with soluble fiber on expression of, 824
see also Cholesteryl ester transfer protein gene; Cholesteryl ester transfer protein genotype
Cholesteryl ester transfer protein (CETP) gene, hyperalphalipoproteinemia due to mutation in intron 1 splice donor site of, 394-397
Cholesteryl ester transfer protein (CETP) genotype, changes in HDL-C subfractions with exercise dependent on, 774-778
Cholinesterase (ChE) in MCS, 424, 425
Chromium (Cr) picolinate supplementation, effects of, on insulin sensitivity, serum lipids, and BW in dexamethasone-treated subjects, 589-594
Chronic alcohol intake, effects of
on energy balance, 787-791
gender-dependent effects on c-Fos and heat shock protein-70 gene expression in different brain regions, 1562-1568
see also Chronic alcohol intake, effects of, on SM
Chronic alcohol intake, effects of, on SM
effects of, on SM lysosomal, cytoplasmic, and proteosomal protease activities, 97-104
on SM 7-OH and oxysterols, 737-742
Chronic autoimmune thyroiditis (AITD), serum MCP-1 in, 1489-1493
Chronic exposure to FFAs or high glucose, pancreatic islet apoptosis induced by, 1340-1347
Chronic glucocorticoid therapy, GH therapy effects in IBD children on, 127-135
Chronic hemodialysis, effects of Zn metabolism on PBMC apoptosis and proliferation in patients on, 1392-1396
Chronic hyperglycemia, BBB adaptation to elevated levels of brain glucose in DM with, 1522-1524
Chronic hyperthyroidism, effects of, on HDL structure and apo A-I kinetics, 443-450
Chronic insomnia, shift in IL-6 and TNF secretion from nighttime to daytime in, 887-892
Chronic iron overload, lipid peroxidation and hepatic protein modification in, 645-651
Chronic leptin therapy, effects of, on basal glucose transport in high-fat diet, 859-863
Chronic lipotoxicity, effects of, on IR, HK1, CPT1, and GLUT2 gene expression in INS-1 cells, 155-162
Chronic N^{ω}-nitro-L-arginine methyl ester (L-NAME), effects of, on PP hypertriglyceridemia in NIDDM and in nondiabetic subjects, 702-707
Chronic progressive external ophthalmoplegia (CPEO), glucose effectiveness in, 796-800
Chronic renal failure (CRF), upregulation of FAS gene expression in, 1605-1610

Chronic total parenteral nutrition (TPN), and effects of infections on role of intraportal L-NNA in hepatic glucose uptake, 274-283
Chylomicron-like emulsion, kinetics of plasma, in normolipidemic obese women after short-period weight loss with energy-restricted diet, 1097-1103
Chymotryptic activity of proteasomes, lovastatin effects on, 1155
Cigarette smoking, *see* Smoking
Cilostazol, effects of, on LpAI and PP lipemia in NIDDM, 1348-1354
Circulating brain natriuretic peptides (BNP) in treadmill-exercising men, 1423-1426
Circulating cholesterol (C), long-term effects of dietary C on synthesis and concentrations of, in infants, 25-33
Circulating estradiol (E_2), adrenal androgen concentrations and, in men on glucocorticoids, steroid-induced osteoporosis and, 1458-1462
Circulating leptin, effects of TNF-α–induced hyperinsulinemia on, during fasting, 1104-1110
Circulating lipoproteins (Lps), effects of immobilization stress on intermediate metabolism and, 925-931
Circulating E-selectin, angiographic assessment of VCAM-1, ICAM-1 and, in men with CAD and CHO metabolism disturbances, 733-736
Circulating soluble Fas ligand (FasL), and disease activity in hyperthyroidism of Graves' disease, 769-773
Cirrhosis, parenchymal liver, relationship of vitamin E status to Lp composition, nutritional factors, and plasma oxidation in, 609-615
Citrate synthase (CS), effects of ovariectomy and estradiol replacement therapy on SM GS, PFK, β-HADH and, 1397-1401
CK (creatine kinase), and FM increase in overfed young men, 452-454
Classical minimal model of glucose kinetics in HTN, 302
cLMWPTP (cytosolic low-molecular-weight protein tyrosine phosphatase), correlation of age of onset of IDDM with, sex ratio and, 419-422
ClO^- (hypochlorite)-induced oxidative stress, NO effects on hepatocytes submitted to, 175-179
c-myc mRNA (messenger ribonucleic acid), alcohol intake and increased, in cardiac and skeletal muscle 1285-1290
CoA (coenzyme A) dehydrogenase, β-hydroxyacyl-, effects of ovariectomy and estradiol replacement therapy on SM GS, PFK, CS and, 1397-1401
CoA (coenzyme A) reductase inhibitors, 3-hydroxy-3-methylglutaryl, *see* Statins
Coagulation, hypofibrinolysis and, in obese NIDDM subjects, PAI-1 and, 471-476
Cognitive function, short-term metformin therapy effects on, 532
Collagen, skin, chronic iron overload effects on, 648
Collagen IV, effects of glycated albumin inhibition on urinary excretion of, and on prevention of renal insufficiency in DM, 901-906
Collagen-cross-linked N telopeptide, urinary levels of type I, correlated with results of bone scintigraphy in prostate cancer, 814-818
Colonic mucosal tyrosine kinase, effects of repetitive deformation and pressure on activity of, 1525-1527
Combined dyslipidemia, NIDDM with, fibric acid versus hepatic statins for, 1355-1359
Combined hyperlipidemia, *see* Familial combined hyperlipidemia
Complement 3 (C3), expression of HSL, PPARγ and, in AT of FCHL subjects, 664-670
Congenital adrenal hyperplasia (CAH), longitudinal metabolic process of bone growth in NESS and, 1377-1380
Congestive heart failure (CHF), ANPs in, 582-588
Conjugated equine estrogens, *see* Estrogen-progestin replacement therapy, postmenopausal, effects of, on C efflux potential; Estrogen-progestogen replacement therapy
Connecting peptides, *see* C-peptides
Conscious subjects, incretin effect of portal glucose associated with pancreatic neural activity in, 1324-1330
Contraceptives, effects of different oral, on plasma nitric oxide and Hcy, and on lipid metabolism, 1216-1221
Contractility, vascular, PI3-K in modulation of, 382-383
Copper-zinc superoxide dismutase (CuZn SOD), retinal and renal, in DM, 1279-1284
Corn starch in HF diet, 918
Coronary artery disease (CAD)
  angiographic assessment of circulating E-selectin, VCAM-1, and ICAM-1 in men with CHO metabolism disturbances and, 733-736
  in IDDM, LEAD and, 250, 251
  in obese and non-obese Japanese subjects, insulin secretion and sensitivity in, 184-188
  risk of, with phenotype B LDL, influence of lipid composition in small, dense LDL particles on oxidation susceptibility and, 1081-1087
Coronary heart disease, *see* Risk factors for CHD
Corticosterone
  plasma, HF and/or LF diet effects on exercise-induced changes in, in obesity, 710
  serum, immobilization stress effects on, 927
  in unilateral hyperaldosteronemia, 352
Corticotropin (adrenocorticotropic hormone; ACTH)
  plasma, in lung cancer associated with hypercalcemia, 872
  during rehabilitation for severe head trauma, 1366
  response of cortisol and, to CRH in postmenopausal women on ERT, AT distribution and, 137-143
  in treadmill-exercising men, 1424
Corticotropin-releasing hormone (CRH), response of cortisol and ACTH to, in postmenopausal women, role of ERT and AT distribution in, 137-143
Cortisol (hydrocortisone)
  exercise and, *see* Cortisol, exercise and
  in IDDM children, serum leptin concentration and, 293, 294
  in NIDDM, insulin replacement effects on, 1496
  plasma, *see* Plasma cortisol
  during rehabilitation for severe head trauma, 1366
  response of, to CHO-restricted diet, 868
  response of ACTH and, to CRH in postmenopausal women, role of ERT and AT distribution in, 137-143
  salivary, polymorphism of exon 3 of POMC gene in relation to serum leptin, obesity and, in Swedish men, 642-644
  serum, in lung cancer associated with hypercalcemia, 872
  short-term metformin therapy effects on urinary excretion of, by normoponderal men, 533
  in unilateral hyperaldosteronemia, 352
Cortisol (hydrocortisone), exercise and
  effects of intermittent exercise of different intensities on cortisol, 659
  genetics of cortisol response to endurance exercise, 360-365
  in treadmill-exercising men, 1424
CP(s), *see* C-peptides
CPEO (chronic progressive external ophthalmoplegia), glucose effectiveness in, 796-800
C-peptides (CPs; connecting peptides)
  atorvastatin effects on, in dyslipidemia with impaired fasting glucose, 336

C-peptides (CPs; connecting peptides) (*Continued*)
and high risk for NIDDM, 745-747
in HTN, *see* C-peptides in HTN
in microalbuminuric men, insulin metabolism and, 751, 752
in NIDDM, *see* C-peptides in NIDDM
in normoponderal men, effects of short-term metformin therapy on, 533
in ovarian somatostatinoma, 1180
plasma, *see* Plasma C-peptides
serum, *see* Serum C-peptides
C-peptides (CPs; connecting peptides) in HTN
glucose metabolism-insulin release and, 299
modified minimal model of kinetics and secretion of, 301-302
C-peptides (CPs; connecting peptides) in NIDDM
declining beta-cell function and urinary excretion of, 144-148
in dyslipidemic NIDDM, atorvastatin effects on, 336
400 or 600 mg/d CS-045 effects and, 46, 47
insulin replacement effects on, 1496
insulin response to dietary protein intake and, 1029
and nateglinide effects on glucose tolerance, 21
and PP lipemia, apo E gene polymorphism-dependent effects of age, BMI and fasting TGs on, 1089
serum, insulin resistance, atherosclerosis and, 942
CPK (creatine phosphokinase) in treadmill-exercising men, 1424
CPT1 (carnitine palmitoyl transferase-1) expression in INS-1 cells, effects of acute and/or chronic lipotoxicity on, 155-162
Cr (chromium) picolinate supplementation, effects of, on insulin sensitivity, serum lipids, and BW in dexamethasone-treated subjects, 589-594
CRABPs (cellular A11-*trans*-retinoic acid binding proteins), RA catabolism and, 478
C-reactive protein (CRP)
high- and low-isoflavone soy diet effects on, 921
in hypercholesterolemia, effects of dietary portfolio of vegetable proteins, fiber, and plant sterols on, 1599
insulin resistance and, in non-obese Japanese NIDDM subjects, 1578-1581
Creatine, effects of supplementation with, on insulin secretion and glucose homeostasis, 518-522
Creatine kinase (CK), and FM increase in overfed young men, 452-454
Creatine phosphokinase (CPK) in treadmill-exercising men, 1424
Creatinine and creatinine clearance
angiotensin II effects on, 894
in CRF, 1606
in IBD in children on chronic glucocorticoid therapy on, 131
inosine effects on, 440
in methionine-induced hyperhomocysteinemia, 1237
and muscle mass in aging women, 936
in NIDDM, insulin response to dietary protein intake and, 1031
in older men and women engaged in lower versus whole body resistive exercise, 992
oral L-carnitine supplementation effects on, 1390
and plasma leptin after unilateral nephrectomy, 207
in prostate cancer, 814-818
serum, *see* Serum creatinine
in STZ-DM, pioglitazone and troglitazone effects on, 405
and thyroid function in elderly subjects, 106
and uric acid syndrome in subjects at risk for NIDDM, 374
CRF (chronic renal failure), upregulation of FAS gene expression in, 1605-1610
CRH (corticotropin-releasing hormone), response of cortisol and ACTH to, in postmenopausal women, role of ERT and AT distribution in, 137-143
Crohn's disease in children on chronic glucocorticoid therapy, GH therapy effects on, 127-135
Cross-linked N telopeptide, urinary levels of type I collagen-, correlated with results of bone scintigraphy in prostate cancer, 814-818
CRP, *see* C-reactive protein
α (alpha)- and β (beta)-Cryptoxanthin, serum, plant sterol effects on, 653, 655
CS (citrate synthase), effects of ovariectomy and estradiol replacement therapy on SM GS, PFK, β-HADH and, 1397-1401
CS-045, *see* Troglitazone, effects of
CTx (C telopeptide), serum, in SCI, bone loss and, 961
CuZn SOD (copper-zinc superoxide dismutase), retinal and renal, in DM, 1279-1284
CV (cardiovascular) system, *see entries beginning with terms*: Aortic, Arterial, Coronary, Heart, Vascular, Venous *element*: Card- *specific blood vessels and conditions*
Cyanocobalamin, *see* Vitamin B_{12}
Cyclic adenosine monophosphate, *see* cAMP; cAMP agonists
Cyclic guanosine monophosphate (cGMP), 8-bromo-, effects of, on hepatocytes subjected to ClO^--induced stress, 175-179
CYP26 (retinoic acid 4-hydroxylase), RA catabolism mediated by, and cell proliferation in head and neck squamous cell carcinoma, 477-481
Cystathionine-β-synthase (CβS)
CS-045 effects on hepatic and erythrocyte SAM and SAH, MTHFR and, Hcy metabolism and, 783-786
severe MAT I/III deficiency and deficiency in, 981-988
Cysteine dioxygenase mRNA (messenger ribonucleic acid) in AT taurine biosynthesis, 1191-1197
Cysteine sulfinic acid decarboxylase mRNA (messenger ribonucleic acid) in AT taurine biosynthesis, 1191-1197
Cytokines
proinflammatory, in middle-age men and women, effects of low- and high-isoflavone soy diet on, 919-924
see also specific cytokines
Cytoplasmic skeletal muscle (SM) protease activities, effects of acute and chronic alcohol intake, 97-104
Cytoskeleton
isoproterenol effects on p85 phosphorylation association with, 381-382
in regulation of gluconeogenesis, *see* Cytoskeleton in regulation of gluconeogenesis
Cytoskeleton in regulation of gluconeogenesis, 79-91
Ca signaling and, 80-81, 83
data contradicting hypothesis on, 86-87
enzyme association and dissociation in, 84-85
enzyme recruitment and translocation in, 85-86
Cytosolic low-molecular-weight protein tyrosine phosphatase (cLMWPTP), correlation of age of onset of IDDM with, sex ratio and, 419-422

Day-long plasma glucose, relationship between FPG and concentrations of, in NIDDM treated by dietary management, 457-459
Daytime secretion, shift from nighttime secretion of TNF and IL-6 to, in chronic insomnia, 887-892
DBP (diastolic blood pressure), *see* Blood pressure
Decarboxylase mRNA (messenger ribonucleic acid), cysteine sulfinic acid, in AT taurine biosynthesis, 1191-1197
Deformation, effects of repetitive pressure and, on small bowel and colonic mucosal tyrosine kinase activity, 1525-1527
Dehydrocholesterol, hepatic and testicular, simvastatin, pravastatin, and BM 15.766 effects on, 494-496

Dehydroepiandrostenedione (beta-hydroxy-5-androsten-17-one) in postmenopausal women, ACTH and cortisol response to CRH and, 139, 140
Dehydroepiandrosterone (DHEA), effects of, on apolipoprotein A-I gene expression in HepG2 cell line, 376-379
Dehydroepiandrosterone sulfate (DHEAS), serum, in men on glucocorticoids, SIOP and, 1460
Dehydrogenase
beta-cell mitochondrial glycerol phosphate, glycolysis-derived NADH and, 318-321
β-hydroxyacyl-CoA, effects of ovariectomy and estradiol replacement therapy on SM GS, PFK, CS and, 1397-1401
isozyme of lactate, and SM lactate transport in STZ-DM, 810
oxoglutarate, and FM increase in overfed young men, 452-454
Dehydrolanosterol, hepatic and testicular, simvastatin, pravastatin, and BM 15.766 effects on, 494-496
Delta (Δ)-5-avenasterol
effects of, on serum-fat soluble vitamins and carotenoids, 653
in phytosterol-enriched margarine, 190
Delta (Δ)-7-stigmasterol in phytosterol-enriched margarine, 190
11-Deoxycorticosterone (DOC) in unilateral hyperaldosteronemia, 352
2-Deoxyglucose (2-DG) in alloxan-induced DM, 14
Depolarization, mitochondrial, in hyperglycemia-induced HAEC apoptosis, NAC prevention of, 1384-1388
Desensitization of glucose in INS-1 cells due to glucose metabolites, 671-677
Desmosterol
hepatic and testicular, simvastatin, pravastatin, and BM 15.766 effects on, 494-496
in phytosterol-enriched margarine, 191
Development, *see* Growth and development
Dexamethasone (DEX)
Cr picolinate supplementation effects on insulin sensitivity, serum lipids, and BW in subjects on, 589-594
effects of, on [^{3}H]ouabain binding capacity of SM in relatives of NIDDM subjects, 1331-1339
D442G cholesteryl ester transfer protein (CETP) genotypes, allele frequency of, 396
2-DG (2-deoxyglucose) in alloxan-induced DM, 14
DHEA (dehydroepiandrosterone) effects of, on apolipoprotein A-I gene expression in HepG2 cell line, 376-379
DHEAS (dehydroepiandrosterone sulfate), serum, in men on glucocorticoids, SIOP and, 1460
DHT (5α-dihydrotestosterone), effects of, on apo A-I mRNA, 376-379
Diabetes mellitus (DM)
beta-cell GR in non-obese subjects with, during postnatal development, 765-768
with chronic hyperglycemia, BBB adaptation to elevated brain glucose levels in, 1522-1524
effects of L-arginine supplementation on wound healing in, 1269-1273
effects of protein-free diets on incidence of, in DM-prone subjects, 569-574
gestational, effects of, on erythrocyte membrane sialic acid, 605-608
glycated albumin in, *see* Glycated albumin in DM
in Japanese subjects, *see* Diabetes mellitus in Japanese subjects
quantitative competitive PCR measurement of renal and retinal antioxidative enzymes in, 1279-1284
see also Alloxan-induced diabetes mellitus; Free fatty acids in DM; Insulin-dependent diabetes mellitus; Non–insulin-dependent diabetes mellitus; Streptozotocin-induced diabetes mellitus
Diabetes mellitus (DM) in Japanese subjects
late-onset, with homozygous *NeuroD1* and *Pax4* mutations, beta-cell function in 1161-1165
obese and/or non-obese subjects with CAD and, insulin secretion and sensitivity in, 184-188
see also Japanese subjects, NIDDM
Diabetic neuropathy in non-obese NIDDM subjects, NG and glibenclamide effects on blood glucose and, 1452-1457
Diabetic retinopathy in IDDM, LEAD and, 250, 251
Diagnosis
of familial combined hyperlipidemia in kindreds of FCHL subjects using plasma lipid- and apo B–based diagnostic criteria, 218-224
see also specific conditions and diagnostic techniques
Diastolic blood pressure, *see* Blood pressure
Diet
apo E genotype effects on HDL-C changes induced by, 853-858
effects of estrogen-progestogen replacement therapy, simvastatin, ETP and/or, in hypercholesterolemic early postmenopausal women, compared, 1463-1470
relationship of vitamin E status to Lp composition, plasma oxidation and, in parenchymal liver cirrhosis, 609-615
see also Appetite; Breakfast; Calories; Energy intake; Food intake; Nutrition; Overfeeding; Supplementation; Thermic effect of a meal *entries beginning with terms*: Dietary, Fasting, Postprandial *specific diets and specific food substances*
Dietary carbohydrates, *see* Carbohydrate(s)
Dietary cholesterol (C) intake
with CHO-restricted diet, 866
with dietary portfolio of vegetable proteins, fiber, and plant sterols, 1597
with high- and low-isoflavone soy diet, 920
long-term effects of, on synthesis and circulating cholesterol concentrations in infants, 25-33
relationship between fat intake and, and effects of phytosterol-enriched margarine on plasma Lps in mild-to-moderate hypercholesterolemia, 189-194
Dietary fat intake
with breast milk and formula, 27
with CHO-restricted diet, 866
with dietary portfolio of vegetable proteins, fiber, and plant sterols, 1597
by normolipidemic obese women on energy-restricted diet, 1099
relationship between cholesterol and, and effects of phytosterol-enriched margarine on plasma Lps in mild-to-moderate hypercholesterolemia, 189-194
as risk factor for CHD, 196
see also Dietary fat intake, and exercise; Dietary fat intake by obese women; High-fat diet; Low-fat diet; Oil(s)
Dietary fat intake, and exercise
endurance exercise and effects of HF and high-CHO diets on dietary fat oxidation, 683-685
long-term effects of low-intensity exercise on metabolism of, in obese weight-reduced men, 1003-1010
by older men and women engaged in lower versus whole body resistive exercise, 990
Dietary fat intake by obese women
by postmenopausal women, and apo E genotype effects on diet-induced changes in HDL-C and, 855
race and PP TG response to, by obese women, LPL and, 211-217
Dietary fatty acids, *see* Fatty acid(s)
Dietary fiber, *see* Fiber
Dietary management
of hypercholesterolemia with combined plant sterols, vegetable proteins, and fiber, 1596-1604

Dietary management (*Continued*)
of NIDDM, relationship between FPG and PP plasma glucose concentrations and, 457-459
see also Supplementation; Total parenteral nutrition *and specific diets*
Dietary protein intake
with alcohol-containing diet, 1563
with *Camelina sativa* oil–containing diet, 1256
in NIDDM, effects of fasting-induced decrease in plasma glucose on insulin response to, 1027-1033
by older men and women engaged in lower versus whole body resistive exercise, 990
and risk factors for CHD, 196
vegetable, *see* Vegetable proteins
see also Dietary protein intake by obese women; Dietary protein intake with various diets; High-protein diet, adaptation to, BAT and
Dietary protein intake by obese women
by normolipidemic women on energy-restricted diet, 1099
by postmenopausal women and, 855
Dietary protein intake with various diets
CHO-restricted diet, 866
HF diet, 709
high- and low-isoflavone soy diet, 920
with phytosterol-enriched margarine, 191
and protein-free diet effects on diabetes incidence in diabetes-prone subjects, 569-574
Dietary xylitol, effects of, on biomechanical properties of bone in elderly subjects, 92-96
Differential half-maximal effects of insulin and analogs on in situ glucose transport and protein synthesis in skeletal muscle, 1065-1070
5α (5alpha)-Dihydrotestosterone (DHT), effects of, on apo A-I mRNA, 376-379
Dimethylarginine, asymmetric, in NIDDM, metformin effects on, 843-846
3,5-Dimethylpyrazole (DMP), effects of, on insulin release in response to nutrient secretagogues and cAMP agonists, 110-114
sn-1,2-Dioctanoylglycerol (DOCG), effects of, on insulin release, 111-113
Dioxin (2,3,7,8-tetrachlorodibenzo-*p*-dioxin; TCDD), TNF-α stimulation and inhibition of glucose transport and LPL in adipocytes by, 65-68
Dioxygenase mRNA (messenger ribonucleic acid), cysteine, in AT taurine biosynthesis, 1191-1197
Dismutase, Mn and CuZn superoxide retinal and renal, in DM, measurement of, 1279-1284
DM, *see* Diabetes mellitus
DMP (3,5-dimethylpyrazole), effects of, on insulin release in response to nutrient secretagogues and cAMP agonists, 110-114
DOC (11-deoxycorticosterone) in unilateral hyperaldosteronemia, 352
DOCG (*sn*-1,2-dioctanoylglycerol), effects of, on insulin release, 111-113
Dose
glucagon dose-response curve for HGP and glucose disposal, 1111-1119
hypoglycemic and nonhypoglycemic effects of 400 or 600 mg/d CS-045 in NIDDM, 44-51
insulin, relationship between serum leptin concentrations in IDDM children and, 292-296
long-acting 60 mg lanreotide, for acromegaly, 387-393
Dual-energy x-ray absorptiometry (DXA), bone loss evaluation in SCI with bone biochemical markers and, 958-963
Dyslipidemia
with impaired fasting glucose, atorvastatin effects on, 334-342
insulin resistance and, associated with *LMNA* gene mutation in Japanese subjects, 1017-1021
NIDDM, *see* Dyslipidemia, NIDDM with
PP, in alloxan-induced DM, hepatic and intestinal MTP and, 847-852
see also Hyperlipidemia
Dyslipidemia, NIDDM with
atorvastatin effects on, 334-342
combined, fibric acid versus hepatic statins for, 1355-1359

E, *see* Epinephrine
E_2, *see* Estradiol
Early adolescents, determination of insulin sensitivity and glucose effectiveness in, with one- and two-compartment-labeled minimal model, 1582-1586
Early phase insulin release and secretion, effects of nateglinide on glucose tolerance in NIDDM through enhancement of, 20-24
Early postmenopausal women
hypercholesterolemic, effects of estrogen-progestogen replacement therapy, simvastatin, diet, and/or ETP on, compared, 1463-1470
plasma glycerol in middle-age, premenopausal and, compared, 322-326
ECs (endothelial cells), *see* Human aortic endothelial cells; Human umbilical vascular endothelial cells; Nuclear factor-κB, ECs and
EE, *see* Energy expenditure
Efficacy of 400 or 600 mg/d CS-045, 46
Efflux potential of cholesterol, *see* Estrogen-progestin replacement therapy, postmenopausal, effects of, on C efflux potential
eGDR (estimated glucose disposal rate), glycemia and/or, as predictor of LEAD in IDDM, 248-254
Elcatonin, effects of, on Ca-deficient diet-induced decrease in BMD and elevated estrogen in elderly male subjects, 1230-1234
Elderly, the, *see* Older subjects
Enalapril, effects of, on inner medullary collecting duct aquaporin 2 and AVP V_2, in cardiomyopathy, 970-975
Endocrine effects of L-NMMA, 60
Endothelial cells (ECs), *see* Human aortic endothelial cells; Human umbilical vascular endothelial cells; Nuclear factor-κB, ECs and
Endothelial nitric oxide synthase (eNOS)
effects of PI3-K inhibition on, 382-383
TNF-α effects on IR content and phosphorylation in HAECs and on insulin-induced increase in, 487-491
Endothelin-1 (ET-1), plasma, in IDDM and NIDDM with insulin resistance and atherosclerosis, 946
End-stage renal disease (ESRD), hydroxocobalamin effects on hyperhomocysteinemia in, 881-886
Endurance exercise
effects of, on plasma LpAI and LpAI:AII in sedentary subjects, 1053-1060
effects of high-fat and high-carbohydrate diets on performance in, compared, 678-690
genetics of cortisol response to, 360-365
by insulin-resistant obese NIDDM men, BP response to, 1247-1252
Energy balance, chronic alcohol intake effects on, 787-791
Energy expenditure (EE)
effects of Trp64Arg β_3-adrenoceptor gene polymorphism on, in obese postmenopausal women, race and, 801-805

Energy expenditure (EE) (*Continued*)
by older men and women engaged in lower versus whole body resistive exercise, 993-994
sleep, in OSAS, effects of laser-assisted uvuloplasty on, 622-627
Energy intake
with CHO-restricted diet, 866
with dietary portfolio of vegetable proteins, fiber, and plant sterols, 1597
with high- and low-isoflavone soy diet, 920
by older men and women engaged in lower versus whole body resistive exercise, 989-997
with phytosterol-enriched margarine, 191, 192
restricted, *see* Energy-restricted diet
and risk factors for CHD, 196
see also Food intake; Diet
Energy-restricted diet
effects of LF diet or, on HF diet-induced insulin resistance, 695-701
intentional weight cycling by young women on, 149-154
kinetics of plasma chylomicron-like emulsion in, after short-period weight loss with, 1097-1103
eNOS, *see* Endothelial nitric oxide synthase
Enteral glutamine (Gln), effects of, on whole-body leucine kinetics in hypercatabolic fed subjects, 628-635
Environmental regulation of Na^+/K^+ ATPase in DM, 284-291
Epilepsy, valproic acid effects on PP serum insulin in, 1274-1278
Epinephrine (E; adrenaline)
glucose-induced stimulation of, 761-764
low-intensity exercise effects on, 1008
in NIDDM, insulin replacement effects on, 1496
Equine estrogens, conjugated, *see* Estrogen-progestin replacement therapy, postmenopausal, effects of, on C efflux potential; Estrogen-progestogen replacement therapy
ERT, *see* Estrogen replacement therapy, postmenopausal
Erythrocyte(s) (RBCs; red blood cells)
in hypercholesterolemia, effects of combined vegetable proteins, fiber, and plant sterols on, 1599
in treadmill-exercising men, 1424
see also entries beginning with term: Erythrocyte
Erythrocyte ((RBCs; red blood cells) *S*-adenosylmethionine (SAM) and *S*-adenosylhomocysteine (SAH), CS-045 effects on plasma Hcy, CβS and MTHFR in Hcy metabolism and, 783-786
Erythrocyte (RBCs; red blood cells) glutathione pathways in IDDM, oxidative stress effects on, 1360-1362
Erythrocyte (RBCs; red blood cells) membrane, GDM effects on sialic acid in, 605-608
Erythrocyte (RBCs; red blood cells) membrane phospholipid (PL), composition of, in obese hyperinsulinemic nondiabetic women, weight loss effects on, 1261-1268
Erythrocyte (RBCs; red blood cells) Na^+/K^+ ATPase in DM, 286
ESRD (end-stage renal disease), hydroxocobalamin effects on hyperhomocysteinemia in, 881-886
Esterified cholesterol (C) in alloxan-induced DM, hepatic or intestinal MTP effects on PP dyslipidemia and, 849, 850
Estimated glucose disposal rate (eGDR), glycemia and/or, as predictor of LEAD in IDDM, 248-254
Estradiol (E_2)
adrenal androgen concentrations and circulating, in men on glucocorticoids, steroid-induced osteoporosis and, 1458-1462
calcium-deficient diet effects on, in elderly male subjects, 1231
effects of DHEA and, on apo A-I mRNA in HepG2 cell line, 376-379
during rehabilitation for severe head trauma, 1366
Estradiol (E_2) (*Continued*)
in 10- to 15-year-old male adolescents, serum T association with lower HDL-C and, 433, 434
see also β-Estradiol in postmenopausal women; Estradiol replacement therapy
β (beta)-Estradiol (E_2) in postmenopausal women
ACTH and cortisol response to CRH and, 139
in hypercholesterolemic early postmenopausal women, effects of ETP, simvastatin, estrogen-progestogen replacement therapy, and/or diet on, 1464
Estradiol (E_2) replacement therapy, effects of ovariectomy and, on skeletal muscle GS, PFK, CS, and β-HADH, 1397-1401
Estrogen
calcium-deficient diet effects on, in elderly male subjects, 1230-1234
see also Estrogen replacement therapy, postmenopausal
Estrogen-progestin replacement therapy, postmenopausal, effects of, on C efflux potential
effects of sequential therapy on proteins regulating HDL levels and C efflux, 1410-1417
effects of tibolone and, on serum C efflux, 523-530
Estrogen-progestogen replacement therapy, effects of simvastatin, ETP, diet and/or, in early hypercholesterolemic postmenopausal women, compared, 1463-1470
Estrogen replacement therapy (ERT), postmenopausal
early postmenopausal women, effects of, on plasma glycerol, 322-326
plasma cholesteryl ester transfer enhanced by, 599-304
role of AT distribution and, in ACTH and cortisol response to CRH, 137-143
thrombophilia, atherothrombosis and, 724-732
see also Estrogen-progestin replacement therapy, postmenopausal, effects of, on C efflux potential; Estrogen-progestogen replacement therapy
Estrogen transdermal patch (ETP), effects of estrogen-progestogen replacement therapy, diet, simvastatin and/or, in hypercholesterolemic early postmenopausal women, compared, 1463-1470
Estrone
calcium-deficient diet effects on, in elderly male subjects, 1231
see also Estrone in postmenopausal women
Estrone in postmenopausal women
ACTH and cortisol response to CRH and, 139, 140
in hypercholesterolemic early postmenopausal women, effects of ETP, simvastatin, estrogen-progestogen replacement therapy, and/or diet on, 1464
ET-1 (endothelin-1), plasma, in IDDM and NIDDM with insulin resistance and atherosclerosis, 946
Ethanol, *see* Alcohol
ETP (estrogen transdermal patch), effects of estrogen-progestogen replacement therapy, simvastatin, diet and/or, in hypercholesterolemic early postmenopausal women, compared, 1463-1470
European ancestry, and relationship between WC and metabolic risk factors, 1427-1432
Exercise
aerobic, *see* Aerobic exercise
CETP genotype-dependent effects of, on HDL-C subfractions, 774-778
effects of, on MCFA and LCFA oxidation in skeletal muscle, 460-464
endurance, *see* Endurance exercise
intermittent, of different intensities, effects of, on plasma amylin, 657-663

Exercise (*Continued*)
lower versus whole body resistive, energy intake of older men and women engaged in, 989-997
strenuous, role of hypothalamic SS activity inhibition in, GH release during, 1093-1096
see also High-fat diet, exercise and; Men, exercising; Women, older exercising
Exon 3 polymorphism of POMC gene in relation to serum leptin, salivary cortisol, and obesity, 642-644
Exposure, chronic, to FFAs or high glucose, pancreatic islet apoptosis induced by, 1340-1347
Extended-release niacin therapy of atherogenic lipids and Lp(a) in IDDM and NIDDM, 1120-1127
External ophthalmoplegia, chronic progressive, glucose effectiveness in, 796-800
Extreme hypoglycemia and hyperglycemia, ovarian somatostatinoma in ovarian teratoma with alternating, 1180-1183
Extremities, arterial disease of lower, in IDDM, glycemia and/or eGDR as predictor of, 248-254

F, *see* Fructose
FA(s), *see* Fatty acid(s)
FABP-2 (fatty acid binding protein-2) gene polymorphism, intestinal, and lipid phenotypic expression in FCHL, 1298-1305
Factor V (FV) Leiden gene mutation, heterozygosity for prothrombin gene mutation and, and thrombophilia and atherosclerosis with postmenopausal ERT, 724-732
Familial combined hyperlipidemia (FCHL)
effects of LPL gene polymorphism on lipid phenotype expression in, 1298-1305
plasma lipid- and apo B–based diagnostic criteria for, in FCHL kindreds, 218-224
and PPARγ, HSL, and C3 expression in AT, 664-670
Familial hypercholesterolemia (FH), atorvastatin in heterozygous and homozygous, treated with LDL apheresis, 976-980
Familial partial lipodystrophy (FPLD), *LMNA* mutation and, 1017-1021
Family history of CAD men, 734
FAO (fatty acid β-oxidation) disorders, mitochondrial, similarities between fibroblast acylcarnitine in RC defects and, 366-371
Fas ligand (FasL), circulating soluble, and disease activity in hyperthyroidism of Graves' disease, 769-773
FAS (fatty acid synthase) gene expression, upregulation of, in CRF, 1605-1610
Fasting
effects of TNF-α–induced hyperinsulinemia on circulating leptin during, 1104-1110
in NIDDM, effects of plasma glucose decrease induced by, on insulin response to dietary protein intake, 1027-1033
see also entries beginning with term: Fasting
Fasting blood glucose (FBG)
in MS, serum ceruloplasmin and, 839-841
see also Fasting blood glucose in IDDM; Fasting blood glucose in NIDDM
Fasting blood glucose (FBG) in IDDM
in children, serum leptin concentration and, 293-295
Na^+/K^+ ATPase regulation and, 284
Fasting blood glucose (FBG) in NIDDM
monosaccharide ingestion and, 950
Na^+/K^+ ATPase regulation and, 284
in NIDDM men, low-glycemic index breakfast with soluble fiber and, 820
Fasting C-peptides (CPs; connecting peptides)
in late-onset DM Japanese subjects, 1162, 1163
Fasting C-peptides (CPs; connecting peptides) (*Continued*)
L-NMMA effects on, 62
Fasting free fatty acids (FFAs)
and high risk for NIDDM, 745-747
in HIV-infected subjects, *see* Fasting free fatty acids in HIV-infected subjects
and risk factors for CHD, 197
in visceral obesity, 1043, 1045
Fasting free fatty acids (FFAs) in HIV-infected subjects
on antiretroviral therapy, lipolysis and, 1145, 1146
with lipodystrophy, 262-264
Fasting glucose
in dyslipidemia, atorvastatin effects on Lp profile and LDL particles in, 334-342
in HIV infection, 262
in hyperinsulinemic postmenopausal women, 239
in NIDDM, *see* Fasting glucose in NIDDM
in obesity, *see* Fasting glucose in obesity
as risk factor for metabolic syndrome in women, 1574
and uric acid syndrome in subjects at risk for NIDDM, 373, 374
valproic acid effects on, in epilepsy, 1275, 1276
see also Fasting blood glucose; Fasting plasma glucose
Fasting glucose in NIDDM
with carotid artery IMT in Japanese subjects, 540
with combined dyslipidemia, 1356
insulin and IGF-1 action in SM and, 1172
in non-obese insulin-resistant Japanese subjects, 1579
with obesity, soluble serum E-selectin and, 933
TZD effects on, 171
see also Fasting blood glucose in NIDDM
Fasting glucose in obesity
in NIDDM, soluble serum E-selectin and, 933
in obese nondiabetic men, 1480
plasma, in nondiabetic hyperinsulinemic women, 1263
in visceral obesity, 1043
Fasting insulin
in HIV-infected subjects, 262
in hyperinsulinemic postmenopausal women, 239
levels of, and plasma pollutant level in response to weight loss, 482-486
in MS, serum ceruloplasmin and, 839, 840
in NIDDM, *see* Fasting insulin in NIDDM
in obesity, *see* Fasting insulin in obesity
plasma, *see* Fasting plasma insulin
in visceral obesity, 1043
Fasting insulin in NIDDM
and high risk for NIDDM, 745-747
and IGF-1 action in SM and, 1172
in non-obese insulin-resistant Japanese subjects, 1579
Fasting insulin in obesity
in obese nondiabetic men, 1480
in obese prepubertal children with MCS, 423-428
Fasting plasma C-peptides (connecting peptides) in HIV infection, 308, 311
Fasting plasma glucose (FPG)
in alloxan-induced DM, 14
creatine supplementation effects on, 519
and high risk for NIDDM, 745-747
in HIV infection, 308, 311
in NIDDM, *see* Fasting plasma glucose in NIDDM
in NIDDM subjects' relatives, 1332
in non-obese subjects with CAD, insulin secretion and, 185
in obesity, *see* Fasting plasma glucose in obesity
in older MS subjects, VDR polymorphism and, 358

Fasting plasma glucose (FPG) in NIDDM
beta-cell function and, 145
cilostazol effects on, 1350
dietary management of NIDDM and relationship between PP plasma glucose concentrations and, 457-459
and glucagon dose-response curve for hepatic glucose production, 1112
in mild NIDDM, 1049, 1050
with remnant-like Lp particles, 966
see also Fasting plasma glucose in NIDDM with obesity
Fasting plasma glucose (FPG) in NIDDM with obesity
hypofibrinolysis and coagulation and, 472, 474
in Korean subjects, ADRB2 gene polymorphism and, 834-836
in obese NIDDM men, 1249, 1250
Fasting plasma glucose (FPG) in obesity
with CAD, insulin secretion and, 185
with insulin resistance, 467
with NIDDM, *see* Fasting plasma glucose in NIDDM with obesity
Fasting plasma insulin (FPI)
in alloxan-induced DM, 14
in HIV infection, 308, 311
in mild NIDDM, 1049, 1050
in non-obese subjects with CAD, insulin secretion and, 185
in obesity, *see* Fasting plasma insulin in obesity
in older MS subjects, VDR polymorphism and, 358
Fasting plasma insulin (FPI) in obesity
with insulin resistance, 467
insulin secretion and, 185
in nondiabetic hyperinsulinemic obese women, 1263
Fasting triglycerides (TGs)
level of, as risk factor for CHD, 197
and PP lipemia in NIDDM, 1089
Fat, *see* Adipose tissue; Dietary fat intake; Fat-free mass; Fat mass *entries beginning with term*: Fatty *elements*: Adip-, Lip- *and specific types of fat*
Fat-free mass (FFM; lean body mass)
appendicular, and prevalence of sarcopenia in women, 69-74
CHO-restricted diet effects on, 867
effects of ovariectomy and estradiol replacement therapy on, 1399
exercise and, *see* Fat-free mass in exercising subjects
in HIV-infected men on antiretroviral therapy, lipolysis and, 1145
in middle-age and premenopausal women, 324, 325
in NIDDM, *see* Fat-free mass in NIDDM
in non-obese subjects, *see* Fat-free mass in non-obese subjects
in obesity, *see* Fat-free mass in obesity
in overfed young men, 452-454
in postmenopausal women, *see* Fat-free mass in postmenopausal women
in SCI, bone loss and, 960
Fat-free mass (FFM; lean body mass) in exercising subjects
in endurance-exercising sedentary subjects, 1056
in older men and women engaged in lower versus whole body resistive exercise, 992
Fat-free mass (FFM; lean body mass) in NIDDM
and progressive defect of insulin action on GS, 550
TZD effects on, 171
Fat-free mass (FFM; lean body mass) in non-obese subjects
in non-obese men, AT compartments and kinetics of apo B-100 and, 1207
in non-obese young women, weight cycling effects on, 151
Fat-free mass (FFM; lean body mass) in obesity
ICAM-1 levels and, 76, 77
in obese postmenopausal women, apo E genotype effects on diet-induced changes in HDL-C and, 855
Fat-free mass (FFM; lean body mass) in obesity (*Continued*)
in obese weight-reduced men, long-term effects of low-intensity exercise on, 1005
weight loss and changes in, after dietary restriction and structured exercise or lifestyle, 1529, 1530
Fat-free mass (FFM; lean body mass) in postmenopausal women
in early postmenopausal women, 324, 325
obese women, apo E genotype effects on diet-induced changes in, 855
Fat mass (FM)
diet effects on, *see* Fat mass, diet effects on
effects of ovariectomy and estradiol replacement therapy on, 1399
fasting insulin level, plasma pollutant level, weight loss and, 484
in HIV-infected men on antiretroviral therapy, lipolysis and, 1145
in NIDDM, TZD effects on, 171
in normoponderal men, effects of short-term metformin therapy on, 531-536
in obesity, *see* Fat mass in obesity
in SCI, bone loss and, 960
Fat mass (FM), diet effects on
CHO-restricted diet effects, 867
in overfed young men, skeletal muscle characteristics and, 451-456
Fat mass (FM) in obesity
ICAM-1 levels and, 76, 77
in obese weight-reduced men, long-term effects of low-intensity exercise on, 1005
in postmenopausal women, apo E genotype effects on diet-induced changes in HDL-C and, 855
weight loss and changes in, after dietary restriction and structured aerobic exercise or lifestyle, 1529, 1530
Fat-soluble vitamins and carotenoids, serum, effects of plant sterol on, 652-656
Fatty acid(s) (FAs)
high-protein diet effects on, 345, 347
insulin-mediated flux of, in NIDDM, TZD effects on, 169-174
medium- and long-chain, *see* Long-chain fatty acids; Medium-chain fatty acids
nonesterified, *see* Free fatty acids
β-oxidation disorders of mitochondrial, fibroblast acylcarnitine in RC defects and, compared, 366-371
plasma, *see* Plasma fatty acids
saturated, *see* Saturated fatty acids
serum, effects of α-linoleic acid–rich *Camelina sativa* oil on composition of, in hypercholesterolemia, 1253-1260
unsaturated, *see* Unsaturated fatty acids
Fatty acid binding protein-2 (FABP-2) gene polymorphism, intestinal, and lipid phenotypic expression in FCHL, 1298-1305
Fatty acid synthase (FAS) gene expression, upregulation of, in CRF, 1605-1610
FBG, *see* Fasting blood glucose
FCHL, *see* Familial combined hyperlipidemia
Fetal nutrition, muscle oxygen supply in childhood and, 1569-1572
FFAs, *see* Free fatty acids
FV (factor V) Leiden gene mutation, heterozygosity for, ERT, thrombophilia, atherosclerosis and 724-732
FFM, *see* Fat-free mass
FF-MAS (follicular fluid meiosis-activating sterol), simvastatin, pravastatin, and BM 15.766 effects on, 494-496
FH (familial hypercholesterolemia), atorvastatin in heterozygous and homozygous, treated with LDL apheresis, 976-980
Fiber
viscous, effects of vegetable proteins, phytosterols and, on hypercholesterolemia, 1596-1604

Fiber (*Continued*)
see also Soluble fiber intake
Fibric acid for combined dyslipidemia with NIDDM, hepatic statins versus, 1355-1359
Fibrinogen
in hypercholesterolemic early postmenopausal women, effects of ETP, diet, simvastatin, and/or estrogen-progestogen replacement therapy on, 1468
in IDDM, LEAD and, 250, 251
phytosterol-enriched margarine effects on, 191
see also Fibrinogen in NIDDM
Fibrinogen in NIDDM
effects of 400 or 600 mg/d CS-045 on, 46
in non-obese insulin-resistant Japanese subjects, 1579
Fibroblast acylcarnitine in respiratory chain defects and mitochondrial fatty acid β-oxidation disorders, compared, 366-371
58-year-old men, microalbuminuria and insulin metabolism in, 750-753
Fluid intake, vitamin C effects on, 515
Fluoxetine (FXTN), effects of, on insulin resistance in pancreatectomized subjects, 38-43
FM, *see* Fat mass
FPLD (familial partial lipodystrophy), *LMNA* mutation and, 1017-1021
Folate
in methionine-induced hyperhomocysteinemia, 1237
serum, in ESRD, 882, 883
Folic acid in alcohol-containing diet, 1563
Follicle-stimulating hormone (FSH)
during rehabilitation for severe head trauma, 1366
see also Follicle-stimulating hormone in postmenopausal women
Follicle-stimulating hormone (FSH) in postmenopausal women
ACTH and cortisol response to CRH and, 139
in hypercholesterolemic early postmenopausal women, effects of ETP, simvastatin, estrogen-progestogen replacement therapy, and/or diet on, 1464
in hyperinsulinemic postmenopausal and perimenopausal women, 238, 239
Follicular fluid meiosis-activating sterol (FF-MAS), simvastatin, pravastatin, and BM 15.766 effects on, 494-496
Food intake
chronic L-NAME effects on, in NIDDM and in nondiabetics, 703
monosaccharide ingestion effects on, 954
by pancreatectomized subjects, FXTN effects on, 40
TNF-α effects on, 1105, 1107
vitamin C supplementation effects on, 515
see also Diet; Energy intake *and entries beginning with term*: Postprandial
FPG, *see* Fasting plasma glucose
FPI, *see* Fasting plasma insulin
Free cholesterol (C)
in alloxan-induced DM, hepatic or intestinal MTP effects on PP dyslipidemia and, 849, 850
chronic hyperthyroidism effects on, 446
in NIDDM men, effects of low-glycemic index breakfast with soluble fiber on, 823
postmenopausal sequential estrogen-progestin replacement therapy effects on, 1413
psyllium effects on, sex and hormonal status and, 502, 503
Free fatty acids (FFAs; nonesterified fatty acids)
and AT lipolytic function in obese women, 1515
biotin effects on, 164
in DM, *see* Free fatty acids in DM
Free fatty acids (FFAs; nonesterified fatty acids) (*Continued*)
effects of TNF neutralization on, 1062-1063
in endurance exercise, effects of high-fat and high-carbohydrate diets on, compared, 685
in FCHL, and PPARγ, HSL, and C3 expression in AT, 666-668
in infected chronic TPN subjects, 280, 281
insulin regulation of, 779-782
and insulin response to glucose in HIV infection with AT redistribution, 260-266
in MCS, 425, 426
L-NMMA effects on, 62
in non-obese men, AT compartments and kinetics of apo B-100 and, 1207, 1208
in obesity, *see* Free fatty acids in obesity
pancreatic islet apoptosis induced by chronic exposure to high glucose or, 1340-1347
plasma, *see* Plasma free fatty acids
PP response of, to sucrose by men at risk for CHD, 195-200
and troglitazone inhibition of neointimal formation after balloon injury, 999
Free fatty acids (FFAs; nonesterified fatty acids) in DM
with obesity, defective insulin action on GS and, 551
see also Free fatty acids in NIDDM
Free fatty acids (FFAs; nonesterified fatty acids) in NIDDM
with carotid artery IMT in Japanese subjects, 539-543
400 or 600 mg/d CS-045 effects on, 47, 48
insulin replacement effects on clearance of, 1494-1500
and insulin response to dietary protein intake, 1030
in NIDDM men, low-glycemic index breakfast with soluble fiber and, 823
in obese Korean subjects, ADRB2 gene polymorphism and, 834-836
Free fatty acids (FFAs; nonesterified fatty acids) in obesity
in DM, defective insulin action on GS and, 551
with insulin resistance, 717-720, 722
in NIDDM Korean subjects, ADRB2 gene polymorphism and, 834-836
see also Plasma free fatty acids in obesity
Free leptin, and plasma leptin after unilateral nephrectomy, 207
Free testosterone (FT)
assays measuring, evaluated, 554-559
associated with lower HDL-C in 10- to 15-year-old male adolescents, apo A-I and A-II concentrations and, 432-437
in men on glucocorticoids, SIOP and, 1460
in postmenopausal women, ACTH and cortisol response to CRH and, 139, 140
Free thyroxine (T_4) during rehabilitation for severe head trauma, 1366
Frequency of ADRB2 gene polymorphism, 834-835
Fructosamine in NIDDM, effects of 400 or 600 mg/d CS-045 on, 46, 47
Fructose (F)
atorvastatin effects on hepatic VLDL production in insulin resistance induced by, 409-418
biochemical effects of long-term intake of, on renal histology, 1538-1547
in NIDDM, glycemic, hormonal, and appetite responses to, 949-957
FSH, *see* Follicle-stimulating hormone
FT, *see* Free testosterone
L-Fucose, effects of concentration of, on monocyte adhesion to endothelial cell monolayers and activation of nuclear factor-κB, 225-234
Furosemide, effects of, in unilateral hyperaldosteronemia, 350-355

FXTN (fluoxetine), effects of, on insulin resistance in pancreatectomized subjects, 38-43

Gamma (γ)-globulin (immunoglobulin G; IgG), serum, in LPG, 202
Gamma-glutamyltransferase, *see* γ-Glutamyltransferase
Gamma-tocopherol, *see* Vitamin E
Gastric inhibitory peptide (GIP)
in NIDDM, monosaccharide ingestion and, 952-953
and risk factor for CHD, 197
GD (Graves' disease), circulating soluble Fas ligand and disease activity in hyperthyroidism of, 769-773
GDM (gestational diabetes mellitus), effects of, on erythrocyte membrane sialic acid, 605-608
Gelatin in HF diet, 918
Gender, *see* Sex
Gene expression, *see* mRNA
Gene transfer, GK, to SM in NIDDM, effects of, on insulin-sensitive glucose uptake, 121-126
Genetics
of cortisol response to endurance exercise, 360-365
of Na^+/K^+ ATPase regulation in DM, 284-289
see also Allele distribution and frequency; Ancestry; Familial combined hyperlipidemia; Family history; Gene transfer; Genotype(s); Haplotype(s); mRNA; Mutation; Phenotype; Phenotype B; Polymorphism *and specific genes*
Genotype(s)
apo E2 and apo E3/3, remnant-like Lp particles in NIDDM with, 964-969
CETP, *see* Genotypes, CETP
of cLMWPTP, correlation of age of onset of IDDM with, sex ratio and, 419-422
effects of apo E, on diet-induced changes in HDL-C in obese postmenopausal women, 853-858
LMNA gene, 1018 1019
VDR polymorphism, 357
Genotypes, CETP
D442G, allele frequency of, 396
exercise and changes in HDL-C subfractions dependent on, 774-778
Gestational diabetes mellitus (GDM), effects of, on erythrocyte membrane sialic acid, 605-608
GH, *see* Growth hormone
GH/IGF-1 (growth hormone/insulin-like growth factor-1) axis during rehabilitation for severe head trauma, 1363-1369
GHRH (growth hormone-releasing hormone), PD/GHRH stimulation test to detect GH deficiency in pituitary adenoma, 34-37
GIP, *see* Gastric inhibitory peptide
GK (glucokinase) gene transfer to SM in NIDDM, effects of, on insulin-sensitive glucose uptake, 121-126
Glibenclamide, *see* Nateglinide, effects of glibenclamide and, compared
Glipizide GITS/metformin, effects of, on plasma LDL-arterial proteoglycan interaction in NIDDM, 1223-1229
Gln (glutamine), enteral, effects of, on whole-body leucine kinetics in hypercatabolic fed subjects, 628-635
Glomerulopathy, Lp, HUVEC and TG-rich Lp interaction with apo E gene $Arg^{25} \rightarrow Cys$ mutation in, 201-205
GLP-1, *see* Glucagon-like peptide-1
Glucagon (hyperglycemic-glycogenolytic factor)
CHO-restricted diet and, 868
in exercise, *see* Glucagon in exercise
glucose dependent on AVP-induced release of, 1184-1190
glucose-induced catecholamine stimulation effects on, 763
in NIDDM, *see* Glucagon in NIDDM
Glucagon (hyperglycemic-glycogenolytic factor) (*Continued*)
plasma, *see* Plasma glucagon
portal glucose incretin effect on, 1325
responses of, to hypoglycemia, neuroglycopenia, arginine, and carbachol in alloxan-induced DM, 12-19
see also Hyperglucagonemia
Glucagon (hyperglycemic-glycogenolytic factor) in exercise
effects of intermittent exercise of different intensities on, 659
in endurance exercise, effects of high-fat or high-carbohydrate diets on, compared, 685
Glucagon (hyperglycemic-glycogenolytic factor) in NIDDM
glucagon dose-response curve for HGP and glucose disposal and, 1111-1119
insulin replacement effects on, 1496
insulin response to dietary protein intake and, 1030
plasma FA composition, glucose production and, 1473
Glucagon-like peptide-1 (GLP-1)
in NIDDM, monosaccharide ingestion and, 951-952
in ovarian somatostatinoma, 1181
and risk factor for CHD, 197
Glucocorticoid(s)
adrenal androgen concentrations and circulating E_2 in men on, steroid-induced osteoporosis and, 1458-1462
chronic, for IBD children, 127-135
Glucocorticoid receptor (GR) of beta-cells in non-obese diabetic subjects during postnatal development, 765-768
Glucokinase (GK) gene transfer to SM in NIDDM, effects of, on insulin-sensitive glucose uptake, 121-126
Gluconeogenesis
cytoskeleton in regulation of, 79-91
hepatic, in older and young subjects, 876-880
Glucose
and apo A-I and B distribution in urban Mexican population, 563-565
catecholamine stimulation induced by, 761-764
in CPEO, 796-800
Cr picolinate supplementation effects on, 590, 591
dependent or AVP-induced insulin and glucagon release, 1184-1190
desensitization of, in INS-1 cells, due to metabolites of, 671-677
diet effects on, *see* Glucose, diet effects on
effects of TNF neutralization on, 1062-1063
elevated levels of brain, in DM with chronic hyperglycemia, BBB adaptation to, 1522-1524
estimated disposal rate of, LEAD prediction with, 248-254
in exercise, *see* Glucose, exercise effects on
fasting, *see* Fasting glucose
in FCHL, PPARγ, HSL, and C3 expression in AT and, 666-668
FFAs and, *see* Glucose, FFAs and
hepatic, *see* Hepatic glucose
in HIV infection, *see* Glucose in HIV infection
in HTN, 300
incretin effects of portal, associated with pancreatic neural activity in conscious subjects, 1324-1330
insulin sensitivity and effectiveness of, in late prepubertal children and early adolescents one- and two-compartment-labeled minimal model in determination of, 1582-1586
kinetics of, *see* Kinetics, glucose
and lipolytic function of AT in obese women, race and, 1515
in MCS, 425, 426
in microalbuminuric men, 751, 752
in NIDDM, *see* Glucose in NIDDM
NO role in production of, 57-64
in non-obese men, *see* Glucose in non-obese men

Glucose (*Continued*)
in normotensive nondiabetic subjects, carotid artery IMT and, 256, 257
in obesity, *see* Glucose in obesity
pancreatic islet apoptosis induced by chronic exposure to high, 1340-1347
plasma, *see* Plasma glucose
polymorphism of exon 3 of POMC gene and, 643
and PP TG response to fat-containing meal by non-obese women, 213, 214
preclinical carotid artery atherosclerosis and homeostasis of, in women, 52-56
Pro12Ala polymorphism of PPARγ2 gene effects on, in Japanese subjects, 1408
and risk factor for CHD, 197
and risk factors for CV disease, 1036, 1038, 1072, 1073
serum, *see* Serum glucose
splanchnic galactose extraction regulated by coingestion of, 827-832
WC and metabolic risk factors and, 1428, 1429
see also 2-Deoxyglucose; B-Glucose; D-Glucose; [U-^{14}C]Glucose; Glucose disposal; Glucose homeostasis; Glucose intolerance; Glucose tolerance in NIDDM; Glucose transport; Glucose uptake; Glucotoxicity; Glycemia; Impaired glucose tolerance; Insulin-sensitive glucose uptake; Intravenous glucose tolerance test; Oral glucose tolerance test *and entries beginning with elements*: Gluc-, Glyc-
B-Glucose, and influence of hormonal status and metabolic syndrome on bone density, 268, 269
D-Glucose, effects of concentration of, on monocyte adhesion to endothelial cell monolayers and nuclear factor-κB activation, 225-234
[U-^{14}C]Glucose, effects of, on glucose oxidation, 111
Glucose, diet effects on
dietary fat-containing meal effects, 213, 214
fiber and multivitamin effects, 1168
high-fat and high-carbohydrate diet effects in endurance exercise, 685
Glucose, exercise effects on
effects of high-fat and high-carbohydrate diets on glucose in endurance exercise, 685
intermittent exercise of different intensities, 659
low-intensity exercise effects, 1008
Glucose, FFAs and
FFA concentration and insulin response to glucose in HIV infection with AT redistribution, 260-266
FFA regulation and, 780
pancreatic islet apoptosis induced by chronic exposure to FFAs or high glucose, 1340-1347
Glucose disposal
glycemia and/or estimated rate of, as predictor of LEAD in IDDM, 248-254
in NIDDM, glucagon dose-response curve for HGP and, 1111-1119
Glucose in HIV infection
and antiprotease therapy, 307-313
AT redistribution, FFA concentrations, and insulin response to, 260-266
in HIV-infected men on antiretroviral therapy, lipolysis and, 1145, 1146
Glucose homeostasis, 514-522
creatine supplementation effects on insulin secretion and, 518-522
in obese hyperglycemic subjects, vitamin C supplementation effects on, 514-517
Glucose homeostasis, 514-522 (*Continued*)
in women with preclinical carotid atherosclerosis, 52-56
Glucose intolerance
BGLIIA*2/BGLIIB*1 GH haplotype associated with GH deficit-related growth retardation, 1-4
role of obesity with insulin resistance in, 716-723
Glucose in NIDDM
and effects of GK gene transfer to SM on insulin-sensitive glucose uptake, 121-126
effects of glipizide GITS/metformin control of, on plasma LDL-arterial proteoglycan binding in, 1223-1229
400 or 600 mg/d CS-045 effects on, 46, 47
glucagon dose-response curve for HGP and disposal of, 1111-1119
glycemic, hormonal, and appetite responses to, 949-957
insulin replacement effects on and FFA clearance, and hepatic and renal release of, 1494-1500
in Japanese NIDDM men, pioglitazone effects on, 315
in mild NIDDM, metabolism of, in lean subjects, 1047-1052
plasma FA composition and production of, 1471-1477
and PP lipemia, apo E gene polymorphism-dependent effects of age, BMI, and fasting TGs on, 1089
see also Fasting glucose in NIDDM; Glucose tolerance in NIDDM; Plasma glucose in NIDDM
Glucose in non-obese men
AT compartments and kinetics of apo B-100 and, 1207
with mild NIDDM, metabolism of, 1047-1052
normoponderal, effects of short-term metformin therapy on, 533
Glucose in obesity
plasma, *see* Plasma glucose in obesity
polymorphism of exon 3 of POMC gene and, 643
PP TG response by obese women to fat-containing meal, 213, 214
see also Plasma glucose in obesity
Glucose tolerance, *see* Glucose intolerance; Glucose tolerance in NIDDM; Impaired glucose tolerance; Intravenous glucose tolerance test; Oral glucose tolerance test
Glucose tolerance in NIDDM
declining beta-cell function and, 144-148
nateglinide effects on, through early phase insulin secretion enhancement, 20-24
Glucose transport
basal, effects of chronic leptin therapy on, high-fat diet and, 859-863
in skeletal muscle, *see* Skeletal muscle, glucose transport in
stimulation of TNF-α and inhibition of LPL in adipocytes and, by TCDD, 65-68
see also GLUT2; GLUT4
Glucose uptake
GLUT4, glycolytic enzymes and, in BAT, adaptation to high-protein diet and, 1501-505
hepatic, effects of infections on intraportal L-NNA role in, in chronic TPN, 274-283
insulin-sensitive, effects of GK gene transfer to SM on, in NIDDM, 121-126
muscle, effects of α- and β-adrenergic inhibition on, differences in blood flow and, 1505-1513
α (alpha)-Glucosidase inhibitor, effects of sulfonylurea drug with, on duration of glycemic control in NIDDM, 1548-1552
Glucotoxicity in beta-cells, biotin effects on, 163-168
GLUT2 (glucose transporter) gene expression in INS-1 cells, effects of acute and/or chronic lipotoxicity on, 155-162
GLUT4 (glucose transporter), glucose uptake, glycolytic enzymes and, in BAT, adaptation to high-protein diet and, 1501-505

Glutamine (Gln), enteral, effects of, on whole-body leucine kinetics in hypercatabolic subjects, 628-635
γ (gamma)-Glutamyltransferase (GT)
CV disease risk factors associated with elevated, in hyperlipidemia, 1071-1076
in parenchymal liver cirrhosis, 611
Glutathione
oxidative stress effects on pathways of RBC, in IDDM, 1360-1362
see also Glutathione peroxidase
Glutathione peroxidase (GTx)
chronic iron overload effects on, 647
retinal and renal, in DM, measurement of, 1279-1284
Gluten, wheat, in protein-free diets, 570
Glycated (glycosylated) albumin in DM
effects of inhibition of, on collagen IV excretion and renal insufficiency prevention, 901-906
in NIDDM, effects of nateglinide on glucose tolerance on, 21
Glycated (glycosylated) Hb (hemoglobin)
vitamin C supplementation effects on, 315
see also HbA_{1c}
Glycation (glycosylation)
insulin, vitamin C supplementation effects on glucose homeostasis and, in obese hyperglycemic subjects, 514-517
see also Glycated albumin; Glycated Hb
Glycemia
and/or estimated glucose disposal rate as predictor of LEAD in IDDM, 248-254
see also Glycemic control; Glycemic response; Hyperglycemia; Hypoglycemia; Low-glycemic index breakfast; Normoglycemia *and specific conditions*
Glycemic control, *see* Glycemic control in NIDDM; Insulin replacement *and specific antiglycemic agents*
Glycemic control in NIDDM
effects of alpha-glucosidase inhibitor with sulfonylurea drug on duration of, 1548-1552
with 400 or 600mg/d troglitazone, HDL and VLDL distribution and, 44-51
with insulin replacement, effects of, on FFA clearance and hepatic and renal glucose release, 1494-1500
Glycemic response to fructose and glucose ingestion in NIDDM, 949-957
Glycerol
blood, portal glucose incretin effect on, 1324, 1325
in endurance exercise, effects of high-fat and high-carbohydrate diets on, compared, 685
in infected chronic TPN subjects, 280, 281
and lipolytic function of AT in obese women, race and, 1515
in NIDDM, insulin replacement effects on, 1496
plasma, *see* Plasma glycerol
see also Triacylglycerols
Glycerol phosphate dehydrogenase (GPD), beta-cell mitochondrial, glycolysis-derived NADH and, 318-321
Glycine, blood, portal glucose incretin effect on, 1324, 1325
Glycogen
hepatic, *see* Hepatic glycogen
in HIV infection, 308
muscle, *see* Muscle glycogen
Glycogen synthase (GS)
effects of ovariectomy and estradiol replacement therapy on SM PFK, CS, β-HADH and, 1397-1401
in obesity with NIDDM, progressive defect of insulin action on, 549-553
Glycolysis-derived NADH (reduced nicotinamide adenine nucleotide), beta-cell pathways for oxidation of, 318-321
Glycolytic enzymes, glucose uptake, GLUT4 and, in BAT, adaptation to high-protein diet and, 1501-1505
Glycoprotein (GP), insulin receptor autophosphorylation and plasma cell membrane, in obese insulin-resistant subjects, 465-470
Glycosylation, *see* Glycation
Glycoxidized low-density lipoprotein (LDL), effects of, on MCP-1 mRNA in HUVECs, 1135-1142
GMP (guanosine monophosphate), 8-bromo cyclic, effects of, on hepatocytes exposed to ClO^--induced oxidative stress, 175-179
GP (glycoprotein), insulin receptor autophosphorylation and plasma cell membrane, in obese insulin-resistant subjects, 465-470
GPD (glycerol phosphate dehydrogenase), beta-cell mitochondrial, glycolysis-derived NADH and, 318-321
GR (glucocorticoid receptor) of beta-cells in non-obese diabetic subjects during postnatal development, 765-768
Graves' disease (GD), circulating soluble Fas ligand and disease activity in hyperthyroidism of, 769-773
Growth and development
acromegalic, *see* Growth hormone in acromegaly
of IBD children on chronic glucocorticoid therapy, GH therapy effects on, 130
longitudinal metabolic process of bone, in CAH and NESS, 1377-1380
postnatal, beta-cell GR in non-obese diabetic subjects during, 765-768
see also Growth retardation; Hyperplasia
Growth hormone (GH)
in acromegaly, *see* Growth hormone in acromegaly
deficiency in, *see* Growth hormone, deficiency in
release of, during strenuous exercise, role of hypothalamic SS activity inhibition in, 1093-1096
therapy with, *see* Growth hormone, therapy with
Growth hormone (GH), deficiency in
BGLIIA*2/BGLIIB*1 haplotype of, associated with glucose intolerance in NIDDM with growth retardation due to, 1-4
PD/GHRH stimulation test to detect, in pituitary adenoma, 34-37
see also Growth hormone, therapy with
Growth hormone (GH), therapy with
effects of, in IBD children on chronic glucocorticoid therapy, 127-135
effects of IGF-1 and, on Lp(a) levels, 508-513
Growth hormone (GH) in acromegaly
response of preoperative, to TRH test and OGTT, 616-621
SR-LAN 60 effects on levels of, 387-393
Growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis during rehabilitation for severe head trauma, 1363-1369
Growth hormone-releasing hormone (GHRH), PD/GHRH stimulation test to detect GH deficiency in pituitary adenoma, 34-37
Growth retardation, GH deficit-related, in glucose-intolerant NIDDM children, BGLIIA*2/BGLIIB*1 GH haplotype associated with, 1-4
GS, *see* Glycogen synthase
GT, *see* γ-Glutamyltransferase
GTx, *see* Glutathione peroxidase
Guanine, beer effects on, 1321
Guanosine, beer effects on, 1321
Guanosine monophosphate (GMP), 8-bromo cyclic, effects of, on hepatocytes exposed to ClO^--induced oxidative stress, 175-179

β (beta)-HADH (β-hydroxyacyl-CoA dehydrogenase), effects of ovariectomy and E_2 replacement therapy on SM GS, PFK, CS and, 1397-1401

HAECs, *see* Human aortic endothelial cells
Half-maximal effects, differential, of insulin and analogs on in situ glucose transport and protein synthesis in skeletal muscle, 1065-1070
Haplotype(s), BGLIIA*2/BGLIIB*1 GH, associated with glucose intolerance in NIDDM and GH deficit-related growth retardation, 1-4
Hb (hemoglobin)
  glycated, vitamin C supplementation effects on, 315; *see also* HbA_{1c}
  and thyroid function in elderly subjects and centenarians, 106
  in treadmill-exercising men, 1424
HbA_{1c} (hemoglobin A_{1c})
  in CAD men, 734
  in CPEO, 797
  and high risk for NIDDM, 745-747
  in IDDM, *see* HbA_{1c} in IDDM
  in late-onset DM in Japanese subjects, 1162, 1163
  in NIDDM, *see* HbA_{1c} in NIDDM
  in NIDDM subjects' relatives, 1332
  in obesity, ICAM-1 levels and 76-77
  oral L-carnitine supplementation effects on, 1390
HbA_{1c} (hemoglobin A_{1c}) in IDDM
  age of NIDDM onset and, 420
  in children, serum leptin concentration and, 293-295
  insulin resistance, atherosclerosis and, 942
  LEAD and, 250, 251
  Na^+/K^+ ATPase regulation and, 284
  and oxidative stress effects on RBC glutathione pathways, 1361
  PP biphasic insulin aspart therapy and, 897
HbA_{1c} (hemoglobin A_{1c}) in Japanese NIDDM subjects
  with carotid artery IMT, 540, 541
  in men, pioglitazone effects on, 315
  see also HbA_{1c} in Japanese non-obese insulin-resistant NIDDM subjects
HbA_{1c} (hemoglobin A_{1c}) in Japanese non-obese insulin-resistant NIDDM subjects
  CRP and, 1579
  regional AT relationship to serum TGs and insulin resistance and, 545
HbA_{1c} (hemoglobin A_{1c}) in NIDDM
  dietary management and, 457
  and glycemic control with alpha-glucosidase inhibitor and sulfonylurea drug, 1549, 1550
  hypoglycemic and nonhypoglycemic effects of 400 or 600 mg/d CS-045 and, 46, 47
  insulin and IGF-1 action in SM and, 1172
  insulin resistance, atherosclerosis and, 942
  ischemic stroke and, 245, 246
  in Japanese NIDDM subjects, *see* HbA_{1c} in Japanese NIDDM subjects
  and metformin effects on asymmetric ADMA, 844
  monosaccharide ingestion and, 950
  Na^+/K^+ ATPase regulation and, 284
  nateglinide effects on, 21
  with obesity, *see* HbA_{1c} in NIDDM with obesity
  PP hyperglucagonemia and, 637
  and PP lipemia, apo E gene polymorphism-dependent effects of age, BMI and fasting TGs on, 1089
  with remnant-like Lp particles, 966
  TZD effects on, 171
  see also HbA_{1c} in NIDDM men
HbA_{1c} (hemoglobin A_{1c}) in NIDDM men
  in Japanese men, pioglitazone effects on, 315
HbA_{1c} (hemoglobin A_{1c}) in NIDDM men (*Continued*)
  low-glycemic index breakfast with soluble fiber effects on, 820, 822
HbA_{1c} (hemoglobin A_{1c}) in NIDDM with obesity
  hypofibrinolysis and coagulation and, 472
  soluble serum E-selectin and, 933
Hct, *see* Hematocrit
Hcy, *see* Homocysteine
HDL, *see* High-density lipoprotein(s)
HDL-C, *see* High-density lipoprotein-cholesterol
Head and neck squamous cell carcinoma (HNSCC), retinoic acid 4-hydroxylase–mediated RA catabolism and cell proliferation in, 477-481
Head trauma, severe, GH/IGF-1 axis in, during rehabilitation, 1363-1369
Heart disease, *see* Risk factors for CV disease; Risk factors for CHD
Heart failure, congestive, ANPs in, 582-588
Heart rate (HR; pulse rate)
  in IDDM, LEAD and, 250, 251
  of infected subjects on chronic TPN, 276
  of normoponderal men, effects of short-term metformin therapy on, 532, 533
Heat shock protein-70 (HSP-70), gender-dependent chronic alcohol intake on gene expression of c-Fos and, in different brain regions, 1562-1568
Height
  of chronic AITD subjects, 1490
  of European and/or Chinese ancestry subjects, WC and metabolic risk factors and, 1428, 1429
  of exercising subjects, *see* Height of exercising subjects
  of HIV-infected subjects, *see* Height of HIV-infected subjects
  of IBD children on chronic glucocorticoid therapy, 128
  longitudinal metabolic process of bone growth in NESS, 1377-1380
  of malnourished children with and without acute infection, 1419
  of MCS subjects, 424
  of middle-age, premenopausal, 324
  of NIDDM men, *see* Height of NIDDM men
  of non-obese young women, weight cycling effects on, 150
  of postmenopausal women, *see* Height of postmenopausal women
  and sarcopenia, 70
  of SCI subjects, 960
  and TBP in women, 181, 182
  of 10- to 15-year-old male adolescents, serum T association with lower HDL-C and, 433, 434
  of women smokers, 1314
Height of exercising subjects
  of older men and women engaged in lower versus whole body resistive exercise, 992
  oxidation of MCFAs and LCFAs in skeletal muscle and, 461
Height of HIV-infected subjects
  of HIV-infected men on antiretroviral therapy, 1145
  response to glucose and, 308
Height of NIDDM men
  and effects of low-glycemic index breakfast, 820
  of Japanese men, pioglitazone effects and, 315
Height of postmenopausal women
  of early postmenopausal women, 324
  on ERT, plasma CE transfer and, 601
Hematocrit (Hct)
  in cardiomyopathy, enalapril effects on, 971
  in OSAS, 623
  in treadmill-exercising men, 1424

Hemodialysis, chronic, effects of Zn metabolism on PBMC apoptosis and proliferation in patients on, 1392-1396
Hemodynamics
effects of L-NMMA on, 60
in infected subjects on chronic TPN, 276
see also Blood flow; Blood pressure; Heart rate
Hemoglobin, *see* Hb
Hepatic *S*-adenosylmethionine (SAM) and *S*-adenosylhomocysteine (SAH), CS-045 effects on plasma Hcy, and CβS and MTHFR in Hcy metabolism, 783-786
Hepatic enzymes, *see* Alanine aminotransferase; Aspartate aminotransferase; γ-Glutamyltransferase
Hepatic gluconeogenesis in older and young subjects, 876-880
Hepatic glucose
effects of infections on role of intraportal L-NNA in uptake of, in chronic TPN, 274-283
insulin replacement effects on FFA clearance, renal glucose release, and release of, in NIDDM, 1494-1500
see also Hepatic glucose production
Hepatic glucose production (HGP)
autoregulation of, during hyperglucagonemia, 1128-1134
in NIDDM, dose-response curve of glucagon production of, 1111-1119
Hepatic glycogen
FXTN effects on, in pancreatectomized subjects, 41
HF diet and correlation between hepatic lipid content and, and insulin resistance, NO-1886 effects and, 792-795
immobilization stress effects on, 927
Hepatic insulin sensitivity (S_I), hypertriglyceridemia and, 409-418
Hepatic lipids, HF diet and correlation between hepatic glycogen and, in insulin resistance, NO-1886 effects and, 792-795
Hepatic microsomal triglyceride transfer protein (MTP), and PP dyslipidemia in alloxan-induced DM, 847-852
Hepatic protein
chronic iron overload effects on, 645-651
microsomal triglyceride transfer, and PP dyslipidemia in alloxan-induced DM and, 847-852
Hepatic statins for combined dyslipidemia with NIDDM, fibric acid versus, 1355-1359
Hepatic sterols, neutral, simvastatin, pravastatin, and BM 15.766 effects on, 492-499
Hepatic triglyceride lipase (HTGL), and PP TG response to fat-containing meal by obese and non-obese women, 211, 213-217
Hepatic very-low-density lipoprotein (VLDL) in fructose-induced insulin resistance, atorvastatin effects on, 409-418
Hepatocytes submitted to ClO^--induced oxidative stress, NO effects on, 175-179
HepG2 (hepatoma) cell line
berberine effects on, in hyperglycemia, 1439-1443
DHEA effects on apolipoprotein A-I gene expression in, 376-379
Heredity, *see* Genetics
Heterozygosity for factor V Leiden gene and prothrombin gene mutations, ERT, thrombophilia, atherosclerosis and, 724-732
Heterozygous familial hypercholesterolemia (FH) treated with LDL apheresis, atorvastatin in, 976-980
Hexokinase (HK)
BAT, adaptation to high-protein diet and, 1501-1505
effects of GK gene transfer to SM on, in NIDDM, 122-123
Hexokinase type 1 (HK1) gene expression in INS-1 cells, effects of acute and/or chronic lipotoxicity on, 155-162
HF, *see* High-fat diet
HGP, *see* Hepatic glucose production
High-carbohydrate diet, *see* High-fat diet, effects of high-CHO or, exercise and
High-density lipoprotein(s) (HDL; α-lipoprotein)
chronic hyperthyroidism effects on structure of, 443-450
effects of FFA regulation by insulin on, 780
effects of sequential estrogen-progestin replacement therapy in postmenopausal women on cholesterol efflux capacity and proteins regulating, 1410-1417
fiber and multivitamin effects on, 1168
in HIV-infected men on antiretroviral therapy, lipolysis and, 1145
during lactation, 1447, 1449
in NIDDM, influence of particle distribution of, on hypoglycemic and nonhypoglycemic effects of 400 or 600 mg/d CS-045, 44-51
in non-obese young women, weight cycling effects on, 151
and risk of CAD, 1082
see also High-density lipoprotein-cholesterol; High-density lipoprotein$_2$; Hyperalphalipoproteinemia; Lipoprotein(a)
High-density lipoprotein-cholesterol (HDL-C)
in alloxan-induced DM, 849
anti-oxidized LDL antibody effects on, 430
and apo A-I and B distribution in urban Mexican population, 563-565
atorvastatin effects on, *see* High-density lipoprotein-cholesterol, atorvastatin effects on
in CAD men, 734
diet effects on, *see* High-density lipoprotein-cholesterol, diet effects on
in elderly subjects, thyroid function and, 106
in epilepsy, 1275
exercise and, *see* High-density lipoprotein-cholesterol, exercise and
in FCHL, *see* High-density lipoprotein-cholesterol in FCHL
400 or 600 mg/d CS-045 effects on, 44-51
and high risk for NIDDM, 745-747
in HIV infection, 262
in hypercholesterolemia, effects of dietary portfolio of vegetable proteins, fiber, and plant sterols on, 1599, 1601, 1602
in hyperlipidemic subjects on HF diet, effects of exercise on, 1592
in IDDM, *see* High-density lipoprotein-cholesterol in IDDM
and inhibition of neointimal formation inhibition after balloon injury, 999
in LPG, 202
in MCS, 425, 426
in microalbuminuric men, insulin metabolism and, 751, 752
in MS, serum ceruloplasmin and, 839-841
in NIDDM, *see* High-density lipoprotein-cholesterol in NIDDM
in nondiabetic subjects, *see* High-density lipoprotein-cholesterol in nondiabetic subjects
in non-obese men, AT compartments and kinetics of apo B-100 and, 1207, 1208
in normotensive nondiabetic subjects, carotid artery IMT and, 256, 257
in obesity, *see* High-density lipoprotein-cholesterol in obesity
in parenchymal liver cirrhosis, 612
in postmenopausal women, *see* High-density lipoprotein-cholesterol in postmenopausal women
and preclinical carotid artery atherosclerosis in women, 53
Pro12Ala polymorphism of PPARγ2 gene effects on, in Japanese subjects, 1408
as risk factor for metabolic syndrome in women, 1574
and risk factors for CHD, 196
and risk factors for CV disease, 1036, 1038, 1072, 1073
serum, *see* Serum high-density lipoprotein-cholesterol

High-density lipoprotein-cholesterol (HDL-C) (*Continued*)
serum T associated with lower, in 10- to 15-year-old male adolescents, apo A-I and A-II concentrations and, 432-437
sex- and age-specific plasma Hcy correlation with MDA and, 1434
smoking, LCAT, and subfractions of, in young women, 1313-1316
WC, metabolic risk factors and, 1428, 1429
see also High-density lipoprotein$_2$-cholesterol; High-density lipoprotein$_3$-cholesterol
High-density lipoprotein-cholesterol (HDL-C), atorvastatin effects on
in dyslipidemia combined with impaired fasting glucose, 336
in heterozygous and homozygous FH subjects, 978
High-density lipoprotein-cholesterol (HDL-C), diet effects on
in early postmenopausal hypercholesterolemic women, simvastatin, ETP, and estrogen-progestogen replacement therapy effects compared with, 1465
fat-containing meal effects, 213, 214
intentional weight-cycling and, in non-obese young women, 151
in obese women, *see* High-density lipoprotein-cholesterol, diet effects on, in obese women
oral L-carnitine supplementation effects on, 1390
phytosterol-enriched margarine effects, 191
plasma, in infants, 29
High-density lipoprotein-cholesterol (HDL-C), diet effects on, in obese women
energy-restricted diet effects in obese normolipidemic women, 1099
in postmenopausal women, apo E genotype effects on diet-induced changes in, 853-858
and PP TG response to fat-containing meal in NIDDM women, 213, 214
High-density lipoprotein-cholesterol (HDL-C), exercise and
and changes in subfractions of HDL-C dependent on CETP genotype, 774-778
endurance exercise effects on, in sedentary subjects, 1056
High-density lipoprotein-cholesterol (HDL-C), postmenopausal ERT effects on
atherothrombosis, thrombophilia and, 727, 728
of ETP, diet, simvastatin, and/or estrogen-progestogen therapy in hypercholesterolemic early postmenopausal women, 1465
plasma CE transfer and, 601
of sequential estrogen-progestin therapy, 1412, 1413
of tibolone and/or CEEs, 526, 527
High-density lipoprotein-cholesterol (HDL-C) in dyslipidemic NIDDM
atorvastatin effects on, 336
combined dyslipidemia, 1350, 1351
High-density lipoprotein-cholesterol (HDL-C) in FCHL
in FCHL kindreds, 219, 221, 222
gene LPL polymorphism and, 1302, 1303
and PPARγ, HSL, and C3 expression in AT, 666-668
High-density lipoprotein-cholesterol (HDL-C) in IDDM
insulin resistance, atherosclerosis and, 942
LEAD and, 250, 251
High-density lipoprotein-cholesterol (HDL-C) in Japanese NIDDM subjects
with carotid artery IMT, 540, 541
see also High-density lipoprotein-cholesterol in non-obese insulin-resistant Japanese NIDDM subjects
High-density lipoprotein-cholesterol (HDL-C) in NIDDM
cilostazol effects on, 1350, 1351
in dyslipidemic NIDDM, *see* High-density lipoprotein-cholesterol in dyslipidemic NIDDM
High-density lipoprotein-cholesterol (HDL-C) in NIDDM (*Continued*)
glycemic control in NIDDM with alpha-glucosidase inhibitor and sulfonylurea drug and, 1549
ischemic stroke and, 245, 246
in Japanese subjects, *see* High-density lipoprotein-cholesterol in Japanese NIDDM subjects
with obesity, *see* High-density lipoprotein-cholesterol in NIDDM with obesity
and PP lipemia, apo E gene polymorphism-dependent effects of age, BMI, and fasting TGs on, 1089
with remnant-like Lp particles, 966
serum, insulin resistance, atherosclerosis and, 942, 944, 945
High-density lipoprotein-cholesterol (HDL-C) in NIDDM with obesity
hypofibrinolysis and coagulation and, 472, 474
in Korean subjects, ADRB2 gene polymorphism and, 834-836
in obese women, *see* High-density lipoprotein-cholesterol in obese NIDDM women
soluble serum E-selectin and, 933
High-density lipoprotein-cholesterol (HDL-C) in non-obese insulin-resistant Japanese NIDDM subjects
CRP and, 1579
regional AT relationship to serum TGs and insulin resistance and, 545
High-density lipoprotein-cholesterol (HDL-C) in obese NIDDM women
in hyperinsulinemic obese women, 1263
and PP TG response to fat-containing meal, 213, 214
High-density lipoprotein-cholesterol (HDL-C) in obese nondiabetic subjects
in nondiabetic hyperinsulinemic obese women, 1263
in obese nondiabetic men, 1480
High-density lipoprotein-cholesterol (HDL-C) in obese women
apo E genotype effects on diet-induced changes in, 853-858
in nondiabetic hyperinsulinemic obese women, 1263
see also High-density lipoprotein-cholesterol, diet effects on, in obese women; High-density lipoprotein-cholesterol in obese NIDDM women
High-density lipoprotein-cholesterol (HDL-C) in obesity
with NIDDM, *see* High-density lipoprotein-cholesterol in NIDDM with obesity
polymorphism of exon 3 of POMC gene and, 643
TZD effects on, 171
in visceral obesity, 1043
see also High-density lipoprotein-cholesterol in obese nondiabetic subjects; High-density lipoprotein-cholesterol in obese women
High-density lipoprotein-cholesterol (HDL-C) in postmenopausal women
hyperinsulinemic women, 239-241
in obese women, apo E genotype effects on diet-induced changes in, 853-858
see also High-density lipoprotein-cholesterol, postmenopausal ERT effects on
High-density lipoprotein$_1$, *see* Lipoprotein(a)
High-density lipoprotein$_2$ (HDL_2)
in IDDM and NIDDM, extended-release niacin therapy effects on, 1123
see also High density lipoprotein$_2$-cholesterol
High-density lipoprotein$_2$-cholesterol (HDL_2-C)
exercise, CETP genotype, and changes in, 776
400 or 600 mg/d CS-045 effects on, 44-51
in IDDM and NIDDM, extended-release niacin therapy effects on, 1123

High-density lipoprotein$_2$-cholesterol (HDL_2-C) (*Continued*)
in postmenopausal women, *see* High-density lipoprotein$_2$-cholesterol in postmenopausal women
smoking, LCAT, and subfractions of, in young women, 1314
High-density lipoprotein$_2$-cholesterol (HDL_2-C) in postmenopausal women
on ERT, plasma CE transfer and, 601
in obese women, apo E genotype effects in diet-induced changes in, 856
High-density lipoprotein$_3$-cholesterol (HDL_3-C)
exercise, CETP genotype, and changes in, 776
400 or 600 mg/d CS-045 effects on, 44-51
in postmenopausal women on ERT, plasma CE transfer and, 601
smoking, LCAT, and subfractions of, in young women, 1314
High-fat (HF) diet
basal glucose transport in, effects of chronic leptin therapy on, 859-863
effects of intracellular Ca^{2+} chelation and, on insulin sensitivity, 912-918
see also High-fat diet, exercise and; High-fat diet, insulin resistance and
High-fat (HF) diet, effects of high-CHO or, exercise and
on endurance exercise performance, 678-690
lipolysis in AT and, 1291-1297
High-fat (HF) diet, exercise and
effects of LF diet and, on exercise-induced changes in metabolic parameters in obesity, 708-715
HF diet and effects of exercise on hyperlipidemia, 1587-1595
see also High-fat diet, effects of high-CHO or, exercise and
High-fat (HF) diet, insulin resistance and
HF diet and correlation between hepatic lipids and glycogen in insulin resistance, NO-1886 effects on, 792-795
LF diet or energy restriction effects on HF diet-induced insulin resistance, 695-701
High- and low-isoflavone soy (phytoestrogen) diet, effects of, on inflammatory biomarkers and proinflammatory cytokines in middle-age men and women, 919-924
High-protein diet, adaptation to, BAT and
GLUT4, glucose uptake, glycolytic enzymes and, 1501-505
lipogenesis reactivation and, role of sympathetic nervous system and insulin in, 343-349
High risk for NIDDM, relationship of subclinical inflammation to insulin resistance but not to impaired insulin secretion and, 743-749
Histochemistry of beta cells in oxidation of glycolysis-derived NADH, 318-321
Histology
renal, long-term fructose intake effects on, 1538-1547
of unilateral hyperaldosteronemia, 354
HIV (human immunodeficiency virus) infection
with AT redistribution, insulin response to glucose associated with FFA concentrations in, 260-266
and lipolysis in HIV-infected men on antiretroviral therapy, 1143-1147
metabolic response to glucose in, before and after antiprotease therapy of, 307-313
HK, *see* Hexokinase
HK1 (type 1 hexokinase) gene expression in INS-1 cells, effects of acute and/or chronic lipotoxicity on, 155-162
HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors, *see* Statins
HNSCC (head and neck squamous cell carcinoma), retinoic acid 4-hydroxylase-mediated RA catabolism and cell proliferation in, 477-481
HOMA (homeostasis model assessment) insulin resistance index
in dyslipidemia combined with impaired fasting glucose, atorvastatin effects on, 337
in epilepsy, 1275
in HIV-infected men on antiretroviral therapy, lipolysis and, 1145, 1146
insulin sensitivity and, 236
in NIDDM, *see* HOMA insulin resistance index in NIDDM
in obesity, *see* HOMA insulin resistance index in obesity
in older MS subjects, VDR polymorphism and, 358
and PP TG response to fat-containing meal by non-obese women, 213, 214
HOMA (homeostasis model assessment) insulin resistance index in NIDDM
in dyslipidemic NIDDM with impaired glucose tolerance, atorvastatin effects on, 337
pioglitazone effects on, 315
serum leptin concentrations and, 304-306
HOMA (homeostasis model assessment) insulin resistance index in obesity
beta-cell function and, in obese pubertal and prepubertal children, 1011-1016
in endurance-exercising obese NIDDM men, 1249, 1250
in nondiabetic hyperinsulinemic obese women, 1263
Homeostasis
Ca, in spinal cord injury, 960
see also Glucose homeostasis
Homeostasis model assessment insulin resistance index, *see* HOMA insulin resistance index
Homocysteine (Hcy)
fiber and multivitamin effects on, 1166-1170
in hypercholesterolemia, effects of dietary portfolio of vegetable proteins, fiber, and plant sterols on, 1599
in postmenopausal women on ERT, *see* Homocysteine in postmenopausal women on ERT
in renal failure, pharmacology of vitamin B_{12} and, 399-402
see also Hyperhomocysteinemia; Plasma homocysteine
Homocysteine (Hcy) in postmenopausal women on ERT
atherothrombosis, thrombophilia and, 727, 728
in hypercholesterolemic early postmenopausal women, effects of ETP, diet, simvastatin, and/or estrogen-progestogen therapy on, 1468
Homozygous familial hypercholesterolemia (FH) treated with LDL apheresis, atorvastatin in, 976-980
Homozygous *NeuroD1* and *Pax4* mutations, beta-cell function and late-onset DM with, in Japanese subjects, 1161-1165
Hormonal responses
to CHO-restricted diet, body composition and, 864-870
to fructose and glucose ingestion in NIDDM, 949-957
see also specific hormones
Hormonal status
influence of metabolic syndrome and, on bone density, 267-270
influence of sex and, on psyllium effects on Lp remodeling and composition, 500-507
see also specific hormones and conditions
Hormone replacement therapy (HRT)
as risk factor for metabolic syndrome, 1574
see also Estradiol replacement therapy; Estrogen replacement therapy, postmenopausal
Hormone-sensitive lipase (HSL) mRNA (messenger ribonucleic acid) in AT
FCHL subjects, 664-670
race and AT lipolytic function in obese women, 1514-1516

HPA (hypothalamic-pituitary-adrenal) axis in postmenopausal women, estrogen effects on, 137-143
HR, *see* Heart rate
HRT, *see* Hormone replacement therapy
HSL, *see* Hormone-sensitive lipase mRNA in AT
HSP70 (heat shock protein-70) gene expression, gender-dependent chronic alcohol intake effects on cFos and, in different brain regions, 1562-1568
HTG, *see* Hypertriglyceridemia
HTGL (hepatic triglyceride lipase), and PP TG response to fat-containing meal by obese and non-obese women, 211, 213-217
HTN, *see* Hypertension
Human aortic endothelial cells (HAECs)
  mitochondrial depolarization in hyperglycemia-induced apoptosis of, NAC prevention of, 1384-1388
  TNF-α effects on IR content and phosphorylation of, 487-491
Human growth hormone, recombinant, *see* Growth hormone, therapy with
Human immunodeficiency virus, *see* HIV infection
Human umbilical vascular endothelial cells (HUVECs)
  glycoxidized LDL effects on MCP-1 mRNA in, 1135-1142
  interaction of TG-rich Lps and, with apoE gene Arg^{25}→Cys mutation in Lp glomerulopathy, 201-205
HUVECs, *see* Human umbilical vascular endothelial cells
Hydrocortisone, *see* Cortisol
Hydroxocobalamin, effects of, on hyperhomocysteinemia in ESRD, 881-886
β (beta)-Hydroxyacyl-CoA dehydrogenase (β-HADH), effects of ovariectomy and estradiol replacement therapy on SM GS, PFK, CS and, 1397-1401
β-Hydroxy-5-androsten-17-one (dehydroepiandrostenedione) in postmenopausal women, ACTH and cortisol response to CRH and, 139, 140
β-Hydroxybutyrate, *see* Plasma β-hydroxybutyrate
7-Hydroxycholesterol (7-OH), chronic alcohol effects on oxysterols and, in skeletal muscle, 737-742
18-Hydroxycorticosterone in unilateral hyperaldosteronemia, 352
18-Hydroxy-11-deoxycorticosterone (18-OH-DOC) in unilateral hyperaldosteronemia, 352
4-Hydroxylase, retinoic acid, RA catabolism mediated by, and cell proliferation in head and neck squamous cell carcinoma, 477-481
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, *see* Statins
17-Hydroxyprogesterone in postmenopausal women, ACTH and cortisol response to CRH and, 139, 140
Hyperaldosteronemia, unilateral, due to multiple adrenocortical micronodules, adrenal venous sampling in detection of, 350-355
Hyperaldosteronism, idiopathic, unilateral hyperaldosteronemia compared with, 350-355
Hyperalphalipoproteinemia due to mutation in intron 1 splice donor site of CETP gene, 394-397
Hypercalcemia, lung cancer-associated, elevated PTH and PTHrP in, 871-875
Hypercatabolism, enteral glutamine effects on whole-body leucine in, 628-635
Hypercholesterolemia
  early postmenopausal women with, effects of estrogen-progestogen replacement therapy, simvastatin, ETP, and/or diet on, compared, 1463-1470
  effects of dietary portfolio with plant sterols, vegetable proteins, and fiber on, 1596-1604
Hypercholesterolemia (*Continued*)
  effects of α-linoleic acid–rich *Camelina sativa* oil on serum fatty acid composition and serum lipids in, 1253-1260
  heterozygous and homozygous familial, treated with LDL apheresis, atorvastatin in, 976-980
  mild, cholesterol release from cell membranes to PP plasma in, olive and safflower oil effects on, 1306-1312
  mild-to-moderate, relationship between cholesterol and dietary fat intake and effects of phytosterol-enriched margarine on plasma Lps in, 189-194
Hyperglucagonemia
  autoregulation of HGP during, 1128-1134
  PP, in IDDM, pramlintide effects on, 636-641
Hyperglycemia
  berberine effects in, 1439-1443
  chronic, and BBB adaptation to elevated levels of brain glucose in DM with, 1522-1524
  mitochondrial depolarization in HAEC apoptosis induced by, NAC prevention of, 1384-1388
  obesity with, vitamin C supplementation effects on insulin glycation and glucose homeostasis in, 514-517
  ovarian somatostatinoma in ovarian teratoma with alternating extreme hypoglycemia and, 1180-1183
  see also specific conditions
Hyperglycemic-glycogenolytic factor, *see* Glucagon
Hyperhomocysteinemia
  in ESRD, hydroxocobalamin effects on, 881-886
  Lp(a) increase in methionine-induced, associated with renal metabolic dysfunction, 1235-1240
Hyperinsulinemia
  androgen levels and, in perimenopausal and postmenopausal women, 238-243
  effects of TNF-α–induced, on circulating leptin during fasting, 1104-1110
  obese nondiabetic women with, weight loss effects on composition of erythrocyte membrane PL in, 1261-1268
Hyperlipidemia
  CV disease risk factors associated with γ-GT, ALT, and AST in, 1071-1076
  HF diet and effects of exercise on, 1587-1595
  see also Familial combined hyperlipidemia; Hyperalphalipoproteinemia; Hypercholesterolemia; Hypertriglyceridemia
Hyperplasia
  unilateral and primary adrenal, unilateral hyperaldosteronemia compared with, 350-355
  see also Adrenal hyperplasia
Hypertension (HTN)
  in CAD men, 734
  exercise effects on, *see* Hypertension, exercise effects on
  in FCHL, 1299
  glucose metabolism-insulin release interaction in, during IVGTT, 297-303
  in IDDM, LEAD and, 250, 251
  insulin sensitivity in, *see* Insulin sensitivity in HTN
  in postmenopausal women on ERT, *see* Hypertension in postmenopausal women on ERT
Hypertension (HTN), exercise effects on
  effects of aerobic exercise on, in older hypertensive women independently of plasma TNF-α levels, 1402-1406
  in endurance-exercising obese NIDDM men, insulin resistance and, 1249, 1250
Hypertension (HTN) in postmenopausal women on ERT
  atherothrombosis, thrombophilia and, 727, 728

Hypertension (HTN) in postmenopausal women on ERT (*Continued*)
in hypercholesterolemic early postmenopausal women, effects of ETP, simvastatin, estrogen-progestogen replacement therapy, and/or diet on, 1464
Hyperthyroidism
effects of chronic, on HDL structure and apo A-I kinetics, 443-450
of Graves' disease, circulating soluble Fas ligand and disease activity in, 769-773
Hypertriglyceridemia (HTG)
hepatic insulin sensitivity and, 409-418
PP, chronic L-NAME effects on, in NIDDM and in nondiabetic subjects, 702-707
Hypochlorite (ClO^-), NO effects on hepatocytes submitted to oxidative stress induced by, 175-179
Hypofibrinolysis, coagulation and, in obese NIDDM subjects, PAI-1 and, 471-476
Hypoglycemia
acute and prolonged effects of insulin-induced, on pituitary-thyroid axis, 1370-1374
glucagon responses to neuroglycopenia, arginine, carbachol and, in alloxan-induced DM, 12-19
ovarian somatostatinoma in ovarian teratoma with alternating extreme hyperglycemia and, 1180-1183
Hypothalamic obesity, T_3 supplementation for, 1381-1383
Hypothalamic-pituitary-adrenal (HPA) axis in postmenopausal women, estrogen effects on, 137-143
Hypothalamic somatostatin (SS), inhibition of, in GH release during strenuous exercise, 1093-1096
Hypoxanthine
beer effects on, 1317-1323
inosine effects on, 438-442
see also Hypoxanthine, urinary excretion of
Hypoxanthine, urinary excretion of
angiotensin effects on, 893-895
beer effects on, 1319, 1320, 1322

IATU (intra-abdominal thickness measured by ultrasonography) predicting risk factors for CV disease, 1034-1040
IBD (inflammatory bowel disease), children on chronic glucocorticoid therapy for, GH therapy effects on, 127-135
ICAM-1, *see* Intercellular adhesion molecule-1
IDDM, *see* Insulin-dependent diabetes mellitus
Idiopathic hyperaldosteronism (IHA), unilateral hyperaldosteronemia compared with, 350-355
IDL-C (intermediate-density lipoprotein-cholesterol) in parenchymal liver cirrhosis, 612
IFN-γ (interferon-γ), ovalbumin-specific immune response to asthma and, 1242-1243
Ig(s), *see specific immunoglobulins*
IgA (immunoglobulin A), serum, in LPG, 202
IgE (immunoglobulin E), ovalbumin-specific, in asthma, 1243
IGF-1, *see* Insulin-like growth factor-1
IGFBP-3 (insulin-like growth factor-binding protein 3) in normoponderal men, effects of short-term metformin therapy on, 533
IgG (immunoglobulin G; gamma-globulin)
ovalbumin-specific, in asthma, 1243
in postmenopausal women on ERT, atherothrombosis, thrombophilia and, 727, 728
serum, in LPG, 202
IgM (immunoglobulin M)
in postmenopausal women on ERT, atherothrombosis, thrombophilia and, 727, 728
IgM (immunoglobulin M) (*Continued*)
serum, in LPG, 202
IGT, *see* Impaired glucose tolerance
IHA (idiopathic hyperaldosteronism), unilateral hyperaldosteronemia compared with, 350-355
IL-2 (interleukin-2), production of, and ovalbumin-specific immune response to asthma, 1243
IL-6, *see* Interleukin-6
IMCD (inner medullary collecting duct), enalapril effects on aquaporin 2 and AVP V_2 in, in cardiomyopathy, 970-975
Immobilization stress, effects of, on intermediate metabolism and circulating Lps, 925-931
Immune response to asthma, ovalbumin-specific, effects of obesity on, 1241-1246
Immunoglobulin, *see entries beginning with acronym*: Ig
Immunohistochemistry of *c-myc*, alcohol intake and, 1287
Immunology, effects of declining beta-cell function in NIDDM on, 144-148
Immunoreactive insulin (iRI) in NIDDM, nateglinide effects on, 22
Impaired glucose tolerance (IGT)
in NIDDM, declining beta-cell function and, 145
in obese and/or non-obese subjects with CAD, insulin secretion and, 184-188
IMT (intima-media thickening), *see* Carotid artery intima-media thickening
Incidence
of DM in diabetes-prone subjects, effects of protein-free diets on, 569-574
see also specific conditions
Incretin
portal glucose incretin effect associated with pancreatic neural activity in conscious subjects, 1324-1330
PP response of, to sucrose by men at risk factor for CHD, 195-200
Indirect calorimetry of progressively defective insulin action on GS in NIDDM with obesity, 550
Infants, long-term effects of dietary C level on synthesis and circulating cholesterol concentrations in, 25-33
Infections
acute, malnourished children with and without, urea production and leucine oxidation in, 1418-1422
effects of, on role of intraportal L-NNA in hepatic glucose uptake in chronic TPN, 274-283
Inflammation, relationship of subclinical, to insulin resistance but not to impaired insulin secretion, high risk for NIDDM and, 743-749
Inflammatory biomarkers, effects of low- and high-isoflavone soy diet on, in middle-age men and women, 919-924
Inflammatory bowel disease (IBD), GH therapy effects in children on chronic glucocorticoid therapy for, 127-135
Inheritance, *see* Genetics
Injury, *see* Trauma and injury
Inner medullary collecting duct (IMCD), enalapril effects on aquaporin 2 and AVP V_2 in, in cardiomyopathy, 970-975
Inosine, effects of, on plasma uridine and purine bases, 438-442
INS-1 cells
glucose desensitization in, due to glucose metabolites, 671-677
see also mRNA, INS-1 cell
In situ glucose transport in skeletal muscle, differential half-maximal effects of insulin and analogs on protein synthesis and, 1065-1070
Insomnia, chronic, shift in IL-6 and TNF secretion from nighttime to daytime in, 887-892
Insulin
acute and prolonged effects of hypoglycemia induced by, on pituitary-thyroid axis, 1370-1374

Insulin (*Continued*)
aging-induced impaired responsiveness of, in skeletal muscle, effects of TNF neutralization on, 1061-1064
in CRF, 1606
differential half-maximal effects of, and analogs on in situ glucose transport and protein synthesis in SM, 1065-1070
effects of, on plasma GH, 3
effects of glucose-induced catecholamine stimulation on, 763
fasting, *see* Fasting insulin
in FCHL, PPARγ, HSL, and C3 expression in AT and, 666-668
in HIV infection with AT redistribution, to 260-266
immunoreactive, nateglinide effects on, 22
in microalbuminuric 58-year-old men, 750-753
in normotensive nondiabetic subjects, carotid artery IMT and, 256, 257
in obesity, *see* Insulin in obesity
in ovarian somatostatinoma, 1180
plasma, *see* Plasma insulin
Pro12Ala polymorphism of PPARγ2 gene effects on, 1408
and risk factors for CHD, 197
serum, *see* Serum insulin
SFA and unsaturated FA regulation by, 779-782
and TNF-α effects on eNOS increase in HAEC IR and phosphorylation, 487-491
WC and metabolic risk factors and, 1428, 1429
see also Diabetes mellitus; Hyperinsulinemia; INS-1 cells; Insulin, diet and; Insulin, exercise and; Insulin in non-obese men; Insulin release and secretion; Insulin replacement; Insulin resistance; Insulin-sensitive glucose uptake; Insulin sensitivity; Insulin-stimulated glucose disposal; Insulinotrophic actions; Proinsulin *and entries beginning with terms*: Insulin-like
Insulin, diet and
insulin response to CHO-restricted diet, 868
and PP TG response to fat-containing meal by obese and non-obese women, 213, 214
role of sympathetic nervous system and, in reactivation of BAT lipogenesis in subjects adapted to high-protein diet, 343-349
see also Plasma insulin, diet effects on
Insulin, exercise and
effects of intermittent exercise of different intensities, 659-661
and high-fat and high-CHO diet effects on insulin during endurance exercise, 685
low-intensity exercise effects on insulin, 1008
Insulin aspart, PP biphasic, for IDDM, 896-900
Insulin-dependent diabetes mellitus (IDDM), 284-296
age of onset of, correlated with cLMWPTP, sex and, 419-422
children with, *see* Children, IDDM
extended-release niacin therapy of atherogenic lipids and Lp(a) in, 1120-1127
genetic and environmental regulation of Na^+/K^+ ATPase in, ATP1-A1 polymorphism and, 284-291
insulin resistance and atherosclerosis in, 941-948
insulin therapy of, *see* Insulin-dependent diabetes mellitus, insulin therapy of
LEAD in, glycemia or estimated glucose disposal rate as predictor of, 248-254
oxidative stress effects on RBC glutathione pathways in, 1360-1362
pramlintide effects on PP hyperglucagonemia in, 636-641
Insulin-dependent diabetes mellitus (IDDM), insulin therapy of
with PP biphasic insulin aspart, 896-900
serum leptin in children with, relationship between BMI, insulin dose, and glycemic control, 292-296
Insulin-like growth factor-1 (IGF-1)
in acromegaly, SR-LAN 60 effects on levels of, 387-393
effects of rGH and, on Lp(a) levels, 508-513
in normoponderal men, effects of short-term metformin therapy on, 533
in postmenopausal women, ACTH and cortisol response to CRH and, 139, 140
response of, to CHO-restricted diet, 868
Insulin-like growth factor-1/growth hormone (IGF-1/GH) axis during rehabilitation for severe head trauma, 1363-1369
Insulin-like growth factor-binding protein 3 (IGFBP-3) in normoponderal men, effects of short-term metformin therapy on, 533
Insulin in non-obese men
AT compartments and kinetics of apo B-100 and, 1207
effects of short-term metformin therapy on, 533
Insulin in obesity
polymorphism of exon 3 of POMC gene and, 643
race and lipolytic function of AT in obese women, 1515
vitamin C supplementation effects on glycation of, in obese hyperglycemic subjects, 514-517
see also Plasma insulin in obesity
Insulin receptor, *see* Phosphorylation, IR
Insulin receptor (IR) gene, expression of, in INS-1 cells, effects of acute and/or chronic lipotoxicity on, 155-162
Insulin receptor substrate-1 (IRS-1) gene polymorphism, and lipid phenotypic expression in FCHL, 1298-1305
Insulin release and secretion
acute and/or chronic lipotoxicity effects on, 155-162
creatine supplementation effects on, 518-522
DMP effects on, in response to nutrient secretagogues and cAMP agonists, 110-114
glucose dependent on AVP-induced glucagon and somatostatin release and, 1184-1190
in INS-1 cells, 674-675
interaction between glucose metabolism and, in HTN during IVGTT, 297-303
in NIDDM, *see* Insulin release and secretion in NIDDM
in non-obese and/or obese Japanese subjects with CAD, 184-188
portal glucose incretin effect on, 1325
Insulin release and secretion in NIDDM
early phase, effects of nateglinide on glucose tolerance through enhancement of, 20-24
hypoglycemic and nonhypoglycemic effects of 400 or 600 mg/d CS-045 on, 46
relationship of subclinical inflammation to insulin resistance but not to, high risk for NIDDM and, 743-749
Insulin replacement
in NIDDM, effects of, on FFA clearance and hepatic and renal glucose release, 1494-1500
see also Insulin-dependent diabetes mellitus, insulin therapy of
Insulin resistance
effects of LDL-C and, on carotid artery IMT in normotensive nondiabetic subjects, 255-259
effects of short-term metformin therapy on, in normoponderal men, 533
fluoxetine effects on, in pancreatectomized subjects, 38-43
fructose-induced, atorvastatin effects on hepatic VLDL in, 409-418
HF diet and, *see* High-fat diet, insulin resistance and
in HIV-infected men on antiretroviral therapy, lipolysis and, 1143-1147
in IDDM, atherosclerosis and, 941-948
in Japanese subjects, *see* Insulin resistance in Japanese subjects

Insulin resistance (*Continued*)
in NIDDM, *see* Insulin resistance in NIDDM
in obesity, *see* Insulin resistance in obesity
OGTT and meal tolerance test of metabolic responses in, 595-598
relationship of subclinical inflammation to, but not to impaired insulin secretion, high risk for NIDDM and, 743-749
see also HOMA insulin resistance index; Insulin sensitivity; Japanese subjects, insulin-resistant; Metabolic syndrome
Insulin resistance in Japanese subjects
and dyslipidemia associated with *LMNA* gene mutation in, 1017-1021
see also Insulin resistance in non-obese Japanese NIDDM
Insulin resistance in NIDDM
atherosclerosis and, 941-948
in obese NIDDM men engaged in endurance exercise, 1247-1252
see also Insulin resistance in non-obese Japanese NIDDM subjects
Insulin resistance in non-obese Japanese NIDDM subjects
CRP and, 1578-1581
LMNA polymorphism and dyslipidemia with, 1020
relationship of regional AT with insulin resistance and serum TGs in, 544-548
Insulin resistance in obesity
ICAM-1 level and its relationship to TNF-α activity in, 75-78
in NIDDM men engaged in endurance exercise, 1247-1252
plasma cell membrane glycoprotein and IR autophosphorylation in, 465-470
in visceral obesity, 1043
Insulin-sensitive glucose uptake, effects of GK gene transfer to SM on, in NIDDM, 121-126
Insulin sensitivity (S_I)
contribution of beta-cell function and, to plasma glucose and insulin concentrations during OGTT, 115-120
Cr picolinate supplementation effects on serum lipids, BW and, in dexamethasone-treated subjects, 589-594
glucose effectiveness and, determined by one- and two-compartment-labeled minimal model in late prepubertal children and early adolescents, 1582-1586
hepatic, hypertriglyceridemia and, 409-418
high-fat diet and effects of intracellular Ca^{2+} chelation on, 912-918
in HTN, *see* Insulin sensitivity in HTN
in NIDDM, hypoglycemic and nonhypoglycemic effects of 400 or 600 mg/d CS-045 on, 46
in non-obese and/or obese Japanese subjects with CAD, 184-188
quantitative insulin sensitivity check index as estimate of, 235-237
role of, in glucose intolerance, 716-723
whole-body, in obese nondiabetic men, LDL particle size, oxidized LDLs and, 1478-1483
see also Insulin resistance; Insulin-sensitive glucose uptake
Insulin sensitivity (S_I) in HTN
glucose metabolism-insulin release interaction and, 300
in older hypertensive women, effects of aerobic exercise on, independently of plasma TNF-α levels, 1402-1406
Insulin-stimulated glucose disposal in middle-age, premenopausal, and early postmenopausal women and, 325
Insulin-stimulated glucose transport in SM, effects of U73122 inhibition of PLC on, 271-273
Insulin therapy, *see* Insulin replacement
Insulinotrophic actions of nateglinide and glibenclamide, compared, 575-581
Intentional weight cycling by non-obese young women on energy-restricted diet on, 149-154
Intercellular adhesion molecule-1 (ICAM-1)
angiographic assessment of circulating E-selectin, VCAM-1 and, in men with CAD and CHO metabolism disturbances, 733-736
in obesity, *see* Intercellular adhesion molecule-1 in obesity
Intercellular adhesion molecule-1 (ICAM-1) in obesity
levels and relationship of soluble, to insulin resistance and TNF-α activity in, 75-78
with NIDDM, soluble serum E-selectin and, 933
Interferon-γ (IFN-γ), production of, and ovalbumin-specific immune response to asthma, 1242-1243
Interleukin-2 (IL-2), production of, and ovalbumin-specific immune response to asthma, 1243
Interleukin-6 (IL-6)
high- and low-isoflavone soy diet effects on, 921
shift from nighttime to daytime secretion of TNF and, in chronic insomnia, 887-892
Intermediate-density lipoprotein-cholesterol (IDL-C) in parenchymal liver cirrhosis, 612
Intermediate metabolism, effects of immobilization stress on circulating Lps and, 925-931
Intermittent exercise of different intensities, effects of, on plasma amylin, 657-663
Intestinal fatty acid binding protein-2 (FABP-2) gene polymorphism, and lipid phenotypic expression in FCHL, 1298-1305
Intestinal leucine (Leu), enteral glutamine effects on, 633
Intestinal microsomal triglyceride transfer protein (MTP), PP dyslipidemia in alloxan-induced DM and, 847-852
Intestinal weight in alloxan-induced DM, hepatic or intestinal MTP effects on, 849
Intima-media thickening, *see* Carotid artery intima-media thickening
Intolerance, glucose, *see* Glucose intolerance
Intra-abdominal adipose tissue (AT)
exercise, CETP genotype, and changes in, 776
in NIDDM, TZD effects on, 171
Intra-abdominal thickness measured by ultrasonography (IATU) predicting risk factors for CV disease, 1034-1040
Intracellular Ca^{2+} (calcium), HF diet and effects of chelation of, on insulin sensitivity, 912-918
Intraportal Nω-nitro-L-arginine (L-NNA), effects of infections on role of, in hepatic glucose uptake in subjects on chronic TPN, 274-283
Intravenous glucose tolerance test (IVGTT)
glucose metabolism-insulin release interaction in HTN during, 297-303
of obese insulin-resistant subjects, 716-723
Intron 1 splice donor site of CETP gene, hyperalphalipoproteinemia due to mutation in, 394-397
Iodine in alcohol-containing diet, 1563
IR, *see* Insulin receptor gene; Phosphorylation, IR
iRI (immunoreactive insulin) in NIDDM, nateglinide effects on, 22
Iron in alcohol-containing diet, 1563
Iron overload, chronic, lipid peroxidation and hepatic protein modification in, 645-651
IRS-1 (insulin receptor substrate-1) gene polymorphism, and lipid phenotypic expression in FCHL, 1298-1305
Ischemic stroke in NIDDM, correlation between carotid artery IMT and, 244-247
Islets of Langerhans, *see* Beta cells
Iso (isoproterenol), vascular relaxation induced by, through NO production by PI3-K, 380-386
Isoflavone (phytoestrogen) soy diet, effects of high- and low-, on proinflammatory cytokines and inflammatory biomarkers, 919-924

N-[trans-4-Isopropyl-cyclohexy-carbonyl]-D-phenylalanine, *see* Nateglinide
Isoproterenol (Iso), vascular relaxation induced by, through NO production by PI3-K, 380-386
IVGTT, *see* Intravenous glucose tolerance test

Japanese subjects
effects of Pro12Ala polymorphism of PPARγ2 gene on serum adiponectin in, 1407-1409
insulin-resistant, *see* Insulin resistance in Japanese subjects
late-onset DM, with homozygous *NeuroD1* and *Pax4* mutations, beta-cell function in, 1161-1165
see also Japanese subjects, NIDDM
Japanese subjects, NIDDM
LMNA gene mutation in, 1018-1019
pioglitazone effects on metabolic parameters, AT distribution, and serum adiponectin in Japanese NIDDM men, 314-317
ultrasound of carotid artery IMT in, 539-543
see also Insulin resistance in non-obese Japanese NIDDM subjects; Japanese subjects, obese NIDDM
Japanese subjects, obese NIDDM
with CAD, insulin secretion and sensitivity in, 184-188
LMNA polymorphism and dyslipidemia with insulin resistance in, 1020

K (potassium)
content of Mg, Na and, and dexamethasone effects on [^{3}H]ouabain binding capacity of SM and, in relatives of NIDDM subjects, 1331-1339
total body, in women, ethnic variations in, 181
see also Kaliuretic peptides; Na^+/K^+ ATPase
Kaliuretic peptides in CHF, 582-588
KBs, *see* Ketone bodies
Ketoisocaproate (KIC), plasma, enteral glutamine effects on, 631, 633
Ketone bodies (KBs)
plasma, immobilization stress effects on, 927
in STZ-DM subjects, SM lactate transport and, 809
KIC (ketoisocaproate), plasma, enteral glutamine effects on, 631, 633
Kinase, *see* Creatine kinase; Glucokinase gene transfer; Hexokinase; Hexokinase type 1; Phosphatidylinositol-3-kinase; Phosphofructokinase; Phosphokinase; Pyruvate kinase; Tyrosine kinase
Kindreds
of FCHL subjects, plasma lipid- and apo B–based diagnostic criteria for FCHL in, 218-224
of NIDDM subjects, Mg, Na, and K content and dexamethasone effects on [^{3}H]ouabain binding capacity of SM in, 1331-1339
Kinetics
apo A-I, chronic hyperthyroidism effects on, 443-450
apo B-100, *see* Kinetics, apo B-100
calcium, effects of GH therapy of IBD children on chronic glucocorticoid therapy on, 130, 131
FFA, in NIDDM, insulin replacement effects on, 1497
glucose, *see* Kinetics, glucose
in HTN, *see* Kinetics in HTN
plasma chylomicron-like emulsion, in normolipidemic obese women after short-period weight loss due to energy-restricted diet, 1097-1103
whole body leucine, *see* Kinetics, whole body leucine
Kinetics, apo B-100
in non-obese men, AT compartments and, 1206-1210
in visceral obesity, plasma apo C-III and, 1041-1046
Kinetics, glucose
in HTN, 302
MCFA and LCFA effects on, 754-760
in NIDDM, insulin replacement effects on, 1496
Kinetics, whole body leucine
in hypercatabolism, enteral glutamine effects on, 628-635
MCFA and LCFA effects on, 754-760
Kinetics in HTN
C-peptide, 301-302
glucose, 302
Korean subjects, obese NIDDM, ADRB2 gene polymorphism in, 833-837

Lactate
blood, *see* Blood lactate
in NIDDM, insulin replacement effects on, 1496
L-NMMA effects on concentrations of, 62
plasma, *see* Plasma lactate
SM, MTC-1 and MTC-4 influence on STZ-DM effects on transport of, 807-813
Lactate dehydrogenase (LDH) isozyme in SM lactate transport in STZ-DM, 810
Lactation, LPL activity-dependent vitamin E uptake during, 1444-1451
Lactic acid, beer effects on, 1319, 1320
Lanosterol
hepatic and testicular, simvastatin, pravastatin, and BM 15.766 effects on, 494-496
in phytosterol-enriched margarine, 191
LANPs (long-acting atrial natriuretic peptides) in CHF, 582-588
Lanreotide, long-acting 60 mg, for acromegaly, 387-393
Laser-assisted uvuloplasy (LAUP), effects of, on sleep energy expenditure in OSAS, 622-627
Late-onset diabetes mellitus (DM) in Japanese subjects with homozygous *NeuroD1* and *Pax4* mutations, beta-cell function in, 1161-1165
Late prepubertal children, determination of insulin sensitivity and glucose effectiveness in, with one- and two-compartment-labeled minimal model, 1582-1586
Lathosterol
hepatic and testicular, simvastatin, pravastatin, and BM 15.766 effects on, 494-496
in phytosterol-enriched margarine, 191
in visceral obesity, 1043, 1045
LAUP (laser-assisted uvuloplasy), effects of, on sleep energy expenditure in OSAS, 622-627
LBM (lean body mass), *see* Fat-free mass
LCAT, *see* Lecithin:cholesterol acyltransferase
LCFAs, *see* Long-chain fatty acids
LDH (lactate dehydrogenase) isozyme in SM lactate transport in STZ-DM, 810
LDL, *see* Low-density lipoprotein(s)
LDL-C, *see* Low-density lipoprotein-cholesterol
LEAD (lower extremity arterial disease) in IDDM, glycemia or estimated glucose disposal rate as predictor of, 248-254
Lean body mass, *see* Fat-free mass
Lecithin:cholesterol acyltransferase (LCAT)
HDL-C subfractions and, in young smoking women, 1313-1316
in LPG, 202
sequential postmenopausal estrogen-progestin replacement therapy effects on particles of, 1413-1414
Leptin
circulating, effects of TNF-α–induced hyperinsulinemia on, during fasting, 1104-1110

Leptin (*Continued*)
effects of chronic therapy with, on basal glucose transport, 859-863
in NIDDM, *see* Leptin in NIDDM
in obese insulin-resistant subjects, 717, 718, 722
plasma, *see* Plasma leptin
serum, *see* Serum leptin
Leptin in NIDDM
in NIDDM men, effects of low-glycemic index breakfast with soluble fiber on expression of, 824
plasma FA composition, glucose production and, 1473
in Sudanese NIDDM subjects, 304-306
Leucine
oxidation of, in malnourished children with and without acute infection, 1418-1422
see also Kinetics, whole body leucine
LH, *see* Luteinizing hormone
Lifestyle activity, weight loss and physiologic changes after CHO-restricted diet and structured aerobic exercise or lifestyle activity, 1528-1533
Linoleate, SM, 1200, 1201
Linoleic acid
in breast milk and formula, 27
in *Camelina sativa* oil, 1254
nuclear factor-κB–dependent, stimulation of VCAM-1 expression in ECs by, 327-333
α (alpha)-Linoleic acid–rich *Camelina sativa* oil, effects of, on serum fatty acid composition and serum lipids in hypercholesterolemia, 1253-1260
Lipase
hepatic triglyceride, and PP TG response to fat-containing meal by obese and non-obese women, 211, 213-217
see also Hormone-sensitive lipase mRNA in AT; Lipoprotein lipase; Phospholipase C
Lipemia (lipidemia), *see* Dyslipidemia; Normolipidemic women; Postprandial lipemia
Lipid(s)
atherogenic, in IDDM and NIDDM, extended-release niacin therapy of, 1120-1127
effects of different oral contraceptives on levels of, 1216-1221
hepatic, HF diet and correlation between hepatic glycogen and, in insulin resistance, NO-1886 effects and, 792-795
in non-obese young women, weight cycling effects on, 151
oxidation of muscle, exercise and, 461-462
plasma, *see* Plasma lipids
protein modification and peroxidation of, in chronic iron overload, 645-651
serum, *see* Serum lipids
see also Dietary fat intake; Dyslipidemia; Lipid phenotype; Normolipidemic women; Postprandial lipemia; Phospholipid(s) *entries beginning with terms*: Fat, Fatty *element*: Lip- *and specific lipids*
Lipid phenotype, effects of LPL gene polymorphism on expression of, in FCHL, 1298-1305
Lipodystrophy
familial partial, *LMNA* mutation and, 1017-1021
in HIV infection, FFAs in, 260-266
Lipogenesis, reactivation of BAT, in subjects adapted to high-protein diet, role of sympathetic nervous system and insulin in, 343-349
α (alpha)-Lipoic acid (ALA), effects of, on NF-κB activation and monocyte adhesion by D-glucose or L-fucose, 230
Lipolysis
in AT, effects of high-fat and high-CHO diet on, 1291-1297
Lipolysis (*Continued*)
effects of menopausal status on, 322-326
in HIV-infected men on antiretroviral therapy, 1143-1147
Lipolytic function of AT in obese women, race and differences in, 1514-1516
Lipoprotein(s) (Lp)
atorvastatin effects on profile of, in dyslipidemia with impaired fasting glucose or NIDDM, 334-342
circulating, effects of immobilization stress on, 925-931
diet effects on, *see* Lipoprotein(s), diet effects on
in postmenopausal women on ERT, plasma CE transfer and, 601
remnant-like particles of, in NIDDM with apo E3/3 and apo E2 genotypes, 964-969
see also High-density lipoprotein(s); Lipoprotein(a); Lipoprotein AI; Lipoprotein AI:AII; Lipoprotein glomerulopathy; Lipoprotein lipase; Low-density lipoprotein(s)
Lipoprotein(s) (Lp), diet effects on
plasma, phytosterol-enriched margarine effects on, in mild-to-moderate hypercholesterolemia, 189-194
see also Lipoprotein(s), diet effects on composition of
Lipoprotein(s) (Lp), diet effects on composition of
in parenchymal liver cirrhosis, and relationship of vitamin E status to nutritional factors, plasma oxidation, and Lp composition, 609-615
sex and hormonal status influence on psyllium effects on Lp remodeling and composition, 500-507
Lipoprotein(a) [Lp(a); HDL_1]
anti-oxidized LDL antibody effects on, 430
in hypercholesterolemia, effects of dietary portfolio of vegetable proteins, fiber, and plant sterols on, 1599
in IDDM, *see* Lipoprotein(a) in IDDM
IGF-1 and rGH effects on levels of, 508-513
in methionine-induced hyperhomocysteinemia associated with renal metabolic dysfunction, 1235-1240
in NIDDM, *see* Lipoprotein(a) in NIDDM
in postmenopausal subjects, *see* Lipoprotein(a), postmenopausal ERT effects on
Lipoprotein(a) [Lp(a); HDL_1], postmenopausal ERT effects on
atherothrombosis, thrombophilia and, 727, 728
of ETP, diet, simvastatin, and/or estrogen-progestogen therapy in hypercholesterolemic early postmenopausal women, 1465
plasma, tibolone and/or CEE effects on, 526
plasma CE transfer and, 601
Lipoprotein(a) [Lp(a); HDL_1] in IDDM
atherogenic, extended-release niacin therapy of, 1120-1127
serum, with insulin resistance and atherosclerosis, 944-946
Lipoprotein(a) [Lp(a); HDL_1] in NIDDM
atherogenic, extended-release niacin therapy of, 1120-1127
400 or 600 mg/d CS-045 effects on, 47, 48
serum, with insulin resistance and atherosclerosis, 944-946
Lipoprotein AI (LpAI)
in NIDDM, cilostazol effects on PP lipemia and, 1348-1354
plasma, effects of endurance exercise on, in sedentary subjects, 1053-1060
sequential postmenopausal estrogen-progestin replacement therapy effects on particles of, 1413
Lipoprotein AI:AII (LpAI:AII)
plasma, effects of endurance exercise on, in sedentary subjects, 1053-1060
sequential postmenopausal estrogen-progestin replacement therapy effects on particles of, 1413
Lipoprotein glomerulopathy (LPG), HUVEC and TG-rich Lp interaction with apoE gene Arg^{25}→Cys mutation in, 201-205

Lipoprotein lipase (LPL)
in adipocytes, inhibition of, by TCCD, 65-68
in hyperlipidemic subjects on HF diet, effects of exercise on, 1592
in obese women and PP TG response to fat-containing meal, 211-217
in postmenopausal women on ERT, plasma CE transfer and, 601
vitamin E uptake around parturition and during lactation dependent on activity of, 1444-1451
see also Lipoprotein lipase gene polymorphism; Lipoprotein lipase in non-obese women
Lipoprotein lipase (LPL) gene polymorphism, effects of, on lipid phenotype expression in FCHL, 1298-1305
Lipoprotein lipase (LPL) in non-obese women
in non-obese women and PP TG response to fat-containing meal, 211-217
in young women on energy-restricted diet, intentional weight cycling effects on, 151
Lipotoxicity, *see* Beta cells, lipotoxicity effects on
Liver, *see entries beginning with terms*: Hepatic, Liver
Liver cirrhosis, parenchymal, relationship of vitamin E status to Lp composition, nutritional factors, and plasma oxidation in, 609-615
Liver weight
in alloxan-induced DM, hepatic or intestinal MTP effects on PP dyslipidemia and, 849
chronic iron overload effects on, 647
long-term fructose intake effects on, 1539
LMNA gene mutation, insulin resistance and dyslipidemia associated with, in Japanese subjects, 1017-1021
LMWPTP (low-molecular-weight protein tyrosine phosphatases), cytosolic, correlation of age of onset of IDDM with, sex ratio and, 419-422
Long-acting atrial natriuretic peptides (LANPs) in CHF, 582-588
Long-acting lanreotide, 60 mg, for acromegaly, 387-393
Long-chain fatty acids (LCFAs)
effects of MCFAs and, on whole body leucine and glucose kinetics, 754-760
see also Long-chain fatty acids, oxidation of
Long-chain fatty acids (LCFAs), oxidation of
exercise effects on oxidation, 460-464
oral L-carnitine supplementation effects on, 1389-1391
Long-term effects
of dietary cholesterol level on cholesterol synthesis and circulating cholesterol concentrations in infants, 25-33
of low-intensity exercise on dietary fat metabolism in obese weight-reduced men, 1003-1010
Long-term fructose (F) intake, biochemical consequences and effects of, on renal histology, 1538-1547
Long-term therapy with strontium ranelate, effects of, on vertebral bone mass, 906-911
Longitudinal metabolic process of bone growth in NESS and CAH, 1377-1380
Lovastatin, effects of, on proteasome activities in 20 S proteasome preparations and MC3T3-E1 osteoblastic cells, 1153-1160
Low-density lipoprotein(s) (LDL; β-lipoprotein)
atorvastatin and, *see* Atorvastatin, LDL and
effects of fiber and multivitamin on, 1166-1170
glycoxidized, effects of, on MCP-1 mRNA in HUVECs, 1135-1142
in HIV-infected men on antiretroviral therapy, lipolysis and, 1145
in non-obese young women, weight cycling effects on, 151
oxidized, *see* Oxidation, LDL
plasma, in NIDDM, effects of glipizide GITS/metformin on interaction between arterial proteoglycans and, 1223-1229
Low-density lipoprotein(s) (LDL; β-lipoprotein) (*Continued*)
risk of CAD with phenotype B LDL, influence of lipid composition in small, dense particles of, *see* Small, dense particles of LDLs
see also Low-density lipoprotein antibodies; Low-density lipoprotein-cholesterol
Low-density lipoprotein (LDL; β-lipoprotein) antibodies (Abs), anti-oxidized, C levels and, 429-431
Low-density lipoprotein-cholesterol (LDL-C)
anti-oxidized LDL antibody effects on, 430
and apo A-I and B distribution in urban Mexican population, 563-565
atorvastatin effects on, *see* Low-density lipoprotein-cholesterol, atorvastatin effects on
in CAD men, 734
diet effects on, *see* Low-density lipoprotein-cholesterol, diet effects on
effects of FFA regulation by insulin on, 780
in epilepsy, 1275
exercise and, *see* Low-density lipoprotein-cholesterol, exercise effects on
in FCHL, LPL gene polymorphism and, 1302, 1303
400 or 600 mg/d CS-045 effects on, 44-51
in hyperlipidemic subjects on HF diet, effects of exercise on, 1592; *see also* Low-density lipoprotein-cholesterol in hypercholesterolemia
in IDDM, insulin resistance, atherosclerosis and, 942
in MCS, 425
in NIDDM, *see* Low-density lipoprotein-cholesterol in NIDDM
in non-obese men, AT compartments and kinetics of apo B-100 and, 1207, 1208
in normotensive nondiabetic subjects, carotid artery IMT and, 255-259
in obesity, *see* Low-density lipoprotein-cholesterol in obesity
in parenchymal liver cirrhosis, 612
in postmenopausal women, *see* Low-density lipoprotein-cholesterol in postmenopausal women
in preclinical carotid artery atherosclerosis in women, 53
Pro12Ala polymorphism of PPARγ2 gene effects on, in Japanese subjects, 1408; *see also* Low-density lipoprotein-cholesterol in Japanese NIDDM subjects
risk of CAD with phenotype B LDL and, 1082
serum, *see* Serum low-density lipoprotein cholesterol
sex- and age-specific plasma Hcy correlation with MDA and, 1434
smoking, LCAT, and subfractions of, in young women, 1314
WC, metabolic risk factors and, 1428, 1429
Low-density lipoprotein-cholesterol (LDL-C), atorvastatin effects on
in dyslipidemia with impaired fasting glucose, 336
in heterozygous and homozygous FH treated with LDL apheresis, 977, 978
Low-density lipoprotein-cholesterol (LDL-C), diet effects on
fiber and multivitamin effects on, 1167, 1168
oral L-carnitine supplementation effects on, 1390
phytosterol-enriched margarine effects, 191, 192
plasma, in infants, 29
and PP TG response to fat-containing meal by obese and non-obese women, 213, 214
psyllium effects on, sex, hormonal status and, 503
see also Low-density lipoprotein-cholesterol, diet effects on, in obese women; Low-density lipoprotein-cholesterol, diet effects on, in postmenopausal women
Low-density lipoprotein-cholesterol (LDL-C), diet effects on, in obese women
in nondiabetic hyperinsulinemic obese women, 1263

Low-density lipoprotein-cholesterol (LDL-C), diet effects on, in obese women (*Continued*)
in normolipidemic women on energy-restricted diet, 1099
in postmenopausal women, apo E genotype effects on diet-induced changes in, 856
PP TG response to fat-containing meal and, 213, 214
Low-density lipoprotein-cholesterol (LDL-C), diet effects on, in postmenopausal women
in hypercholesterolemic early postmenopausal women, effects of simvastatin, ETP, and/or estrogen-progesterone replacement therapy effects on, compared, 1465
in obese postmenopausal women, apo E genotype effects on diet-induced changes in, 856
Low-density lipoprotein-cholesterol (LDL-C), exercise effects on
CETP genotype, exercise, and changes in LDL-C, 776
endurance exercise effects in sedentary subjects, 1056
Low-density lipoprotein-cholesterol (LDL-C), postmenopausal ERT effects and
atherosclerosis, thrombophilia and, 727, 728
ETP, estrogen-progestogen therapy, diet, and/or simvastatin in hypercholesterolemic early postmenopausal women, 1465
of sequential estrogen-progestin therapy on, 1412, 1413
of tibolone and/or CEEs, 526-527
Low-density lipoprotein-cholesterol (LDL-C) in dyslipidemic NIDDM
atorvastatin effects on, in 336
combined dyslipidemia, 1356, 1357
Low-density lipoprotein-cholesterol (LDL-C) in hypercholesterolemia
effects of dietary portfolio of vegetable proteins, fiber, and plant sterols on, 1599, 1601, 1602
in hypercholesterolemic early postmenopausal women, effects of simvastatin, ETP, and/or estrogen-progesterone replacement therapy effects on, compared, 1465
Low-density lipoprotein-cholesterol (LDL-C) in Japanese NIDDM subjects
with IMT, 540, 541
see also Low-density lipoprotein-cholesterol in non-obese insulin-resistant Japanese NIDDM subjects
Low-density lipoprotein-cholesterol (LDL-C) in NIDDM
cilostazol effects on, 1350, 1351
in dyslipidemic NIDDM, *see* Low-density lipoprotein-cholesterol in dyslipidemic NIDDM
insulin resistance and, *see* Low-density lipoprotein-cholesterol in NIDDM, insulin resistance and
in Japanese subjects, *see* Low-density lipoprotein-cholesterol in Japanese NIDDM subjects
with obesity, *see* Low-density lipoprotein-cholesterol in obesity
and PP lipemia, apo E gene polymorphism-dependent effects of age, BMI, and fasting TGs on, 1089
TZD effects on, 171
Low-density lipoprotein-cholesterol (LDL-C) in NIDDM, insulin resistance and
atherosclerosis and, 942
see also Low-density lipoprotein-cholesterol in non-obese insulin-resistant Japanese NIDDM subjects
Low-density lipoprotein-cholesterol (LDL-C) in non-obese insulin-resistant Japanese NIDDM subjects
CRP and, 1579
regional AT relationship to serum TGs and, 545
Low-density lipoprotein-cholesterol (LDL-C) in obesity
in nondiabetic obese men, 1480
in obese NIDDM Korean subjects, ADRB2 gene polymorphism and, 834-836
Low-density lipoprotein-cholesterol (LDL-C) in obesity (*Continued*)
in obese postmenopausal women, ago E genotype effects on diet-induced changes in, 856; *see also* Low-density lipoprotein-cholesterol, diet effects on, in obese women
polymorphism of exon 3 of POMC gene and, 643
in visceral obesity, 1043
Low-density lipoprotein-cholesterol (LDL-C) in postmenopausal women
hyperinsulinemic women, 239-241
obese women, apo E genotype effects on diet-induced changes in, 856
see also Low-density lipoprotein-cholesterol, diet effects on, in postmenopausal women; Low-density lipoprotein-cholesterol, postmenopausal ERT effects on
Low-fat (LF) diet
effects of, on exercise-induced changes in metabolic parameters in obesity, 708-715
effects of energy-restricted diet or, on HF diet-induced insulin resistance, 695-701
Low-glycemic index breakfast with soluble fiber in NIDDM men, 819-826
Low- and high-isoflavone (phytoestrogen) soy diet, effects of, on inflammatory biomarkers and proinflammatory cytokines in middle-age men and women, 919-924
Low-intensity exercise, long-term effects of, on dietary fat metabolism in obese weight-reduced men, 1003-1010
Low-molecular-weight protein tyrosine phosphatase (LMWPTP), cytosolic, age of onset of IDDM correlation with, sex ratio and, 419-422
Lower body resistive exercise, energy intake of older men and women engaged in whole body resistive exercise versus, 989-997
Lower extremity arterial disease (LEAD) in IDDM, glycemia or estimated glucose disposal rate as predictor of, 248-254
Lp, *see* Lipoprotein(s)
LPG (lipoprotein glomerulopathy), HUVEC and TG-rich Lp interaction with apo E gene $Arg^{25} \rightarrow Cys$ mutation in, 201-205
LPL, *see* Lipoprotein lipase
LTM_A (appendicular lean tissue mass), *see* Fat-free mass
Lung cancer associated with hypercalcemia induced by elevated levels of PTH and PTHrP, 871-875
Lutein, serum, plant sterol effects on, 653, 655
Luteinizing hormone (LH)
during rehabilitation for severe head trauma, 1366
see also Luteinizing hormone in postmenopausal women
Luteinizing hormone (LH) in postmenopausal women
ACTH and cortisol response to CRH and, 139
in hyperinsulinemic women, 238-241
Lycopene, serum, plant sterol effect on, 653, 655
Lymphocytes, total, and thyroid function in elderly subjects, 106
Lysophosphatidylcholine (lyso-PC) in glycoxidized LDL, 1135-1142
Lysosomal skeletal muscle (SM) protease activities, effects of acute and chronic alcohol intake on, 97-104

Macrophages in NIDDM, RLp effects on cholesteryl ester synthesis in, 966
Magnesium (Mg), content of Na, K and, and dexamethasone effects on [^{3}H]ouabain binding capacity of SM and, in relatives of NIDDM subjects, 1331-1339
Male adolescents, 10- to 15-year-old white and black, serum T associated with lower HDL-C in, apo A-I and A-II concentrations and, 432-437
Male subjects
older, Ca-deficient diet effects on BMD and estrogen in, 1230-1234

Male subjects (*Continued*)
see also Male adolescents; Men
Malignancy-associated hypercalcemia (MMH) associated with elevated PTH and PTHrP levels, 871-875
Malnourished children with and without acute infection, urea production and leucine oxidation in, 1418-1422
Malondialdehyde (MDA), sex- and age-specific plasma Hcy correlation with, 1433-1438
Mammary gland, vitamin E uptake by, around parturition and during lactation not dependent on LPL activity, 1444-1451
Manganese superoxide dismutase (Mn SOD), measurement of retinal and renal, in DM, 1279-1284
Margarine, effects of phytosterol-enriched, on plasma Lps in mild-to-moderate hypercholesterolemia, influence of relationship between cholesterol and dietary fat intake on, 189-194
MAS (meiosis-activating sterol), follicular and testicular, simvastatin, pravastatin, and BM 15.766 effects on, 494-496
MAT I/III (methionine adenosyltransferase I/III) deficiency, severe, plasma total Hcy in, 981-988
Maximum oxygen capacity, *see* $\dot{V}O_{2max}$
MC3T3-E1 osteoblastic cells, lovastatin effects on proteasome activities in, 1153-1160
MCFAs, *see* Medium-chain fatty acids
MCP-1, *see* Monocyte chemoattractant protein-1; Monocyte chemoattractant protein-1 mRNA
MCS (metabolic cardiovascular syndrome) in obese prepubertal children, fasting insulin in, 423-428
MDA (malondialdehyde), sex- and age-specific plasma Hcy correlation with, 1433-1438
Meal tolerance test, OGTT and, of metabolic responses in insulin resistance, 595-598
Medium-chain fatty acids (MCFAs)
effects of LCFAs and, on whole body leucine and glucose kinetics, 754-760
oxidation of, exercise effects on, 460-464
Medullary collecting duct, inner, enalapril effects on aquaporin 2 and AVP V_2 of, in cardiomyopathy, 970-975
Meiosis-activating sterol (MAS), follicular and testicular, simvastatin, pravastatin, and BM 15.766 effects on, 494-496
Men
with CAD and CHO metabolism disturbances, angiographic assessment of circulating E-selectin, VCAM-1, and ICAM-1 in, 733-736
exercising, *see* Men, exercising
58-year-old microalbuminuric, insulin metabolism in, 750-753
on glucocorticoids, adrenal androgen concentrations and circulating E_2 in, steroid-induced osteoporosis and, 1458-1462
HIV-infected, on antiretroviral therapy, lipolysis in, 1143-1147
middle-age, effects of low- and high-isoflavone soy diet on proinflammatory cytokines and inflammatory biomarkers in, 919-924
NIDDM, *see* Men, NIDDM
non-obese, *see* Men, non-obese
obese, *see* Men, obese
older, *see* Older subjects
at risk for CHD, postprandial TG, NEFA, and/or incretin responses to sucrose by, 195-200
young, skeletal muscle characteristics and increased FM in, in response to overfeeding, 451-456
see also Sex *and specific conditions*
Men, exercising
older men engaged in lower versus whole body resistive exercise, energy intake of, 989-997
Men, exercising (*Continued*)
on treadmill, circulating BNPs in, 1423-1426
see also Exercise; Men, obese exercising
Men, NIDDM
insulin-resistant, BP response to endurance exercise by, 1247-1252
Japanese, pioglitazone effects on metabolic parameters, AT distribution, and serum adiponectin in, 314-317
low-glycemic index breakfast with soluble fiber in, 819-826
see also Non–insulin-dependent diabetes mellitus
Men, non-obese
AT compartments and kinetics of apo B-100 in, 1206-1210
effects of short-term metformin therapy on serum leptin concentrations, body weight, and fat mass in, 531-536
Men, obese
nondiabetic, whole-body insulin sensitivity, LDL particle size, and oxidized LDLs in, 1478-1483
Swedish, polymorphism of exon of POMC gene in relation to salivary cortisol, serum leptin in, 642-644
see also Men, obese exercising; Obesity
Men, obese, weight loss by
fasting insulin level and plasma pollutant levels in response to, 482-486
see also Men, obese exercising, weight loss by
Men, obese exercising
insulin-resistant NIDDM, BP response to endurance exercise in, 1247-1252
see also Men, obese exercising, weight loss by
Men, obese exercising, weight loss by
long-term effects of low-intensity exercise on dietary fat metabolism in, 1003-1010
weight loss and physiologic changes after structured aerobic exercise or lifestyle activity in, 1528-1533
Menatetrenone, effects of, on Ca-deficient diet-induced decreased BMD and elevated estrogen in elderly male subjects, 1230-1234
Menopausal status
effects of, on lipolysis, 322-326
as risk factor for metabolic syndrome in women, 1574
see also Perimenopausal women; Premenopausal women; Women, postmenopausal
Mesangial expansion in STZ-DM, troglitazone and pioglitazone effects and, 404
Messenger ribonucleic acid, *see* mRNA
Met, *see* Methionine
Metabolic cardiovascular syndrome (MCS) in obese prepubertal children, fasting insulin levels in, 423-428
Metabolic process, longitudinal bone growth, in CAH and NESS, 1377-1380
Metabolic rate, *see* Resting metabolic rate
Metabolic risk factors, relationship between WC and, in subjects of European and/or Chinese ancestry, 1427-1432
Metabolic syndrome (MS; insulin resistance syndrome; syndrome X)
influence of hormonal status and, on bone density, 267-270
serum ceruloplasmin in, 838-842
in women, psychological risk factors for, 1573-1577
see also Metabolic syndrome, NIDDM and
Metabolic syndrome (MS; insulin resistance syndrome; syndrome X), NIDDM and
relationship between uric acid syndrome and MS in subjects at risk for NIDDM, 372-375
VDR polymorphism in older subjects with MS or NIDDM, 356-359
Metformin
effects of, in hyperglycemia, berberine compared with, 1439-1443

Metformin (*Continued*)
effects of short-term, on serum leptin, body weight, and FM in normoponderal men, 531-536
in NIDDM, *see* Metformin effects in NIDDM
Metformin effects in NIDDM
on asymmetric ADMA, 843-846
glipizide GITS/metformin effects on plasma LDL-arterial proteoglycan interaction, 1223-1229
Methionine (Met)
CS-045 effects on hepatic and erythrocyte *S*-adenosylmethionine, SAH, CβS, and MTHFR in Hcy metabolism, 783-786
in HF diet, 918
Lp(a) increase in methionine-induced hyperhomocysteinemia associated with renal metabolic dysfunction, 1235-1240
Methionine adenosyltransferase (MAT) I/III deficiency, severe, plasma total Hcy in, 981-988
Methylenetetrahydrofolate reductase (MTHFR), CβS and, in Hcy metabolism, CS-045 effects on hepatic and RBC SAM and SAH, plasma Hcy and, 783-786
Methylmalonic acid (MMA), serum, in ESRD, 882, 883
17-α (alpha)-Methyltestosterone (MTT), effects on apo A-I mRNA, 376-379
Mexican population, urban, apo A-I and B distribution in, 560-568
Mg (magnesium), content of Na, K and, and dexamethasone effects on [^{3}H]ouabain binding capacity of SM in relatives of NIDDM subjects, 1331-1339
mGPD (mitochondrial glycerol phosphate dehydrogenase), beta-cell, glycolysis-derived NADH and, 318-321
Microalbuminuria
and high risk for NIDDM, 745-747
insulin metabolism and, in 58-year-old men, 750-753
Microsomal triglyceride transfer protein (MTP)
in fructose-induced insulin resistance, atorvastatin effects on, 414
hepatic or intestinal, PP dyslipidemia in alloxan-induced DM and, 847-852
Microvascular response, renal, in obesity, 1553-1561
Middle-age men, effects of low- and high-isoflavone soy diet on proinflammatory cytokines and inflammatory biomarkers in, 919-924
Middle-age women
effects of low- and high-isoflavone soy diet on proinflammatory cytokines and inflammatory biomarkers in, 919-924
plasma glycerol in premenopausal, early postmenopausal and, compared, 322-326
Mild hypercholesterolemia, cholesterol release from cell membranes to PP plasma in, olive and safflower oil effects on, 1306-1312
Mild-to-moderate hypercholesterolemia, effects of relationship between cholesterol and dietary fat intake and effects of phytosterol-enriched margarine on plasma Lps in, 189-194
Mild non–insulin-dependent diabetes mellitus (NIDDM), glucose metabolism in lean subjects with, 1047-1052
Milk, long-term effects of cholesterol content of, on synthesis and concentrations of circulating cholesterol in infants, 25-33
Milk protein in protein-free diets, 570
Minerals in HF diet, 918
Minimal model
glucose metabolism-insulin release interaction in HTN during IVGTT analyzed with, 297-303
one- and two-compartment–labeled, insulin sensitivity and glucose effectiveness in late prepubertal children and early adolescents determined with, 1582-1586
Mitochondrial depolarization in hyperglycemia-induced HAEC apoptosis, NAC preventing, 1384-1388
Mitochondrial fatty acid β (beta)-oxidation (FAO) disorders, fibroblast acylcarnitine in RC defects and, compared, 366-371
Mitochondrial glycerol phosphate dehydrogenase (mGPD), beta-cell, glycolysis-derived NADH and, 318-321
MMA (methylmalonic acid), serum, in ESRD, hydroxocobalamin effects on, 883
MMH (malignancy-associated hypercalcemia) associated with elevated PTH and PTHrP levels, 871-875
Mn SOD (manganese superoxide dismutase), quantitative competitive PCR measurement of retinal and renal, in DM, 1279-1284
MNCV (motor nerve conduction velocity) in non-obese NIDDM subjects, NG and glibenclamide effects on, 1454-1455
Moderate hypercholesterolemia, relationship between cholesterol and dietary fat intake and effects of phytosterol-enriched margarine on plasma Lps in, 189-194
Modified minimal model of C-peptide kinetics and secretion in HTN, 301-302
Monocarboxylate transporter 1 (MTC-1) and monocarboxylate transporter 4 (MTC-4), STZ-DM effects on skeletal muscle lactate transport and, 807-813
Monocyte(s)
effects of D-glucose or L-fucose concentrations on adhesion of, to endothelial cell monolayers and activation of nuclear factor-κB, 225-234
see also Mononuclear cells *and entries beginning with term*: Monocyte
Monocyte chemoattractant protein-1 (MCP-1), serum, in chronic autoimmune thyroiditis, 1489-1493
Monocyte chemoattractant protein-1 (MCP-1) mRNA (messenger ribonucleic acid), glycoxidized LDL effects on, in HUVECs, 1135-1142
N^G-Monomethyl-L-arginine, monoacetate salt (L-NMMA), effects of, on NO production, 57-64
Mononuclear cells, apoptosis and proliferation of peripheral blood, in chronic hemodialysis patients, effects of Zn metabolism on, 1392-1396
Monophosphate, *see* cAMP; cAMP agonists; Guanosine monophosphate
Monosaccharides
glycemic, hormonal, and appetite responses to, in NIDDM, 949-957
see also specific monosaccharides
Monounsaturated fatty acids (MUFAs)
apo E genotype effects on diet-induced changes in, in obese postmenopausal women, 855
in *Camelina sativa* oil, 1254, 1256
in CHO-restricted diet, 866
in dietary portfolio of vegetable proteins, fiber, and plant sterols, 1597
in high- and low-isoflavone soy diet, 920
in phytosterol-enriched margarine, 190, 191
Morphology of MC3T3-E1 cell, lovastatin effects on, 1155
Motor nerve conduction velocity (MNCV) in non-obese NIDDM subjects with diabetic neuropathy, NG and glibenclamide effects on, 1454-1455
mRNA (messenger ribonucleic acid)
acute and/or chronic lipotoxicity effects on, 155-162
apolipoprotein A-I, DHEA effects on, 376-379
AVP V_2 and aquaporin 2, in cardiomyopathy, enalapril effects on, 972
c-Fos and HSP70, gender-dependent chronic alcohol intake effects on, in different brain regions, 1562-1568

mRNA (messenger ribonucleic acid) (*Continued*)
c-myc, of cardiac and skeletal muscle, alcohol intake and increased, 1285-1290
cysteine dioxygenase and cysteine sulfinic acid decarboxylase, in AT taurine biosynthesis, 1191-1197
FAS, upregulation of, in CRF, 1605-1610
HSL, *see* Hormone-sensitive lipase mRNA in AT
INS-1 cell, *see* mRNA, INS-1 cell
leptin and CETP, in NIDDM men, effects of low-glycemic index breakfast with soluble fiber on, 824
monocyte chemoattractant protein-1, glycoxidized LDL effects on, in HUVECs, 1135-1142
PPARγ, *see* mRNA, PPARγ
PPARγ2 gene, effects of Pro12Ala polymorphism of, on serum adiponectin in Japanese subjects, 1407-1409
of retinal and renal antioxidative enzymes in DM measured with quantitative competitive PCR, 1279-1284
VCAM-1, in ECs, nuclear factor-κB–dependent linoleic acid-stimulated action of, 327-333
mRNA (messenger ribonucleic acid), INS-1 cell
insulin, 672-674
IR, HK1, CPT1, and GLUT2, effects of acute and/or chronic lipotoxicity on, 155-162
mRNA (messenger ribonucleic acid), PPARγ
HSL and C3 expression and, in AT of FCHL subjects, 664-670
in NIDDM men, effects of low-glycemic index breakfast with soluble fiber on, 824
MS, *see* Metabolic syndrome
MTC-1 (monocarboxylate transporter 1) and MTC-4 (monocarboxylate transporter 4), STZ-DM effects on skeletal muscle lactate transport and, 807-813
MTFHR (methylenetetrahydrofolate reductase), CβS and, in Hcy metabolism, CS-045 effects on hepatic and RBC SAM and SAH, plasma Hcy and, 783-786
MTP, *see* Microsomal triglyceride transfer protein
MTT (17α-methyltestosterone), effects on apo A-I mRNA, 376-379
Mucosal tyrosine kinase, small bowel and colonic, effects of repetitive deformation and pressure on activity of, 1525-1527
MUFAs, *see* Monounsaturated fatty acids
Multiple adrenocortical micronodules, unilateral hyperaldosteronemia due to, adrenal venous sampling in detection of, 350-355
Multivitamin
effects of fiber with, on LDL and Hcy, 1166-1170
see also specific vitamins
Muscle
fetal nutrition and oxygen supply to, in childhood, 1569-1572
see also Cardiomyopathy; Muscle cells; Muscle glucose; Muscle glycogen; Muscle mass; Skeletal muscle *and specific muscles*
Muscle cells, vascular smooth, troglitazone effects on, 998-1002
Muscle glucose, effects of α- and β-adrenergic inhibition on uptake of, blood flow and, 1505-1513
Muscle glycogen
immobilization stress effects on, 927
see also Skeletal muscle glycogen
Mutation
apo E gene Arg^{25}→Cys, TG-rich Lp and HUVEC interaction with, in Lp glomerulopathy, 201-205
heterozygous prothrombin gene and factor V Leiden gene, ERT, thrombophilia, atherosclerosis and, 724-732
homozygous *NeuroD1* and *Pax4*, late-onset DM with, in Japanese subjects, beta-cell function in, 1161-1165
in intron 1 splice donor site of CETP gene, hyperalphalipoproteinemia due to, 394-397
Mutation (*Continued*)
LMNA gene, insulin resistance and dyslipidemia associated with, in Japanese subjects, 1017-1021
see also Polymorphism
Na (sodium)
content of Mg, K and, and dexamethasone effects on [^{3}H]ouabain binding capacity of SM in relatives of NIDDM subjects, 1331-1339
plasma, in cardiomyopathy, 971
see also Na^+/K^+ ATPase

NAC (*N*-acetyl-L-cysteine), mitochondrial depolarization in hyperglycemia-induced HAEC apoptosis prevented with, 1384-1388
NAD, *see* Nicotinamide adenine dinucleotide
Na^+/K^+ ATPase (sodium/potassium adenosine triphosphatase)
and erythrocyte membrane sialic acid content, 606
genetic and environmental regulation of, in DM, 284-291
muscle, in relatives of NIDDM subjects, 1333
L-NAME, *see* N^{ω}-Nitro-L-arginine methyl ester
Nateglinide
[N-(trans-4-isopropyl-cyclohexy-carbonyl)-D-phenylalanine; NG]
effects of, on glucose tolerance in NIDDM through enhancement of early phase insulin secretion, 20-24
glibenclamide and, *see* Nateglinide, effects of glibenclamide and, compared
Nateglinide
[N-(trans-4-isopropyl-cyclohexy-carbonyl)-D-phenylalanine; NG], effects of glibenclamide and, compared
effects of, on blood glucose and diabetic neuropathy in non-obese NIDDM subjects, 1452-1457
insulinotrophic action of, 575-581
Natriuretic peptides
atrial, in CHF, 582-588
circulating brain, in treadmill-exercising men, 1423-1426
NE, *see* Norepinephrine
Neck and head squamous cell carcinoma (SCC), retinoic acid 4-hydroxylase-mediated RA catabolism and cell proliferation in, 477-481
Neointima, effects of troglitazone inhibition on formation of, on blood flow after balloon injury, 998-1002
Nephrectomy, unilateral, plasma leptin concentrations after, 206-210
Nerve conduction velocity, motor, in non-obese NIDDM subjects with diabetic neuropathy, NG and glibenclamide effects on, 1454-1455
Nervous system
sympathetic, role of insulin and, in BAT lipogenesis reactivation, adaptation to high-protein diet and, 343-349
see also Motor nerve conduction velocity *and entries beginning with element*: Neur-
NESS (nonendocrine short stature), longitudinal metabolic process of bone growth in CAH and, 1377-1380
Neural activity, pancreatic, incretin effect of portal glucose associated with, in conscious subjects, 1324-1330
NeuroD1 mutation, and late-onset DM in Japanese subjects associated with, beta-cell function in, 1161-1165
Neuroglycopenia, glucagon responses to hypoglycemia, arginine, carbachol and, in alloxan-induced DM, 12-19
Neuropathy, diabetic, NG and glibenclamide effects on blood glucose and, in non-obese NIDDM subjects, 1452-1457
Neutral sterols in liver and testis, simvastatin, pravastatin, and BM 15.766 effects on, 492-499
NF-κB, *see* Nuclear factor-κB, ECs and

NG, *see* Nateglinide
Niacin therapy, extended-release, of atherogenic lipids and Lp(a) in IDDM and NIDDM, 1120-1127
Nicotinamide
in alcohol-containing diet, 1563
see also Nicotinamide adenine dinucleotide
Nicotinamide adenine dinucleotide (NAD)
effects of, on pancreatic islet apoptosis, 1344
reduced, glycolysis-derived, pathways used by beta-cells for oxidation of, 318-321
NIDDM, *see* Non–insulin-dependent diabetes mellitus
Nighttime secretion of TNF and IL-6 in chronic insomnia, shift from daytime to, 887-892
Nitrates, effects of L-NMMA on concentrations of, 60
Nitric oxide (NO)
effects of, on hepatocytes submitted to ClO^--induced oxidative stress, 175-179
effects of, on MCP-1 mRNA in HUVECs, 1135-1142
effects of different oral contraceptives on plasma levels of, 1216-1221
isoproterenol-induced vascular relaxation through PI3-K production of, 380-386
role of, in glucose production, 57-64
Nitric oxide synthase (NOS)
L-arginine supplementation effects on diabetic wound healing and, 1269-1273
see also Endothelial nitric oxide synthase
Nω-Nitro-L-arginine (L-NNA), intraportal, effects of infections on role of, in hepatic glucose uptake in subjects on chronic TPN, 274-283
N^{ω}-Nitro-L-arginine methyl ester (L-NAME)
effects of chronic, on PP hypertriglyceridemia in NIDDM and in nondiabetic subjects, 702-707
vascular relaxation of vessels exposed to, isoproterenol and, 383
L-NMMA (N^G-monomethyl-L-arginine, monoacetate salt), effects of, on NO production, 57-64
L-NNA (Nω-Nitro-L-arginine), intraportal, effects of infections on role of, in hepatic glucose uptake in subjects on chronic TPN, 274-283
NO, *see* Nitric oxide
Nondiabetic subjects
chronic L-NAME effects on PP HTG in, 702-707
hyperinsulinemic obese women, weight loss effects on composition of erythrocyte membrane PL in, 1261-1268
Japanese, with *LMNA* gene mutation, 1019
normotensive, effects of LDL-C and insulin resistance on carotid artery IMT in, 255-259
obese nondiabetic men, whole-body insulin sensitivity, LDL particle size, and oxidized LDLs in, 1478-1483
Nonendocrine short stature (NESS), longitudinal metabolic process of bone growth in CAH and, 1377-1380
Nonesterified fatty acids, *see* Free fatty acids
Non–insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus)
with apo E3/3 and apo E2 genotypes, remnant-like Lp particles in, 964-969
beta-cell function in, 144-148
carotid artery IMT in, *see* Carotid artery intima-media thickening in NIDDM
chronic L-NAME effects on PP HTG in, 702-707
CS-045 effects on, *see* Non–insulin-dependent diabetes mellitus, troglitazone effects on
diet effects on, *see* Non–insulin-dependent diabetes mellitus, diet effects on
Non–insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus) (*Continued*)
with dyslipidemia, *see* Dyslipidemia, NIDDM with
extended-release niacin therapy of atherogenic lipids and Lp(a) in, 1120-1127
glucose in, *see* Glucose in NIDDM
glycemic control of, *see* Glycerol control of NIDDM
insulin release in, *see* Insulin release and secretion in NIDDM
insulin resistance in, *see* Insulin resistance in NIDDM
in Japanese subjects, *see* Japanese subjects, NIDDM
men with, *see* Men, NIDDM
metformin effects in, *see* Metformin effects in NIDDM
Mg, Na, and K content and [^{3}H]ouabain binding capacity of SM in kindreds of subjects with, 1331-1339
MS in, *see* Metabolic syndrome, NIDDM and
Na^+/K^+ ATPase regulation in, 284-291
in non-obese subjects, *see* Non-obese subjects with NIDDM
normoglycemia effects on CHO oxidation in, 1484-1488
with obesity, *see* Non–insulin-dependent diabetes mellitus with obesity
PAI-1 in, *see* Plasminogen activator inhibitor-1 in NIDDM
polymorphism in, *see* Polymorphism in NIDDM
PP lipemia in, *see* Postprandial lipemia in NIDDM
risk for, *see* Risk for NIDDM
serum leptin in Sudanese subjects with, 304-306
skeletal muscle in, *see* Skeletal muscle in NIDDM
Non–insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus), diet effects on
effects of fasting-induced plasma glucose decrease on insulin response to dietary protein intake, 1027-1033
low-glycemic index breakfast with soluble fiber effects, 819-826
relationship between FPG and PP plasma glucose concentrations and dietary management of NIDDM, 457-459
Non–insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus), troglitazone effects on
hypoglycemic and nonhypoglycemic effects of 400 or 600 mg/d troglitazone in, influence of HDL and VLDL particle distribution on, 44-51
on insulin-mediated FA flux, 169-174
Non–insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus) with obesity
AT distribution in, *see* Adipose tissue distribution in NIDDM
extended-release niacin therapy of atherogenic lipids and Lp(a) in, 1120-1127
in Korean subjects, ADRB2 gene polymorphism in, 833-837
PAI-1, hypofibrinolysis, and coagulation in, 471-476
progressive defect of insulin action on glycogen synthase in, 549-553
Non-obese (lean) men
AT compartments and kinetics of apo B-100 in, 1206-1210
effects of short-term metformin therapy on serum leptin concentrations, body weight, and fat mass in, 531-536
Non-obese (lean) subjects
diabetic, beta-cell GR in, during postnatal development, 765-768
see also Non-obese men; Non-obese subjects with NIDDM; Women, non-obese
Non-obese (lean) subjects with NIDDM
with mild NIDDM, glucose metabolism in, 1047-1052
NG effects on blood glucose and diabetic neuropathy in, 1452-1457
see also Insulin resistance in non-obese Japanese NIDDM subjects
NO-1886 therapy, effects of, on correlation between hepatic lipids and glycogen content in insulin-resistant subjects on HF diet, 792-795

Norepinephrine (NE; noradrenaline)
effects of low-intensity exercise on, 1008
glucose-induced stimulation of, 761-764
plasma, *see* Plasma norepinephrine
Normoglycemia, effects of, on CHO oxidation of, in NIDDM, 1484-1488
Normolipidemic women, obese, kinetics of plasma chylomicron-like emulsion in, after short-period weight loss due to energy-restricted diet, 1097-1103
Normoponderal subjects, *see* Non-obese subjects
Normotensive subjects
glucose metabolism-insulin release interaction during IVGTT of, 297-303
nondiabetic, effects of LDL-C and insulin resistance on carotid artery IMT in, 255-259
NOS, *see* Nitric oxide synthase
Nuclear factor-κB (NF-κB), ECs and
effects of D-glucose or L-fucose concentrations on monocyte adhesion to EC monolayers and activation of, 225-234
linoleic acid-stimulated VCAM-1 expression in ECs dependent on, 327-333
Nutrient secretagogues, DMP effects on insulin release in response to cAMP agonists and, 110-114
Nutrition
fetal, muscle oxygen supply in childhood and, 1569-1572
see also Diet; Malnourished children; Total parenteral nutrition

Obese children
pubertal, beta-cell function and HOMA insulin resistance index in, 1011-1016
see also Obese children, prepubertal
Obese children, prepubertal
beta-cell function and HOMA insulin resistance index in, 1011-1016
metabolic cardiovascular syndrome in, 423-428
Obesity, 465-476
effects of, on ovalbumin-specific immune response in asthma, 1241-1246
HF diet effects on exercise-induced changes in metabolic parameters in, 708-715
hyperglycemia with, vitamin C supplementation effects on insulin glycation and glucose homeostasis in, 514-517
hypothalamic, T_3 supplementation for, 1381-1383
with insulin resistance, *see* Insulin resistance in obesity
in Japanese subjects, *see* Japanese subjects, obese NIDDM
with NIDDM, *see* Non–insulin-dependent diabetes mellitus with obesity
renal microvascular response in, 1553-1561
visceral, plasma apo C-III and kinetics of apo B-100 in, 1041-1046
see also Men, obese; Obese children; Polymorphism in obesity; Women, obese, race and; Women, obese, weight loss by; Women, obese postmenopausal
Obstructive sleep apnea syndrome (OSAS), effects of laser-assisted uvuloplasty on sleep energy expenditure in, 622-627
OC, *see* Osteocalcin
OGDH (oxoglutarate dehydrogenase), and FM increase in overfed young men, 452-454
OGTT, *see* Oral glucose tolerance test
1-25 $(OH)_2$ VD_3 (vitamin D_3), *see* Vitamin D_3
7-OH (7-hydroxycholesterol), chronic alcohol intake effects on, in SM, 737-742
β-OHB (β-hydroxybutyrate), *see* Plasma β-hydroxybutyrate
18-OH-DOC (18-hydroxy-11-deoxycorticosterone) in unilateral hyperaldosteronemia, 352

Oil(s)
effects of α-linoleic acid–rich *Camelina sativa*, on serum fatty acid composition and serum lipids in hypercholesterolemia, 1253-1260
olive, effects of, on cell membrane cholesterol release to PP plasma in mild hypercholesterolemia, 1306-1312
safflower, *see* Safflower oil
Older subjects
dietary xylitol effects on biomechanical properties of bone in, 92-96
hepatic gluconeogenesis in, 876-880
male, Ca-deficient diet effects on BMD and estrogen in, 1230-1234
with MS and/or NIDDM, VDR polymorphism in, 356-359
see also Aging effects; Older subjects, exercising
Older subjects, exercising
energy intake of, with lower versus whole body resistive exercise, 989-997
older hypertensive women, effects of aerobic exercise on S_i in, independently of plasma TNF-α levels, 1402-1406
Oleate, SM, 1200, 1201
Olive oil, effects of, on cell membrane cholesterol release to PP plasma in mild hypercholesterolemia, 1306-1312
Omental subcutaneous preadipocyte differentiation, abdominal preadipocyte differentiation compared with, 1211-1215
One- and two-compartment-labeled minimal model, insulin sensitivity and glucose effectiveness in late prepubertal children and early adolescents determined with, 1582-1586
Ophthalmoplegia, chronic progressive external, glucose effectiveness in, 796-800
Oral L-carnitine supplementation, effects of, on LCFA oxidation, 1389-1391
Oral contraceptives, effects of different, on plasma nitric oxide and Hcy levels, and lipid metabolism, 1216-1221
Oral glucose tolerance test (OGTT)
in acromegaly, preoperative GH response to TRH and, 616-621
effects of insulin sensitivity and beta-cell function on plasma glucose and insulin concentrations during, 115-120
of men with CAD and CHO metabolism disturbances, 733-736
of metabolic responses to insulin resistance and meal tolerance tests, 595-598
and risk for NIDDM, *see* Oral glucose tolerance test, and risk for NIDDM
see also specific conditions
Oral glucose tolerance test (OGTT), and risk for NIDDM
high risk for NIDDM, 743-749
in uric acid syndrome subjects, 372-375
Organ weight
heart, in cardiomyopathy, 971
intestines, in alloxan-induced DM, hepatic or intestinal MTP effects on, 849
kidney, long-term fructose intake effects on, 1539
liver, *see* Liver weight
OSAS (obstructive sleep apnea syndrome), effects of laser-assisted uvuloplasty on sleep energy expenditure in, 622-627
Osteoblastic cells, MC3T3-E1, lovastatin effects on proteasome activities in, 1153-1160
Osteocalcin (OC)
GH therapy effects in IBD children on chronic glucocorticoid therapy on, 131
serum, in SCI, bone loss and, 961
Osteoporosis
ERT effects on, 267-270

Osteoporosis (*Continued*)
steroid-induced, and circulating E_2 and adrenal androgen concentrations in men on glucocorticoids, 1458-1462
[^{3}H]Ouabain binding capacity of SM, Na, Mg, and K content in relatives of NIDDM subjects and, dexamethasone effects on, 1331-1339
Ovalbumin-specific immune response to asthma, effects of obesity on, 1241-1246
Ovarian somatostatinoma in ovarian teratoma alternating extreme hyperglycemia and hypoglycemia in, 1180-1183
Ovarian teratoma, ovarian somatostatinoma in, with alternating extreme hyperglycemia and hypoglycemia, 1180-1183
Ovariectomy, effects of estradiol replacement and, on skeletal muscle GS, PFK, CS, and β-HADH, 1397-1401
Overfeeding, SM characteristics and FM in response to, by young men, 451-456
Oxidation
CHO, in NIDDM, normoglycemia effects on, 1484-1488
exercise effects on, *see* Oxidation, exercise effects on
glucose, in NIDDM with obesity, 551
of glycolysis-derived NADH, pathways used by beta-cells for, 318-321
hepatic protein and skin collagen, chronic iron overload effects on, 647-648
LDL, *see* Oxidation, LDL
leucine, in malnourished children with and without acute infection, 1418-1422
lipid composition in small, dense LDL particles and susceptibility to, risk of CAD with phenotype B LDL and, 1081-1087
plasma, relationship of vitamin status E status with Lp composition, nutritional factors and, in parenchymal liver cirrhosis, 609-615
see also Long-chain fatty acids, oxidation of; β-Oxidation disorders; Oxidative stress; Peroxidation
Oxidation, exercise effects on
endurance exercise and high-fat and high-carbohydrate diets effects on oxidation of proteins, CHOs, and dietary fat, 683-685
on MCFA oxidation, 460-464
Oxidation, LDL
psyllium effects on, sex and hormonal status and, 503
whole-body insulin sensitivity, LDL particle size, and oxidized LDLs in obese nondiabetic men, 1478-1483
β (beta)-Oxidation disorders of mitochondrial fatty acids, fibroblast acylcarnitine in RC defects and, 366-371
Oxidative stress
ClO^--induced, NO effects on hepatocytes submitted to, 175-179
effects of, on RBC glutathione pathways in IDDM, 1360-1362
role of, in pancreatic islet apoptosis induced by chronic exposure to FFAs or high glucose, 1340-1347
Oxoglutarate dehydrogenase (OGDH), and FM increase in overfed young men, 452-454
Oxygen supply to muscle in childhood, fetal nutrition and, 1569-1572
Oxypurinol
beer effects on, 1317-1323
see also Oxypurinol, urinary excretion of
Oxypurinol, urinary excretion of
angiotensin II effects on, 893-895
beer effects on, 1319, 1320, 1322
Oxysterols, chronic alcohol effects on 7-OH and, in skeletal muscle, 737-742

P (phosphorus)
in elderly male subjects, effects of Ca-deficient diet on, 1232
P (phosphorus) (*Continued*)
serum, in SCI, bone loss and, 961
total body, in women, ethnicity and, 180-183
PAH (primary adrenal hyperplasia), unilateral hyperaldosteronemia compared with, 350-355
PAI-1, *see* Plasminogen activator inhibitor-1
Palmitate, SM, 1200, 1201
Pancreatectomy, fluoxetine effects on insulin-resistant subjects having undergone, 38-43
Pancreatic islets
chronic exposure to FFAs or high glucose inducing apoptosis of, 1340-1347
in obesity, HF and/or LF diet effects on exercise-induced changes in, 710-712
see also Beta cells
Pancreatic neural activity, incretin effect of portal glucose associated with, in conscious subjects, 1324-1330
Pantothenic acid in alcohol-containing diet, 1563
Paraoxonase (PON1), serum, effects of SFA replacement with *trans* FAs on activity of, 1534-1537
Parathyroid hormone (PTH)
in elderly male subjects, effects of Ca-deficient diet on, 1232
lung cancer-associated hypercalcemia due to elevated levels of PTHrP and, 871-875
serum, *see* Serum parathyroid hormone
Parathyroid hormone-related protein (PTHrP), lung cancer-associated hypercalcemia due to elevated levels of PTH and, 871-875
Parenchymal liver cirrhosis, relationship of vitamin E status to Lp composition, nutritional factors, and plasma oxidation in, 609-615
Parenteral nutrition, chronic total, and effects of infections on role of intraportal L-NNA on hepatic glucose uptake, 274-283
Partial lipodystrophy, familial, *LMNA* mutation and, 1017-1021
Parturition, LPL activity-dependent mammary gland vitamin E uptake around, 1444-1451
Pax4 mutation, and late-onset DM in Japanese subjects, beta-cell function and, 1161-1165
PBMC (peripheral blood mononuclear cells), effects of Zn metabolism on apoptosis and proliferation in chronic hemodialysis patients, 1392-1396
PCR (polymerase chain reaction), quantitative competitive, mRNA of retinal and renal antioxidative enzymes in DM measured with, 1279-1284
PD/GHRH (pyridostigmine/growth hormone-releasing hormone) stimulation test to detect GH deficiency in pituitary adenoma, 34-37
p85 phosphorylation, isoproterenol effects on association of cytoskeleton with, 381-382
Peptide(s)
as risk factors for CHD, 197
see also C-peptides; Gastric inhibitory peptide; Glucagon-like peptide-1; Natriuretic peptides; Telopeptide *and specific peptides*
Perimenopausal women, hyperinsulinemic, androgens in, 238-243
Peripheral blood mononuclear cells (PBMC), effects of Zn metabolism on apoptosis and proliferation of, in chronic hemodialysis patients, 1392-1396
Peroxidase, *see* Glutathione peroxidase
Peroxidation, lipid, protein modification and, in chronic iron overload, 645-651
Peroxisome proliferator-activated receptor, *see* mRNA, PPARγ; PPARγ2
PFK, *see* Phosphofructokinase
PG, *see* Plasma glucose

Pharmacology of vitamin B_{12}, Hcy, renal failure and, 399-402
Phenotype, lipid, effects of LPL gene polymorphism on expression of, in FCHL, 1298-1305
Phenotype B, LDL, effects of lipid composition in small, dense LDL particles on susceptibility to oxidation and risk of CAD with, 1081-1087
Phentolamine, effects of, on muscle glucose uptake, 1507-1509
Phenylalanine, N-[trans-4-isopropyl-cyclohexy-carbonyl]-D-, *see* Nateglinide
Phosphatase, *see* Alkaline phosphatase; Protein tyrosine phosphatase
Phosphatidylinositol 3-kinase (PI3-K), isoproterenol-induced vascular relaxation through NO production by, 380-386
Phosphofructokinase (PFK)
  BAT, effects of adaptation to high-protein diet on, 1501-1505
  effects of ovariectomy and estradiol replacement therapy on SM GS, CS, β-HADH and, 1397-1401
Phosphokinase (PK)
  creatine, in treadmill-exercising men, 1424
  and FM increase in overfed young men, 452-454
Phospholipase C (PLC), effects of U73122 inhibition of, on insulin-stimulated glucose transport in SM, 271-273
Phospholipid(s) (PLs)
  in alloxan-induced DM, hepatic or intestinal MTP effects, 849, 850
  chronic hyperthyroidism effects on, 445, 446
  erythrocyte membrane, in obese hyperinsulinemic nondiabetic women, weight loss effects on, 1261-1268
  plasma, in NIDDM, glucose production and, 1473
  postmenopausal tibolone and/or CEE effects on, 526
  psyllium effects on composition of, sex and hormonal status and, 502, 503
  sequential postmenopausal estrogen-progestin replacement therapy effects on, 1412, 1413
Phospholipid transfer protein (PLTP), effects of sequential postmenopausal estrogen-progestin replacement therapy effects on, 1414
Phosphorus, *see* P
Phosphorylation
  IR, *see* Phosphorylation, IR
  p85, isoproterenol effects on cytoskeleton association with, 381-382
Phosphorylation, IR
  IR autophosphorylation and plasma cell membrane glycoprotein in obesity with insulin resistance, 465-470
  TNF-α effects on, in HAECs, 487-491
Phylloquinone (vitamin K1) in alcohol-containing diet, 1563
Physical activity
  and total body phosphorus in women, ethnicity and, 181
  see also Exercise
Physiologic changes
  weight loss and, after restricted caloric intake and structured aerobic exercise or lifestyle activity, 1528-1533
  see also specific conditions and physiologic changes
Physiological aging, *see* Aging effects
Phytoestrogen (isoflavone) soy diet, high- and low-, effects of, on proinflammatory cytokines and inflammatory biomarkers in middle-age men and women, 919-924
Phytosterols (plant sterols)
  effects of, on serum carotenoids, 652-656
  serum, as potential risk factor for CHD, 1519-1521
  see also Phytosterols, effects of, in hypercholesterolemia *and specific phytosterols*
Phytosterols (plant sterols), effects of, in hypercholesterolemia
  effects of phytosterol-enriched margarine on plasma Lps in mild-to-moderate hypercholesterolemia, 189-194
Phytosterols (plant sterols), effects of, in hypercholesterolemia (*Continued*)
  effects of vegetable proteins, fiber and, on hypercholesterolemia, 1596-1604
PI (protease inhibitor) therapy, response to glucose in HIV infection before and after, 307-313
Pioglitazone, effects of
  on albuminuria in STZ-DM, 403-408
  on metabolic parameters, AT distribution, and serum adiponectin in Japanese NIDDM men, 314-317
Pituitary adenoma, PD/GHRH stimulation test to detect GH deficiency in, 34-37
Pituitary-adrenal axis, hypothalamic-, estrogen effects on, 137-143
Pituitary-thyroid axis, acute and prolonged effects of insulin-induced hypoglycemia on, 1370-1374
PK, *see* Phosphokinase
PL(s), *see* Phospholipid(s)
Plant sterols, *see* Phytosterols
Plasma
  oxidation of, vitamin E status relation to nutritional factors, Lp composition in parenchymal liver cirrhosis and, 609-615
  PP, cell membrane cholesterol release to, in mild hypercholesterolemia, olive and safflower oil effects on, 1306-1312
  viscosity of, phytosterol-enriched margarine effects on, 191
  see also entries beginning with term: Plasma
Plasma acetoacetate
  MCFA and LCFA effects on, 758
  in STZ-DM subjects, SM lactate transport and, 809
Plasma aldehydes, chronic iron overload effects on, 647
Plasma aldosterone in unilateral hyperaldosteronemia, 351, 353
Plasma amino acids (AAs), GH therapy effects on, in IBD children on chronic glucocorticoid therapy, 130
Plasma amylin, effects of intermittent exercise of different intensities on, 657-663
Plasma angiotensin II in cardiomyopathy, enalapril effects and, 971
Plasma apolipoprotein A-I (apo A-I), postmenopausal tibolone and/or CEE effects on, 526
Plasma apolipoprotein B (apo B)
  in FCHL, PL gene polymorphism and, 1299
  postmenopausal tibolone and/or CEE effects on, 526
Plasma apolipoprotein C-III (apo C-III)
  effects of postmenopausal tibolone and/or CEEs on, 526
  and kinetics of apo B-100 in visceral obesity, 1041-1046
  psyllium effects on, sex and hormonal status and, 502
Plasma apolipoprotein E (apo E)
  postmenopausal tibolone and/or CEE effects on, 526
  psyllium effects on, sex and hormonal status and, 502
Plasma arginine-vasopressin (AVP) V_2 in cardiomyopathy, enalapril effects and, 971
Plasma cell membrane glycoprotein (GP), insulin receptor autophosphorylation and, in obese insulin-resistant subjects, 465-470
Plasma cholesterol (C)
  chronic hyperthyroidism effects on, 445
  in obesity, ICAM-1 levels and, 76, 77
  oral contraceptive effects on, 1218
  stable isotopes in study of metabolism of, 5-11
  see also Total plasma cholesterol
Plasma cholesteryl esters (CEs), ERT enhancing transfer of, 599-304
Plasma chylomicron-like emulsion, kinetics of, in normolipidemic obese women after short-period weight loss with energy-restricted diet, 1097-1103

Plasma corticosterone, HF and/or LF diet effects on exercise-induced changes in, in obesity, 710
Plasma corticotropin (ACTH) in hypercalcemia-associated lung cancer, 872
Plasma cortisol (hydrocortisone)
L-NMMA effects on, 62
portal glucose incretin effect on, 1324, 1325
Plasma C-peptides (CPs; connecting peptides)
fasting, in HIV infection, 308, 311
L-NMMA effects on, 62
Plasma endothelin-1 (ET-1) in IDDM and NIDDM with insulin resistance and atherosclerosis, 946
Plasma epinephrine (E; adrenaline)
effects of high-fat or high-CHO diet on, during exercise, 1294, 1295
L-NMMA effects on, 62
portal glucose incretin effect on, 1324, 1325
Plasma fatty acids (FAs)
effects of, on glucose production in NIDDM, 1471-1477
see also Plasma free fatty acids
Plasma free fatty acids (FFAs; nonesterified fatty acids)
diet and, *see* Plasma free fatty acids, diet and
in HIV infection, 308
immobilization stress effects on, 927
in NIDDM, glucagon dose-response curve for hepatic glucose production and, 1114-1115
in obesity, *see* Plasma free fatty acids in obesity
portal glucose incretin effect on, 1324, 1325
Plasma free fatty acids (FFAs; nonesterified fatty acids), diet and
high-fat or high-CHO diet effects on, during exercise, 1294, 1295
LF diet or energy restriction effects on, in HF diet-induced insulin resistance, 697
LF and/or HF diet effects on exercise-induced changes in, in obesity, 710-712
MCFA and LCFA effects, 758
Plasma free fatty acids (FFAs; nonesterified fatty acids) in obesity
ICAM-1 levels and, 76, 77
LF and/or HF diet effects on exercise-induced changes in, 710-712
Plasma galactose, splanchnic, extraction of, 828-829
Plasma glucagon (hyperglycemic-glycogenolytic factor)
high-protein diet effects on, 345
MCFA and LCFA effects on, 758
L-NMMA effects on, 62
Plasma glucose (PG)
diet and, *see* Plasma glucose, diet effects on
fasting, *see* Fasting plasma glucose
and high risk for NIDDM, 745-747
insulin sensitivity and beta-cell function contribution to concentrations of, during OGTT, 115-120
MCFA and LCFA effects, 758
in NIDDM, *see* Plasma glucose in NIDDM
in obesity, *see* Plasma glucose in obesity
and splanchnic galactose extraction, 829
TNF-α effects on, 1105, 1107
and troglitazone inhibition of neointimal formation after balloon injury, 999
Plasma glucose (PG), diet effects on
high-protein diet effects, 345
vitamin C supplementation effects, 515
see also Plasma glucose, diet effects on, exercise and
Plasma glucose (PG), diet effects on, exercise and
HF and/or high-CHO diet effects, 1295
Plasma glucose (PG), diet effects on, exercise and (*Continued*)
HF and/or LF diet effects on exercise-induced changes in, in obesity, 710, 712
Plasma glucose (PG) in NIDDM
effects of fasting-induced decrease in, on insulin response to dietary protein intake in NIDDM, 1027-1033
and glucagon dose-response curve for hepatic glucose production, 1114-1115
and in nondiabetics, chronic L-NAME effects on, 704
see also Fasting plasma glucose in NIDDM; Postprandial plasma glucose in NIDDM
Plasma glucose (PG) in obesity
HF and/or LF diet effects on exercise-induced changes in, 710, 712
ICAM-1 levels and, 76, 77
see also Fasting plasma glucose in obesity
Plasma glutamine (Gln), enteral glutamine effects on, 631
Plasma glycerol
effects of high-fat or high-CHO diet on, during exercise, 1294, 1295
immobilization stress effects on, 927
MCFA and LCFA effects on, 758
in middle-age, premenopausal, and early postmenopausal women, compared, 322-326
Plasma growth hormone (GH), effects of insulin and/or clonidine stimulation on, 3
Plasma high-density lipoprotein-cholesterol (HDL-C)
in FCHL, gene LPL polymorphism and, 1299
in infants, diet and, 29
in NIDDM, effects of glipizide GITS/metformin on, 1226
oral contraceptive effects on, 1218
Plasma homocysteine (Hcy)
age- and sex-specific correlation of MDA and, 1433-1438
CS-045 effects on hepatic and erythrocyte SAM and SAH, CβS, and MTHFR in Hcy metabolism and, 783-786
effects of different oral contraceptives on levels of, 1216-1221
in ESRD, 882, 883
in IDDM and NIDDM, insulin resistance, atherosclerosis and, 942, 944, 945
total, *see* Total plasma homocysteine
Plasma β (beta)-hydroxybutyrate (β-OHB)
MCFA and LCFA effects on, 758
in NIDDM, glucose production, 1473
portal glucose incretin effect on, 1324, 1325
in STZ-DM subjects, SM lactate transport and, 809
Plasma insulin
diet effects on, *see* Plasma insulin, diet effects on
fasting, *see* Fasting plasma insulin
immobilization stress effects on, 927
insulin sensitivity and beta-cell function contribution to concentrations of, during OGTT, 115-120
in NIDDM, *see* Plasma insulin in NIDDM
L-NMMA effects on concentrations of, 62
in obesity, *see* Plasma insulin in obesity
and splanchnic galactose extraction, 829-830
TNF-α effects on, 1105-1107
and troglitazone inhibition of neointimal formation after balloon injury, 999
Plasma insulin, diet effects on
HF and/or LF diet effects on exercise-induced changes in, in obesity, 710-712
high-protein diet effects, 345
LF diet or energy restriction effects on HF diet-induced insulin resistance, 697

Plasma insulin, diet effects on (*Continued*)
in NIDDM, monosaccharide ingestion and, 951-952
psyllium effects, sex and hormonal status and, 502
vitamin C supplementation effects, 515
Plasma insulin in NIDDM
monosaccharide ingestion and, 951-952
and in nondiabetics, chronic L-NAME effects on, 704
Plasma insulin in obesity
HF and/or LF diet effects on exercise-induced changes in, 710-712
ICAM-1 levels and, 76, 77
see also Fasting plasma insulin in obesity
Plasma ketoisocaproate (KIC), enteral glutamine effects on, 631, 633
Plasma ketone bodies (KBs), immobilization stress effects on, 927
Plasma lactate
MCFA and LCFA effects on, 758
in NIDDM, glucagon dose-response curve for hepatic glucose production and, 1114-1115
and splanchnic galactose extraction, 829
in STZ-DM subjects, SM lactate transport and, 809
TNF-α effects on, 1105
Plasma leptin
concentrations of, after unilateral nephrectomy, 206-210
enteral glutamine effects on, 631
in NIDDM, TZD effects on, 171
TNF-α effects on, 1105, 1106
Plasma lipids
diagnostic criteria for FCHL based on apo B and, in members of familial combined hyperlipidemia kindreds, 218-224
in fructose-induced insulin resistance, atorvastatin effects on, 411-413
psyllium effects on composition of, sex and hormonal status and, 502
see also specific plasma lipids
Plasma lipoprotein (Lp) in mild-to-moderate hypercholesterolemia, relationship between cholesterol and dietary fat intake and effects of phytosterol-enriched margarine on, 189-194
Plasma lipoprotein(a) [Lp(a)], postmenopausal tibolone and/or CEE effects on, 526
Plasma lipoprotein AI (LpAI) and AI:AII (LpAI:AII), effects of endurance exercise on, in sedentary subjects, 1053-1060
Plasma low-density lipoprotein (LDL), effects of glipizide GITS/metformin on interaction between arterial proteoglycans and, in NIDDM, 1223-1229
Plasma low-density lipoprotein-cholesterol (LDL-C)
in FCHL, gene LPL polymorphism and, 1299
in infants, dietary cholesterol and, 29
in NIDDM, effects of glipizide GITS/metformin on, 1226
Plasma Na (sodium) in cardiomyopathy, 971
Plasma nitric oxide (NO), effects of different oral contraceptives on levels of, 1216-1221
Plasma norepinephrine (NE; noradrenaline)
effects of high-fat and high-CHO diet on, during exercise, 1294, 1295
L-NMMA effects on, 62
Plasma phospholipids in NIDDM, glucose production and, 1473
Plasma pollutants in response to weight loss by men and women, fasting insulin and, 482-486
Plasma renin activity (PRA)
angiotensin II effects on, 894
in unilateral hyperaldosteronemia, 351, 353, 354
Plasma triglycerides (TGs)
chronic hyperthyroidism effects on, 445, 446
in FCHL, LPL gene polymorphism and, 1299
Plasma triglycerides (TGs) (*Continued*)
MCFA and LCFA effects on, 758
in NIDDM, effects of glipizide GITS/metformin on, 1226
in obesity, ICAM-1 levels and, 76, 77
oral contraceptive effects on, 1218
see also Plasma triglycerides, diet effects on
Plasma triglycerides (TGs), diet effects on
HF and/or LF diet effects on exercise-induced changes in, in obesity, 710-712
in infants, 29
LF diet or energy restriction effects in HF diet-induced insulin resistance, 697
psyllium effects, sex and hormonal status and, 502, 503
Plasma tumor necrosis factor-α (TNF-α), levels of, and effects of aerobic exercise on insulin sensitivity in older hypertensive women, 1402-1406
Plasma uric acid, inosine effects on, 438-442
Plasma vitamin E (α-tocopherol), psyllium effects on, sex and hormonal status and, 503
Plasminogen activator inhibitor-1 (PAI-1)
in hypercholesterolemic early postmenopausal women, effects of ETP, diet, simvastatin, and/or estrogen-progestogen replacement therapy on, 1468
see also Plasminogen activator inhibitor-1 in NIDDM
Plasminogen activator inhibitor-1 (PAI-1) in NIDDM
effects of 400 or 600 mg/d CS-045 on, 46, 47
with obesity, hypofibrinolysis and coagulation and, 471-476
PLC (phospholipase C), effects of U73122 inhibition of, on insulin-stimulated glucose transport in SM, 271-273
PI3-K (phosphatidylinositol-3-kinase), isoproterenol-induced vascular relaxation through NO production by, 380-386
PLTP (phospholipid transfer protein), effects of sequential postmenopausal estrogen-progestin replacement therapy effects on, 1414
Pollutants, plasma levels of, in response to weight loss by men and women, fasting insulin and, 482-486
Polymerase chain reaction (PCR), quantitative competitive, mRNA of retinal and renal antioxidative enzymes in DM measured with, 1279-1284
Polymorphism
ADRB3, *see* β_3-Adrenergic receptor gene polymorphism
ATP1-A1, and Na^+/K^+ ATPase regulation in IDDM, 284-289
effects of PPARγ2 Pro12Ala, on serum adiponectin in Japanese subjects, 1407-1409
see also Mutation; Polymorphism in NIDDM; Polymorphism in obesity
Polymorphism in NIDDM
ADRB2 gene, in obese Korean NIDDM subjects, 833-837
apo E gene polymorphism-dependent effects of age, BMI, and fasting TGs on PP lipemia in NIDDM, 1088-1092
ATP1-A1, and Na^+/K^+ ATPase regulation, 284-289
VDR, in older subjects, 356-359
Polymorphism in obesity
of ADRB2 gene in obese Korean NIDDM subjects, 833-837
of POMC gene exon 3 in relation to serum leptin and salivary cortisol in obese Swedish men, 642-644
Trp64Arg β_3-adrenoceptor gene, effects of, on weight loss, body composition, or energy expenditure in obese postmenopausal women, 801-805
Polypeptide, gastric inhibitory, and risk factor for CHD, 197
Polyunsaturated fatty acids (PUFAs)
apo E genotype effects on diet-induced changes in, in obese postmenopausal women, 855
in *Camelina sativa* oil, 1254, 1256

Polyunsaturated fatty acids (PUFAs) (*Continued*)
in CHO-restricted diet, 866
in dietary portfolio of vegetable proteins, fiber, and plant sterols, 1597
in high- and low-isoflavone soy diet, 920
in phytosterol-enriched margarine, 190, 191
POMC (proopiomelanocortin) gene, polymorphism of exon 3 of, in relation to serum leptin, and salivary cortisol in obese Swedish men, 642-644
PON1 (paraoxonase), serum, effects of SFA replacement with *trans* FAs on activity of, 1534-1537
Portal glucose, incretin effect of, associated with pancreatic neural activity in conscious subjects, 1324-1330
Postmenopausal subjects, *see* Women, postmenopausal
Postnatal development, beta-cell GR in non-obese diabetic subjects during, 765-768
Postprandial (PP) biphasic insulin aspart for IDDM, 896-900
Postprandial (PP) dyslipidemia in alloxan-induced DM, hepatic and intestinal MTP and, 847-852
Postprandial (PP) free fatty acids (FFAs; nonesterified fatty acids), response of, to sucrose by men at risk for CHD, 195-200
Postprandial (PP) glucose, glycemic control in NIDDM with alpha-glucosidase inhibitor and sulfonylurea drug and, 1549, 1550
Postprandial (PP) hyperglucagonemia in IDDM, pramlintide effects on, 636-641
Postprandial (PP) hypertriglyceridemia (HTG), chronic L-NAME effects on, in NIDDM and in nondiabetic subjects, 702-707
Postprandial (PP) incretin, response of, to sucrose by men at risk for CHD, 195-200
Postprandial (PP) lipemia
in postmenopausal women on ERT, plasma CE transfer and, 601
see also Postprandial lipemia in NIDDM
Postprandial (PP) lipemia in NIDDM
apo E gene polymorphism-dependent effects of age, BMI, and fasting TGs on lipemia, 1088-1092
cilostazol effects on LpAI and, 1348-1354
Postprandial (PP) plasma, cell membrane cholesterol release to, in mild hypercholesterolemia, olive and safflower oil effects on, 1306-1312
Postprandial (PP) plasma glucose in NIDDM
and nateglinide effects on glucose tolerance, 21
treated with dietary management, relationship between FPG and, 457-459
Postprandial (PP) serum insulin in epilepsy, valproic acid effects on, 1274-1278
Postprandial triglyceride (PP TG) response
to fat-containing meal by lean and obese women, LPL and, 211-217
to sucrose by men at risk for CHD, 195-200
Potassium, *see* K
PP, *see entries beginning with term*: Postprandial
PPARγ, *see* mRNA, PPARγ
PPARγ2 (peroxisome proliferator-activated receptor γ2), effects of Pro12Ala polymorphism of, on serum adiponectin in Japanese subjects, 1407-1409
PRA, *see* Plasma renin activity
Pramlintide, effects of, on PP hyperglucagonemia in IDDM, 636-641
Pravastatin, effects of, on neutral sterols in liver and testes, 492-499
Preadipocyte differentiation, abdominal and omental subcutaneous, compared, 1211-1215
Preclinical carotid artery atherosclerosis in women, and impaired glucose homeostasis, 52-56
Pregestimil in protein-free diets, 570
Premenopausal women
bone density in, influence of hormonal status and metabolic syndrome on, 268, 269
Premenopausal women (*Continued*)
plasma glycerol in middle-age, early postmenopausal and, compared, 322-326
plasma Hcy correlation with MDA in, 1434
Preoperative growth hormone (GH), response of, to TRH test and OGTT in acromegaly, 616-621
Prepubertal children
late, one- and two-compartment–labeled minimal model determining insulin sensitivity and glucose effectiveness in, 1582-1586
see also Obese children, prepubertal
Pressure
effects of repetitive deformation and, on small bowel and colonic mucosal tyrosine kinase activity, 1525-1527
see also Blood pressure
Primary adrenal hyperplasia (PAH), unilateral hyperaldosteronemia compared with, 350-355
Pro12Ala polymorphism of PPARγ2 gene, effects of, on serum adiponectin in Japanese subjects, 1407-1409
Progestin, *see* Estrogen-progestin replacement therapy, postmenopausal, effects of, on C efflux potential
Progestogen-estrogen replacement therapy, effects of simvastatin, ETP, diet and/or, in hypercholesterolemic early postmenopausal women, compared, 1463-1470
Progressive external ophthalmoplegia, chronic, glucose effectiveness in, 796-800
Proinflammatory cytokines, effects of low- and high-isoflavone soy diet on, in middle-age men and women, 919-924
Proinsulin
and high risk for NIDDM, 745-747
microalbuminuria, insulin metabolism and, in men, 751, 752
in ovarian somatostatinoma, 1180
serum, *see* Serum proinsulin
see also Proinsulin in NIDDM
Proinsulin in NIDDM
effects of 400 or 600 mg/d CS-045 and, 46, 47
leptin concentrations and, 305
Prolactin during rehabilitation for severe head trauma, 1366
Prolonged effects of insulin-induced hypoglycemia on pituitary-thyroid axis, 1370-1374
Proopiomelanocortin (POMC) gene, polymorphism of exon 3 of, in relation to serum leptin, salivary cortisol, and obesity in Swedish men, 642-644
Propranolol, effects of, on muscle glucose uptake, 1509-1510
Prostate cancer, urinary levels of type I collagen-cross-linked N telopeptide correlated with results of bone scintigraphy for, 814-818
Protease inhibitor (PI) therapy, metabolic response to glucose in HIV infection before and after, 307-313
Proteasomal activities
lovastatin effects on, in 20 S proteasome preparations and MC3T3-E1 osteoblastic cells, 1153-1160
lysosomal and cytoplasmic SM, effects of acute and chronic alcohol intake on, 97-104
Protein
acylation-stimulating, in FCHL, and PPARγ, HSL, and C3 expression in AT, 667, 668
binding, *see* Binding proteins
breast milk and formula, 27
chronic hyperthyroidism effects on, 446
C-reactive, *see* C-reactive protein
gender-dependent chronic alcohol intake effects on expression of HSP-70 in different brain regions, 1562-1568

Protein (*Continued*)
oxidation of, in endurance exercise of different intensities, effects of HF and high-CHO diets on, compared, 683-685
PTH-related, lung cancer-associated hypercalcemia due to elevated levels of PTH and, 871-875
regulating HDL levels, effects of sequential estrogen-progestin replacement therapy in postmenopausal women on cholesterol efflux capacity and, 1410-1417
in SM, *see* Protein in SM
total, *see* Total protein
transfer, *see* Cholesteryl ester transfer protein; Microsomal triglyceride transfer protein; Phospholipid transfer protein
urinary excretion of, *see* Albuminuria
see also Dietary protein intake; Glycoprotein; Hepatic protein; Lipoprotein(s); Monocyte chemoattractant protein-1; Monocyte chemoattractant protein-1 mRNA; Protein tyrosine phosphatase; Total protein *and specific proteins*
Protein in SM
c-myc mRNA expression and increase in c-myc, 1285-1290
synthesis of, differential half-maximal effects of insulin and analogs on, 1065-1070
Protein tyrosine phosphatase (PTP)
cytosolic low-molecular-weight, correlation of age of onset of IDDM with, sex ratio and, 419-422
in obesity with insulin resistance, 467
Protein-1, *see* Monocyte chemoattractant protein-1; Monocyte chemoattractant protein-1 mRNA
Proteinuria, *see* Albuminuria
Proteoglycans, arterial, effects of glipizide GITS/metformin on interaction between plasma LDLs and, in NIDDM, 1223-1229
Prothrombin gene mutation, ERT, thrombophilia, atherosclerosis, and heterozygosity for, 724-732
Psychological response to endurance exercise, 683
Psychological risk factors for metabolic syndrome in women, 1573-1577
Psyllium, *see* Soluble fiber intake
PTH, *see* Parathyroid hormone
PTHrP (parathyroid hormone-related protein), lung cancer-associated hypercalcemia due to elevated levels of PTH and, 871-875
PTP, *see* Protein tyrosine phosphatase
Pubertal children, obese, beta-cell function and HOMA insulin resistance index in, 1011-1016
PUFAs, *see* Polyunsaturated fatty acids
Pulse rate, *see* Heart rate
Purines bases, *see* Hypoxanthine; Oxypurinol; Xanthine
Pyridostigmine/growth hormone-releasing hormone (PD/GHRH) stimulation test in detection of GH deficiency in pituitary adenoma, 34-37
Pyruvate kinase, BAT, effects of adaptation to high-protein diet on, 1501-1505
Pyruvic acid, beer effects on, 1319, 1320

Quantitative competitive polymerase chain reaction (QC-PCR), mRNA of retinal and renal antioxidative enzymes in DM measured with, 1279-1284
Quantitative insulin sensitivity check index (QUICKI), as estimate of insulin sensitivity in humans, 235-237

RA (A11-*trans*-retinoic acid), retinoic acid 4-hydroxylase-mediated catabolism of, and cell proliferation in head and neck squamous cell carcinoma, 477-481
Race and ethnicity
and cortisol response to endurance exercise, 362, 363
Race and ethnicity (*Continued*)
of DM subjects, *see* Race and ethnicity of DM subjects
fiber and multivitamin effects on LDL and, 1168
polymorphism of exon 3 of POMC gene in relation to salivary cortisol, serum leptin, and obesity in Swedish men, 642-644
of postmenopausal women on ERT, atherothrombosis, thrombophilia and, 727, 728
relationship between WC and metabolic risk factors in subjects of European and/or Chinese ancestry, 1427-1432
and risk factors for CV disease, 1035, 1038
and serum T associated with lower HDL-C in 10- to 15-year-old male adolescents, apo A-I and A-II concentrations and, 432-437
and total body phosphorus in women, 181-183
urban Mexican population, apo A-I and B distribution in, 560-568
see also Japanese subjects; Women, obese, race and
Race and ethnicity of DM subjects
IDDM subjects, PP hyperglucagonemia and, 637
and Na^+/K^+ ATPase activity, 284-291
see also Race and ethnicity of NIDDM subjects
Race and ethnicity of NIDDM subjects
obese Korean subjects, ADRB2 gene polymorphism in, 833-837
Sudanese subjects, serum leptin, 304-306
RBCs (red blood cells), *see* Erythrocyte(s)
RC (respiratory chain) defects, fibroblast acylcarnitine in mitochondrial fatty acid β-oxidation disorders and, compared, 366-371
Reactive oxygen species (ROS), increased D-glucose or L-fucose concentration effects on generation of, 228-229
Recombinant growth hormone, *see* Growth hormone
Red blood cells, *see* Erythrocyte(s)
Reductase
CβS and methylenetetrahydrofolate, in Hcy metabolism, CS-045 effects on hepatic and RBC SAM and SAH and, 783-786
inhibitors of HMG-CoA, *see* Statins
REE, *see* Resting energy expenditure
Regional adipose tissue (AT)
relationship of, with insulin resistance and serum TGs in non-obese Japanese NIDDM subjects, 544-548
see also Subcutaneous adipose tissue; Visceral adipose tissue
Rehabilitation for severe head trauma, GH/IGF-1 axis during, 1363-1369
Relatives, *see* Kindreds
Relaxation, vascular, induced by isoproterenol through NO production by PI3-K, 380-386
Remnant-like lipoprotein (RLp) particles in NIDDM with apo E3/3 and apo E2 genotypes, 964-969
Renal antioxidative enzymes in DM measured with quantitative competitive PCR, 1279-1284
Renal disease
end-stage, hydroxocobalamin effects on hyperhomocysteinemia in, 881-886
lipoprotein glomerulopathy as, HUVEC and TG-rich Lp interaction with apo E gene $Arg^{25} \rightarrow Cys$ mutation in, 201-205
Renal failure
chronic, upregulation of FAS gene expression in, 1605-1610
Hcy, pharmacology of vitamin B_{12} and, 399-402
Renal glucose, release of, in NIDDM, insulin replacement effects on hepatic glucose release, FFA clearance and, 1494-1500
Renal histology, long-term fructose intake effects on, 1538-1547
Renal insufficiency in DM, effects of glycated albumin inhibition on collagen IV urinary excretion and on prevention of, 901-906

Renal metabolic dysfunction, Lp(a) increase in methionine-induced hyperhomocysteinemia associated with, 1235-1240
Renal microvascular response in obesity, 1553-1561
Repetitive deformation and pressure, effects of, on small bowel and colonic mucosal tyrosine kinase activity, 1525-1527
Resistive exercise, lower versus whole body, by older men and women, energy intake and, 989-997
Respiratory chain (RC) defects, fibroblast acylcarnitine in mitochondrial fatty acid β-oxidation disorders and, compared, 366-371
Respiratory quotient (RQ)
of normoponderal men, effects of short-term metformin therapy on, 532, 533
in OSAS, 623, 624
Resting energy expenditure (REE)
changes in, after dietary restriction and structured exercise, 1529
by normoponderal men, effects of short-term metformin therapy on, 532, 533
by older men and women engaged in lower versus whole body resistive exercise, 993
Resting metabolic rate (RMR)
and FM increase in overfed young men, 453, 454
in non-obese young women, weight cycling effects on, 151
Restricted diet, *see* Calorie-restricted diet; Energy-restricted diet
Retarded growth, GH-related, in NIDDM children with glucose intolerance and, BGLIIA*2/BGLIIB*1 GH haplotype and, 1-4
Retinal antioxidative enzymes in DM measured with quantitative competitive PCR, 1279-1284
Retinoic acid (RA), A11-*trans*-, retinoic acid 4-hydroxylase–mediated catabolism of, and cell proliferation in head and neck squamous cell carcinoma, 477-481
Retinoic acid 4-hydroxylase (CYP26), RA catabolism mediated by, and cell proliferation in head and neck squamous cell carcinoma, 477-481
Retinol, *see* Vitamin A
Retinopathy in IDDM, LEAD and, 250, 251
RGH (recombinant growth hormone), *see* Growth hormone
Riboflavin (vitamin B_2) in alcohol-containing diet, 1563
Ribonucleic acid, *see* mRNA
Risk factors
for CAD in phenotype B LDL subjects, and influence of lipid composition in small, dense LDL particles on oxidation susceptibility, 1081-1087
psychological, for metabolic syndrome in women, 1573-1577
WC and metabolic, in European and/or Chinese ancestry subjects, 1427-1432
see also Risk factors for CHD; Risk factors for CV disease; Risk for NIDDM
Risk factors for CHD
change in, over time, 1022-1026
in men, postprandial TG, NEFA, and/or incretin responses to sucrose and, 195-200
serum phytosterols as potential, 1519-1521
Risk factors for CV disease
associated with elevation of γ-GT, AST, and ALT in hyperlipidemia, 1071-1076
IATU predicting, 1034-1040
see also Risk factors for CHD
Risk for NIDDM
high, and relationship of subclinical inflammation to insulin resistance but not to impaired insulin secretion, 743-749
uric acid syndrome and, 372-375
RLp (remnant-like lipoprotein) particles in NIDDM with apo E3/3 and apo E2 genotypes, 964-969
RMR, *see* Resting metabolic rate
ROS (reactive oxygen species), increased D-glucose or L-fucose concentration effects on generation of, 228-229
RQ, *see* Respiratory quotient

S, *see* Sucrose
SA (sialic acid), erythrocyte membrane, GDM effects on, 605-608
SAA (serum amyloid A), high- and low-isoflavone soy diet effects on, 921
Safety
of 400 or 600 mg/d CS-045, 47-48
of GH therapy for IBD children on chronic glucocorticoid therapy, 131
of PP biphasic insulin aspart therapy in NIDDM, 897-898
Safflower oil
effects of, on cell membrane cholesterol release to PP plasma in mild hypercholesterolemia, 1306-1312
in HF diet, 918
SAH (*S*-adenosylhomocysteine) and SAM (*S*-adenosylmethionine), hepatic and RBC, CS-045 effects on plasma Hcy, CβS and MTHFR in Hcy metabolism and, 783-786
Salivary cortisol, polymorphism of exon 3 of POMC gene in relation to serum leptin, obesity and, in Swedish men, 642-644
SAM (*S*-adenosylmethionine) and SAH (*S*-adenosylhomocysteine), hepatic and RBC, CS-045 effects on plasma Hcy, CβS and MTHFR in Hcy metabolism and, 783-786
Sarcopenia in women, appendicular LTM_A and prevalence of, 69-74
SAT (subcutaneous adipose tissue) in NIDDM, pioglitazone effects on, 316
Saturated fatty acids (SFAs)
apo E genotype effects on diet-induced changes in, in obese postmenopausal women, 855
in *Camelina sativa* oil, 1254, 1256
in CHO-restricted diet, 866
in dietary portfolio of vegetable proteins, fiber, and plant sterols, 1597
effects of *trans* fatty acid replacement of, on serum PON1 activity, 1534-1537
in high- and low-isoflavone soy diet, 920
insulin regulation of, 779-782
in phytosterol-enriched margarine, 190-192
SBP (systolic blood pressure), *see* Blood pressure
SCC (squamous cell carcinoma), head and neck, retinoic acid 4-hydroxylase–mediated RA catabolism and cell proliferation in, 477-481
SCI (spinal cord injury), bone biochemical markers and dual-energy x-ray absorptiometry for evaluation of bone loss in, 958-963
Scintigraphy, bone, in prostate cancer, urinary levels of type I collagen-cross-linked N telopeptide correlated with results of, 814-818
Secretagogues, nutrient, DMP effects on insulin release in response to cAMP agonists and, 110-114
Sedentary subjects, effects of endurance exercise on plasma LpAI and LpAI:AII in, 1053-1060
E-Selectin
angiographic assessment of VCAM-1, ICAM-1 and circulating, in men with CAD and CHO metabolism disturbances, 733-736
soluble serum, in NIDDM, correlation of, with obesity but not with AT distribution, 932-934
Sequential estrogen-progestin replacement therapy, postmenopausal, effects of, on cholesterol efflux capacity and proteins regulating HDL levels, 1410-1417

Serine (Ser), blood, portal glucose incretin effect on, 1324, 1325
Serum adiponectin in Japanese subjects
effects of Pro12Ala polymorphism of PPARγ2 gene on, 1407-1409
NIDDM men, pioglitazone effects on metabolic parameters, AT distribution and, 314-317
Serum albumin
in ESRD, 882
in LPG, 202
Serum alkaline phosphatase (ALP) in SCI, bone loss and, 961
Serum amyloid A (SAA), high- and low-isoflavone soy diet effects on, 921
Serum androstenedione in men on glucocorticoids, SIOP and, 1460
Serum C telopeptide in SCI, bone loss and, 961
Serum calcitonin in lung cancer associated with hypercalcemia, 872
Serum cAMP (cyclic adenosine monophosphate) in hypercalcemia-associated lung cancer, 872
Serum α (alpha)- and β (beta)-carotene, plant sterol effects on, 653, 655
Serum carotenoids, plant sterol effects on, 652-656
Serum ceruloplasmin in MS, 838-842
Serum cholesterol (C)
and influence of hormonal status and metabolic syndrome on bone density, 268, 269
postmenopausal tibolone and/or conjugated equine estrogen effects on efflux potential of, 523-530
total, *see* Total serum cholesterol
Serum corticosterone, immobilization stress effects on, 927
Serum cortisol (hydrocortisone) in hypercalcemia-associated lung cancer, 872
Serum C-peptides
in IDDM and NIDDM, insulin resistance and atherosclerosis and, 942
valproic acid effects on, in epilepsy, 1275, 1276
Serum creatinine
in ESRD, 882
in IDDM, LEAD and, 250, 251
in LPG, 202
Serum α (alpha)- and β (beta)-cryptoxanthin, plant sterol effects on, 653, 655
Serum dehydroepiandrosterone sulfate (DHEAS) in men on glucocorticoids, SIOP and, 1460
Serum fat-soluble vitamins, plant sterol effects on, 652-656
Serum fatty acids (FA), effects of α-linoleic acid–rich *Camelina sativa* oil on composition of, in hypercholesterolemia, 1253-1260
Serum folate in ESRD, 882, 883
Serum glucose
FXTN effects on, in pancreatectomized subjects, 40, 41
in IDDM, PP biphasic insulin aspart therapy and, 897
oral L-carnitine supplementation effects on, 1390
Serum high-density lipoprotein (HDL), effects of α-linoleic acid–rich *Camelina sativa* oil on, in hypercholesterolemia, 1254
Serum high-density lipoprotein-cholesterol (HDL-C)
in IDDM and NIDDM, insulin resistance, atherosclerosis and, 942, 944, 945
and influence of hormonal status and metabolic syndrome on bone density, 268, 269
Serum IgA (immunoglobulin A) in LPG, 202
Serum IgG (immunoglobulin G; gamma-globulin) in LPG, 202
Serum IgM (immunoglobulin M) in LPG, 202
Serum insulin
FXTN effects on, in pancreatectomized subjects, 40, 41
PP, in epilepsy, valproic acid effects on, 1274-1278
Serum leptin
in epilepsy, 1275, 1276
in IDDM children, relationship between BMI, insulin dose, glycemic control and, 292-296
in obesity, *see* Serum leptin in obesity
short-term metformin therapy effects on, in normoponderal men, 531-536
in Sudanese NIDDM subjects, 304-306
Serum leptin in obesity
in asthmatic subjects, 1242
POMC gene exon 3 polymorphism in relation to salivary cortisol, obesity, and serum leptin in Swedish men, 642-644
Serum lipids
dexamethasone and Cr picolinate supplementation effects on insulin sensitivity, body weight and, 589-594
in hypercholesterolemia, effects of α-linoleic acid–rich *Camelina sativa* oil on, 1253-1260
in IDDM, PP biphasic insulin aspart therapy and, 897
see also specific serum lipids
Serum lipoprotein(a) [Lp(a)] in IDDM and NIDDM with insulin resistance and atherosclerosis, 944-946
Serum low-density lipoprotein (LDL), effects of α-linoleic acid–rich *Camelina sativa* oil on, in hypercholesterolemia, 1254
Serum low-density lipoprotein-cholesterol (LDL-C)
in IDDM and NIDDM, insulin resistance, atherosclerosis and, 942
and influence of hormonal status and metabolic syndrome on bone density, 268, 269
Serum lutein, plant sterol effects on, 653, 655
Serum lycopene, plant sterol effects on, 653, 655
Serum methylmalonic acid (MMA) in ESRD, 882, 883
Serum monocyte chemoattractant protein-1 (MCP-1) in chronic autoimmune thyroiditis, 1489-1493
Serum osteocalcin (OC) in SCI, bone loss and, 961
Serum P (phosphorus) in SCI, bone loss and, 961
Serum paraoxonase (PON1), effects of SFA replacement with *trans* FAs on activity of, 1534-1537
Serum parathyroid hormone (PTH)
in lung cancer associated with hypercalcemia, 872
in SCI, bone loss and, 961
Serum parathyroid hormone-related protein (PTHrP) in lung cancer associated with hypercalcemia, 872
Serum phytosterols (plant sterols), as potential risk factor for CHD, 1519-1521
Serum proinsulin
in Sudanese NIDDM subjects, 305
valproic acid effects on, in epilepsy, 1275, 1276
Serum retinol, plant sterol effects on, 653, 654
Serum soluble E-selectin, in NIDDM, correlation of, with obesity but not with AT distribution, 932-934
Serum testosterone (T)
associated with lower HDL-C in 10- to 15-year-old male adolescents, apo A-I and A-II concentrations and, 432-437
in men on glucocorticoids, SIOP and, 1460
Serum thyrotropin (TSH)
in lung cancer associated with hypercalcemia, 872
vitamin A effects on concentrations of, 691-694
Serum thyroxine (T_4)
in lung cancer associated with hypercalcemia, 872
vitamin A effects on concentrations of, 691-694
Serum α (alpha)-, β (beta)-, and γ (gamma)-tocopherol, plant sterol effects on, 653, 654
Serum total cholesterol (TC) in IDDM and NIDDM, insulin resistance, atherosclerosis and, 942, 944, 945

Serum triacylglycerols (TAG), total, in hypercholesterolemia, effects of α-linoleic acid–rich *Camelina sativa* oil on, 1254
Serum triglycerides (TGs)
in IDDM, insulin resistance, atherosclerosis and, 942, 944, 945
influence of hormonal status and metabolic syndrome on, 268, 269
in LPG, 202
see also Serum triglycerides in NIDDM with insulin resistance
Serum triglycerides (TGs) in NIDDM with insulin resistance
atherosclerosis and, 942, 944, 945
regional AT relationship to, in non-obese Japanese NIDDM subjects, 544-548
Serum triiodothyronine (T_3) in lung cancer associated with hypercalcemia, 872
Serum urea in ESRD, 882
Serum uric acid
in IDDM and NIDDM with insulin resistance and atherosclerosis, 942, 944-946
in LPG, 202
Serum vitamin B_{12} in ESRD, 882, 883
Serum vitamin D, plant sterol effects on, 654
Serum vitamin D_3 [1-25 $(OH)_2$ VD_3] in lung cancer associated with hypercalcemia, 872
Serum vitamin K, plant sterol effects on, 654
Serum zeaxanthin, plant sterol effects on, 653
Severe head trauma, GH/IGF-1 axis in, during rehabilitation, 1363-1369
Severe methionine adenosyltransferase (MAT) I/III deficiency, plasma total Hcy in, 981-988
Sex
of acromegalic subjects, *see* Sex of acromegalic subjects
age- and sex-specific plasma Hcy correlation with MDA, 1433-1438
and apo A-I and apo B distribution in urban Mexican population, 566
of CPEO patients, 797
of ESRD subjects, 882
of exercising subjects, and changes in HDL-C subfractions, 776
fiber and multivitamin effects on LDL and, 1168
and gender-dependent effects of chronic alcohol intake on c-Fos and heat shock protein-70 gene expression in different brain regions, 1562-1568
of Graves' disease subjects, 770
of head trauma subjects, 1364
of heterozygous and homozygous FH subjects, 977
of HIV-infected subjects, 263, 264
in hyperinsulinemic perimenopausal women, 238-241
of hyperlipidemic subjects on HF diet, 1589, 1592-1594; *see also* Sex of FCHL subjects
of IBD children on chronic glucocorticoid therapy, 128
of IDDM subjects, *see* Sex of IDDM subjects
influence of hormonal status and, on psyllium effects on Lp remodeling and composition, 500-507
of Japanese late-onset DM subjects, 1162, 1163; *see also* Sex of IDDM subjects; Sex of NIDDM subjects
of malnourished children with and without acute infection, 1419
of MAT I/III deficiency subjects, 983
of MCS subjects, 424, 425
of NIDDM subjects, *see* Sex of NIDDM subjects
of older MS subjects, VDR polymorphism and, 357
of OSAS subjects, 623
of pituitary adenoma subjects, 35
as risk factor, *see* Sex, as risk factor
of unilateral hyperaldosteronemia subjects, 351
and uric acid syndrome in subjects at risk for NIDDM, 373, 374
Sex (*Continued*)
see also Men; Women
Sex, as risk factor
for CAD, 1082
for CV disease, 1037, 1073
Sex of acromegalic subjects
lanreotide effects and, 388
and preoperative response to OGTT and TRH test, 617, 618
Sex of FCHL subjects
and kindreds, 221
lipid phenotypic expression and, 1299
and PPARγ, HSL, and C3 expression in AT, 666
Sex hormone-binding globulin (SHBG)
assays measuring, 555
in MCS, 426
response of, to CHO-restricted diet, 868
see also Sex hormone–binding globulin in postmenopausal women
Sex hormone–binding globulin (SHBG) in postmenopausal women
ACTH and cortisol response to CRH and, 139, 140
in hyperinsulinemic women, 238-241
Sex of IDDM subjects
age of onset and, 419-422
insulin resistance, atherosclerosis and, 942
LEAD and, 250, 251
and oxidative stress effects on RBC glutathione pathways, 1361
on PP biphasic insulin aspart therapy and, 897
PP hyperglucagonemia and, 637
Sex of NIDDM subjects
and apo E gene polymorphism-dependent effects of age, BMI, and fasting TGs on PP lipemia in NIDDM, 1089, 1091
with combined dyslipidemia, 1356
declining beta-cell function and, 145
and effects of dietary management on FPG and PP plasma glucose concentrations, 457
and effects of nateglinide on glucose tolerance, 21
and glucagon dose-response curve for hepatic glucose production, 1112
hypoglycemic and nonhypoglycemic effects of 400 or 600 mg/d CS-045 and, 46
with insulin resistance and atherosclerosis, 942; *see also* Sex of NIDDM subjects, Japanese non-obese insulin-resistant
Japanese subjects, *see* Sex of NIDDM subjects, Japanese
leptin concentrations and, 305
monosaccharide ingestion and, 950
Na^+/K^+ ATPase regulation and, 284
obese subjects, *see* Sex of NIDDM subjects, obese
in older subjects, VDR polymorphism and, 357
Sex of NIDDM subjects, Japanese
with carotid artery IMT, 541
see also Sex of NIDDM subjects, Japanese non-obese insulin-resistant
Sex of NIDDM subjects, Japanese non-obese insulin-resistant
CRP and insulin resistance and, 1579
regional AT relationship to serum TGs and insulin resistance and, 545
Sex of NIDDM subjects, obese
and progressive defect of insulin action on GS, 550
soluble serum E-selectin and, 933
Sex steroids
in men on glucocorticoid therapy, 1460
see also specific sex steroids
SFAs, *see* Saturated fatty acids
SHBG, *see* Sex hormone–binding globulin

Short stature, nonendocrine, longitudinal metabolic process of bone growth in CAH and, 1377-1380
Short-term metformin therapy, effects of, on serum leptin, body weight, and FM in normoponderal men, 531-536
Short-term weight loss by normolipidemic obese women on energy-restricted diet, kinetics of plasma chylomicron-like emulsion and, 1097-1103
S_I, *see* Insulin sensitivity
Sialic acid (SA), erythrocyte membrane, GDM effects on, 605-608
Side effects, *see* Adverse effects
Signal transduction in SM of NIDDM subjects, insulin and IGF-1 effects on, 1174-1175
Simvastatin
  effects of, on neutral sterols in liver and testis, 492-499
  effects of estrogen-progestogen replacement therapy, ETP, diet and/or, in hypercholesterolemic early postmenopausal women, compared, 1463-1470
SIOP (steroid-induced osteoporosis), circulating E_2 and adrenal androgen concentrations in men on glucocorticoids and, 1458-1462
Sitostanol, effects of, on serum fat-soluble vitamins and carotenoids, 653
Sitosterol
  hepatic and testicular, simvastatin, pravastatin, and BM 15.766 effects on, 494-496
  in phytosterol-enriched margarine, 190, 191
  serum, as potential risk factor for CHD, 1519-1521
β (beta)-Sitosterol, effects of, on serum fat-soluble vitamins and carotenoids, 653
60 mg long-acting lanreotide (SR-LAN 60) for acromegaly, 387-393
Skeletal muscle (SM)
  aging effects on, *see* Aging effects on SM
  characteristics of, and FM increase in overfed young men, 451-456
  chronic alcohol intake effects on, *see* Chronic alcohol intake, effects of, on SM
  effects of ovariectomy and estradiol replacement therapy on GS, PFK, CS, and β-HADH in, 1397-1401
  exercise effects on MCFA and LCFA oxidation in, 460-464
  Na, Mg, and K content in, and dexamethasone effects on [^{3}H]ouabain binding capacity of, in relatives of NIDDM subjects, 1331-1339
  in NIDDM, *see* Skeletal muscle in NIDDM
  TG synthesis in, 1198-1205
  see also Skeletal muscle, glucose transport in; Skeletal muscle glycogen; Skeletal muscle lactate
Skeletal muscle (SM), glucose transport in
  differential half-maximal effects of insulin and analogs on protein synthesis and, in IDDM and NIDDM, 1065-1070
  effects of U73122 inhibition of PLC on insulin-stimulated glucose transport, 271-273
Skeletal muscle (SM) glycogen
  creatine supplementation and metabolism of, 521
  see also Skeletal muscle glycogen in NIDDM
Skeletal muscle (SM) glycogen in NIDDM
  effects of GK transfer to SM on, 123, 124
  FXTN effects on, in pancreatectomized subjects, 41
Skeletal muscle (SM) lactate, STZ-DM effects on transport of, influence of MTC-1 and MTC-4 on, 807-813
Skeletal muscle (SM) mass in women, aging effects on, 935-939
Skeletal muscle (SM) in NIDDM
  effects of GK gene transfer to, on insulin-sensitive glucose uptake, 121-126
  insulin and IGF-1 effects on, 1171-1179
Skeletal muscle (SM) in NIDDM (*Continued*)
  see also Skeletal muscle glycogen in NIDDM
Skin collagen, chronic iron overload effects on, 648
Sleep apnea syndrome, obstructive, effects of laser-assisted, on uvuloplasty on sleep energy expenditure in, 622-627
Sleep energy expenditure (EE) in OSAS, effects of laser-assisted uvuloplasty on, 622-627
SM, *see* Skeletal muscle
Small, dense particles of LDLs
  effects of lipid composition of, on oxidative susceptibility, risk of CAD with phenotype B LDL and, 1081-1087
  in IDDM and NIDDM, extended-release niacin therapy effects on, 1123
Small bowel mucosal tyrosine kinase, effects of repetitive deformation and pressure on activity of, 1525-1527
Smoking
  and carotid atherosclerosis in women, 53
  by chronic AITD subjects, 1490
  effects of, on bone density, 268-270
  FCHL and, 1299
  with IDDM, LEAD and, 250, 251
  by men, *see* Smoking by men
  and metabolic syndrome in women, 1574
  by MS subjects, serum ceruloplasmin and, 839, 840
  in NIDDM, ischemic stroke and, 245
  and risk factors for CV disease, 1035, 1038, 1072, 1073
  WC and metabolic risk factors and, 1428, 1429
  by women, *see* Smoking by women
Smoking by men
  CAD and, 734
  on glucocorticoids, adrenal androgens and, 1459
  by microalbuminuric men, insulin metabolism and, 751
Smoking by postmenopausal women on ERT
  atherothrombosis, thrombophilia and, 727, 728
  by hypercholesterolemic early postmenopausal women, effects of ETP, simvastatin, estrogen-progestogen therapy, and/or diet and, 1464
Smoking by women
  and carotid artery atherosclerosis, 53
  HDL-C subfractions, LCAT and, in young women, 1313-1316
  see also Smoking by postmenopausal women on ERT
Smooth muscle cells, vascular, troglitazone effects on, 998-1002
SOD (superoxide dismutase), retinal and renal Mn and CuZn, in DM, measurement of, 1279-1284
Sodium, *see* Na
Soluble E-selectin, serum, in NIDDM, correlated with obesity but not with AT distribution, 932-934
Soluble Fas ligand (FasL), circulating, and disease activity in hyperthyroidism of Graves' disease, 769-773
Soluble fiber intake
  with *Camelina sativa* oil–containing diet, 1256
  effects of, on Lp remodeling and composition, sex and hormonal status influence on, 500-507
  effects of multivitamin with, on LDL and Hcy, 1166-1170
  with HF diet, 709
  with high- and low-isoflavone soy diet, 920
  with low-glycemic index breakfast, 819-826
  by older men and women engaged in lower versus whole body resistive exercise, 990
  in phytosterol-enriched margarine, 191
Soluble intercellular adhesion molecule-1 (ICAM-1), levels and relationship of, to insulin resistance and TNF-α activity in obesity, 75-78

Somatostatin (SS), effects of inhibition of hypothalamic, on GH release during strenuous exercise, 1093-1096
Somatostatinoma, ovarian, alternating extreme hyperglycemia and hypoglycemia in, 1180-1183
Soy diet, low- and high-isoflavone, effects of, on inflammatory biomarkers and proinflammatory cytokines in middle-age men and women, 919-924
Soybean meal in protein-free diets, 570
Spinal cord injury (SCI), bone loss in, bone biochemical markers and dual-energy x-ray absorptiometry in evaluation of, 958-963
Splanchnic galactose, extraction of, regulated by coingestion of glucose, 827-832
Splenocytes proliferation, ovalbumin-specific immune response to asthma in obesity and, 1242-1243
Splice donor site, mutation of intron 1, of CETP gene, hyperalphalipoproteinemia due to, 394-397
Squamous cell carcinoma (SCC), head and neck, retinoic acid 4-hydroxylase-mediated RA catabolism and cell proliferation in, 477-481
SR-LAN 60 (60 mg long-acting lanreotide for acromegaly, 387-393
SS (somatostatin), effects of inhibition of hypothalamic, in GH release during strenuous exercise, 1093-1096
Statins
  hepatic, for combined dyslipidemia with NIDDM, fibric acid versus, 1355-1359
  see also Atorvastatin; Lovastatin; Pravastatin; Simvastatin
Stature, nonendocrine short, longitudinal metabolic process of bone growth in CAH and, 1377-1380
Stearate, SM, 1200, 1201
Steroid-induced osteoporosis (SIOP), circulating E_2 and adrenal androgen concentrations in men on glucocorticoids and, 1458-1462
Sterols
  neutral liver and testis, simvastatin, pravastatin, and BM 15.766 effects on, 492-499
  see also specific sterols
Stigmasterol
  effects of, on serum fat-soluble vitamins and carotenoids, 653
  in phytosterol-enriched margarine, 190, 191
Δ (delta)-Stigmasterol in phytosterol-enriched margarine, 190, 191
Strenuous exercise, role of hypothalamic SS inhibition in, GH release during, 1093-1096
Streptozotocin-induced diabetes mellitus (STZ-DM)
  with albuminuria, troglitazone and pioglitazone effects on, 403-408
  skeletal muscle lactate transport in, MTC-1 and MTC-4 influence on, 807-813
Stress
  effects of immobilization, on intermediate metabolism and circulating Lps, 925-931
  see also Oxidative stress
Stroke, ischemic, in NIDDM, correlation between carotid artery IMT and, 244-247
Strontium ranelate, effects of long-term therapy with, on vertebral bone mass, 906-911
Structured aerobic exercise or lifestyle activity, weight loss and physiologic changes after CHO-restricted diet and, 1528-1533
STZ-DM, *see* Streptozotocin-induced diabetes mellitus
Subclinical inflammation, relationship of, to insulin resistance but not to impaired insulin secretion, high risk for NIDDM and, 743-749
Subcutaneous adipose tissue (SAT)
  abdominal, *see* Abdominal adipose tissue, subcutaneous
Subcutaneous adipose tissue (SAT) (*Continued*)
  exercise, CETP genotype, and changes in, 776
  in HIV-infected men on antiretroviral therapy, 1146
  in middle-age, premenopausal, and early postmenopausal women, 324, 325
Subcutaneous preadipocyte differentiation, abdominal, omental preadipocyte differentiation compared with, 1211-1215
Sucrose (S)
  in HF diet, 918
  PP TG, NEFA, and/or incretin response to, by men at risk for CHD, 195-200
Sudanese non–insulin-dependent diabetes mellitus (NIDDM) subjects, leptin in, 304-306
Sulfonylurea drugs, effects of α-glucosidase inhibitor with, on duration of glycemic control in NIDDM, 1548-1552
Superoxide dismutase (SOD), retinal and renal Mn and CuZn, in DM, measurement of, 1279-1284
Supplementation, 514-522
  L-arginine, effects of, on diabetic wound healing, 1269-1273
  Cr picolinate, effects of, on insulin sensitivity, serum lipids, and BW in subjects on dexamethasone, 589-594
  creatine, effects of, on insulin secretion and glucose homeostasis, 518-522
  effects of fiber with multivitamin, on LDL and Hcy, 1166-1170; *see also specific vitamins*
  oral L-carnitine, effects of, on LCFA oxidation, 1389-1391
  T_3, for hypothalamic obesity, 1381-1383
Swedish men, polymorphism of exon 3 of POMC gene in relation to salivary cortisol, serum leptin, and obesity in, 642-644
Sympathetic nervous system, insulin and, in reactivation of BAT lipogenesis in subjects adapted to high-protein diet, 343-349
Symptoms
  of acromegaly, SR-LAN 60 effects on, 390, 391
  of metformin adverse effects, 532
  see also specific conditions
Syndrome X, *see* Metabolic syndrome
Synthase, *see* Citrate synthase; Cystathionine-β-synthase; Fatty acid synthase gene expression; Nitric oxide synthase; Glycogen synthase
Systolic blood pressure, *see* Blood pressure

T, *see* Testosterone
T_3, *see* Triiodothyronine
T_4, *see* Thyroxine
TAG, *see* Triacylglycerols
Taurine, AT, cysteine dioxygenase, and cysteine sulfinic acid decarboxylase mRNA in biosynthesis of, 1191-1197
TBP (total body phosphorus) in women, race and, 180-183
TC, *see* Total cholesterol
TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin; dioxin), TNF-α stimulation and inhibition of glucose transport and LPL in adipocytes by, 65-68
Telopeptide
  N, urinary levels of type I collagen-cross-linked, correlated with bone scintigraphy results in prostate cancer, 814-818
  serum C, in SCI, bone loss and, 961
TEM (thermic effect of a meal), and FM increase in overfed young men, 452-454
10- to 15-year-old adolescents, serum T associated with lower HDL-C in male, apo A-I and A-II concentrations and, 432-437
Teratoma, ovarian, ovarian somatostatinoma with alternating extreme hyperglycemia and hypoglycemia in, 1180-1183
Testicular meiosis-activating sterol (T-MAS), simvastatin, pravastatin, and BM 15.766 effects on, 494-496

Testicular sterols, neutral, simvastatin, pravastatin, and BM 15.766 effects on, 492-499
Testosterone (T)
effects of, on apo A-I mRNA, 376-379
during rehabilitation for severe head trauma, 1366
serum, *see* Serum testosterone
see also Free testosterone; 17-α-Methyltestosterone; Total testosterone
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD; dioxin), TNF-α stimulation and inhibition of glucose transport and LPL in adipocytes by, 65-68
TG(s), *see* Triglyceride(s)
TGL (triglyceride lipase), hepatic, and PP TG response by obese and non-obese women to fat-containing meal, 211, 213-217
TGZ, *see* Troglitazone, effects of
Thermic effect of a meal (TEM), and FM increase in overfed young men, 452-454
Thiamine (vitamin B_1) in alcohol-containing diet, 1563
Thiazolidinediones, *see* Pioglitazone, effects of; Troglitazone, effects of
Thickening of carotid artery intima media, *see* Carotid artery intima-media thickening
Threonine (Thr), blood, portal glucose incretin effect on, 1324, 1325
Thrombophilia, atherothrombosis and, with postmenopausal ERT, heterozygosity for factor V Leiden gene and prothrombin gene mutation and, 724-732
Thyroid function
physiologic aging effects on, 105-109
see also Hyperthyroidism; Thyroxine; Triiodothyronine
Thyroid-pituitary axis, acute and prolonged effects of insulin-induced hypoglycemia on, 1370-1374
Thyroid-stimulating hormone, *see* Thyrotropin
Thyroiditis, chronic autoimmune, serum MCP-1 in, 1489-1493
Thyrotropin (TSH; thyroid-stimulating hormone)
energy-restricted diet effects on, 151
during rehabilitation for severe head trauma, 1366
vitamin A effects on concentrations of, 691-694
see also Serum thyrotropin
Thyrotropin-releasing hormone (TRH) test, preoperative GH response to OGTT and, in acromegaly, 616-621
Thyroxine (T_4)
in non-obese young women, weight cycling effects on, 151
response of, to CHO-restricted diet, 868
serum, *see* Serum thyroxine
total, in chronic AITD, 1490
in treadmill-exercising men, 1424
Tibolone, effects of postmenopausal CEEs and/or, on serum C efflux potential, 523-530
T-MAS (testicular meiosis-activating sterol), simvastatin, pravastatin, and BM 15.766 effects on, 494-496
TNF, *see* Tumor necrosis factor
TNF-α, *see* Tumor necrosis factor-α
Tobacco, *see* Smoking
α-, β-, and γ-Tocopherol, *see* Vitamin E
Tolerability of SR-LAN 60, 390-391
Tolerance, glucose, *see* Glucose intolerance; Glucose tolerance in NIDDM; Impaired glucose tolerance; Intravenous glucose tolerance test; Oral glucose tolerance test
Total body Ca (calcium) in women, ethnic variations in, 181
Total body K (potassium) in women, ethnic variations in, 181
Total body phosphorus (TBP) in women, race and, 180-183
Total cholesterol (TC)
anti-oxidized LDL antibody effects on, 430
Total cholesterol (TC) (*Continued*)
atorvastatin effects on, *see* Total cholesterol, atorvastatin effects on
in CAD men, 734
diet effects on, *see* Total cholesterol, diet effects on
effects of FFA regulation by insulin on, 780
endurance exercise effects on, in sedentary subjects, 1056
in epilepsy, 1275
in European and/or Chinese ancestry subjects, WC and metabolic risk factors and, 1428, 1429
in FCHL, and PPARγ, HSL, and C3 expression in AT, 666-668
and high risk for NIDDM, 745-747
in hypercholesterolemia, effects of dietary portfolio of vegetable proteins, fiber, and plant sterols on, 1599, 1601, 1602
in LPG, 202
in MS, serum ceruloplasmin and, 839, 840
in NIDDM, *see* Total cholesterol in NIDDM
in non-obese subjects, *see* Total cholesterol in non-obese subjects
in obesity, *see* Total cholesterol in obesity
plasma, *see* Total plasma cholesterol
in postmenopausal women, *see* Total cholesterol in postmenopausal women
and preclinical carotid artery atherosclerosis in women, 53
Pro12Ala polymorphism of PPARγ2 gene effects on, in Japanese subjects, 1408
as risk factor, *see* Total cholesterol, as risk factor
serum, *see* Total serum cholesterol
sex- and age-specific plasma Hcy correlation with MDA and, 1434
and thyroid function in elderly subjects, 106
and troglitazone inhibition of neointimal formation after balloon injury, 999
Total cholesterol (TC), atorvastatin effects on
in dyslipidemia combined with impaired fasting glucose or NIDDM, 336
in heterozygous and homozygous FH subjects treated with LDL apheresis, 978
Total cholesterol (TC), diet effects on
energy-restricted diet effects, 151
fiber and multivitamin effects, 1168
in obese postmenopausal women, apo E genotype effects on diet-induced changes in, 856
phytosterol-enriched margarine effects, 191
and PP TG response to fat-containing meal, 213, 214
Total cholesterol (TC), postmenopausal ERT effects on
of ETP, diet, simvastatin, and/or estrogen-progestogen therapy in hypercholesterolemic early postmenopausal women, 1465
plasma CE transfer and, 601
of tibolone and/or CEE, 526
Total cholesterol (TC), as risk factor
for CAD, 1082, 1085
for CV disease, 1036, 1038
Total cholesterol (TC) in dyslipidemic NIDDM
atorvastatin effects on, 336
combined dyslipidemia, 1356
Total cholesterol (TC) in Japanese NIDDM subjects
with carotid artery IMT, 540, 541
non-obese subjects, regional AT relationship to serum TGs and insulin resistance and, 545
Total cholesterol (TC) in NIDDM
cilostazol effects on, 1350, 1351
with dyslipidemia, *see* Total cholesterol in dyslipidemic NIDDM
glycemic control with alpha-glucosidase inhibitor and sulfonylurea drug and, 1549, 1550

Total cholesterol (TC) in NIDDM (*Continued*)
ischemic stroke and, 245
in NIDDM men, effects of low-glycemic index breakfast with soluble fiber on, 823
with obesity, *see* Total cholesterol in NIDDM with obesity
with remnant-like Lp particles, 966
serum, insulin resistance, atherosclerosis and, 942, 944, 945
TZD effects on, 171
see also Total cholesterol in Japanese NIDDM subjects
Total cholesterol (TC) in NIDDM with obesity
hypofibrinolysis and coagulation and, 472, 474
normolipidemic NIDDM women on energy-restricted diet, 1099
soluble serum E-selectin and, 933
Total cholesterol (TC) in non-obese subjects
with CAD, insulin secretion and, 185
and PP TG response to fat-containing meal, 213, 214
young women, weight cycling effects on, 151
Total cholesterol (TC) in obese women
in nondiabetic hyperinsulinemic women, 1263
in normolipidemic NIDDM women on energy-restricted diet, 1099
Total cholesterol (TC) in obesity
with CAD, insulin secretion and, 185
with NIDDM, *see* Total cholesterol in NIDDM with obesity
in nondiabetic men, 1480
in obese women, *see* Total cholesterol in obese women
and PP TG response to fat-containing meal, 213, 214
in visceral obesity, 1043
Total cholesterol (TC) in postmenopausal women
hyperinsulinemic women, 239, 241
see also Total cholesterol, postmenopausal ERT effects on
Total low-density lipoprotein-cholesterol (LDL-C), atherogenic, in IDDM and NIDDM, extended-release niacin therapy effects on, 1123
Total lymphocytes, and effects on aging on, 106
Total parenteral nutrition (TPN), chronic, and effects of infections on role of intraportal L-NNA on hepatic glucose uptake, 274-283
Total phospholipids (PLs), sequential postmenopausal sequential estrogen- progestin replacement therapy effects on, 1412
Total plasma cholesterol (C)
in FCHL, gene LPL polymorphism and, 1299
in HF diet-induced insulin resistance, effects of LF diet or energy restriction on, 697
in infants, dietary cholesterol and, 29
stable isotopes in study of, 8
Total plasma homocysteine (Hcy)
in IDDM and NIDDM, insulin resistance, atherosclerosis and, 942
in severe methionine adenosyltransferase I/III deficiency, 981-988
Total protein
in LPG, 202
in parenchymal liver cirrhosis, 611
thyroid function in elderly subjects and, 106
Total serum cholesterol (C)
effects of α-linoleic acid–rich *Camelina sativa* oil on, 1254
in IDDM, insulin resistance, atherosclerosis and, 942, 944, 945
Total testosterone (TT)
anti-oxidized LDL antibody effects on, 430
in hyperinsulinemic postmenopausal and perimenopausal women, 238-242
response of, to CHO-restricted diet, 868
Total thyroxine (T_4) in chronic AITD, 1490
Total triacylglycerols (TAG), serum, in hypercholesterolemia, effects of α-linoleic acid–rich *Camelina sativa* oil on, 1254
Total triglyceride(s)
in obese nondiabetic men, 1480
Total triglyceride(s) (*Continued*)
postmenopausal sequential estrogen-progestin replacement therapy effects on, 1412
Total triiodothyronine (T_3) in chronic AITD, 1490
Toxicity, *see* Beta cells, lipotoxicity effects on; Glucotoxicity
TPN (total parenteral nutrition), chronic, effects of infections on role of intraportal L-NNA on hepatic glucose uptake in, 274-283
Trans fatty acids (FAs), effects of SFA replacement with, on serum PON1 activity, 1534-1537
A11-*Trans*-retinoic acid (RA), retinoic acid 4-hydroxylase–mediated catabolism of, and cell proliferation in head and neck squamous cell carcinoma, 477-481
Transdermal patch, estrogen, effects of estrogen-progestogen replacement therapy, simvastatin, diet and/or, in early postmenopausal women, compared, 1463-1470
Transfer protein, *see* Cholesteryl ester transfer protein; Microsomal triglyceride transfer protein; Phospholipid transfer protein
Transferase, *see* Alanine aminotransferase; Aspartate aminotransferase; Carnitine palmitoyl transferase-1; γ-Glutamyltransferase; Lecithin:cholesterol acyltransferase; Methionine adenosyltransferase I/III deficiency
Transferrin, and thyroid function in elderly subjects and, 106
Trauma and injury
balloon injury, effects of neointimal formation inhibition by troglitazone on blood flow after, 998-1002
severe head, GH/IGF-1 axis in, during rehabilitation, 1363-1369
spinal cord, bone loss in, bone biochemical markers and dual-energy x-ray absorptiometry in evaluation of, 958-963
Treadmill exercise, circulating BNPs in men engaged in, 1423-1426
TRH (thyrotropin-releasing hormone) test, preoperative GH response to OGTT and, in acromegaly, 616-621
Triacylglycerols (TAG)
in NIDDM, effects of GK gene transfer to SM on, 123, 124
in normolipidemic obese women on energy-restricted diet, 1099
total serum, in hypercholesterolemia, effects of α-linoleic acid–rich *Camelina sativa* oil on, 1254
Triglyceride(s) (TG)
and apo A-I and B distribution in urban Mexican population, 563-565
atorvastatin effects on, *see* Triglyceride(s), atorvastatin effects on
in CAD men, 734
in CPEO, 797
diet effects on, *see* Triglyceride(s), diet effects on
effects of FFA regulation by insulin on, 780
endurance exercise effects on, in sedentary subjects, 1056
in epilepsy, 1275
fasting, *see* Fasting triglycerides
and high risk for NIDDM, 745-747
in HIV infection, *see* Triglyceride(s) in HIV infection
in HTN, glucose metabolism-insulin release interaction and, 299
in hyperlipidemia, *see* Triglyceride(s) in hyperlipidemia
in IDDM, *see* Triglyceride(s) in IDDM
interaction of HUVECs and Lps rich in, with apoE gene Arg^{25}→Cys mutation in Lp glomerulopathy, 201-205
in MCS, 425, 426
in microalbuminuric men, 751, 752
in MS, serum ceruloplasmin and, 839-841
in NIDDM, *see* Triglyceride(s) in NIDDM
in non-obese subjects, *see* Triglyceride(s) in non-obese subjects
in obesity, *see* Triglyceride(s) in obesity
in parenchymal liver cirrhosis, 611, 612
plasma, *see* Plasma triglycerides
in postmenopausal women, *see* Triglyceride(s) in postmenopausal women

Triglyceride(s) (TG) (*Continued*)
PP, *see* Postprandial triglyceride response
and preclinical carotid atherosclerosis in women, 53
Pro12Ala polymorphism of PPARγ2 gene effects on, in Japanese subjects, 1408
as risk factor, *see* Triglyceride(s), as risk factor
serum, *see* Serum triglycerides
sex- and age-specific plasma Hcy correlation with MDA and, 1434
SM, *see* Triglyceride(s), SM
smoking, LCAT, and subfractions of, in young women, 1314
in 10- to 15-year-old male adolescents, serum T association with lower HDL-C and, 433, 434
and thyroid function in elderly subjects, 106
and troglitazone inhibition of neointimal formation after balloon injury, 999
and uric acid syndrome in subjects at risk for NIDDM, 373, 374
vitamin E concentration in, 1445-1448
WC, metabolic risk factors and, 1428, 1429
see also Hypertriglyceridemia; Microsomal triglyceride transfer protein
Triglyceride(s) (TG), atorvastatin effects on
in dyslipidemia combined with impaired fasting glucose, 336
in heterozygous and homozygous FH treated with LDL apheresis, 978
Triglyceride(s) (TG), diet effects on
apo E genotype effects on diet-induced changes in, in obese postmenopausal women, 856
energy-restricted diet effects, 151
fiber and multivitamin effects, 1168
in NIDDM, *see* Triglyceride(s) in NIDDM, diet effects on
oral L-carnitine supplementation effects on, 1390
see also Plasma triglycerides, diet effects on
Triglyceride(s) (TG), postmenopausal ERT effects on
atherothrombosis, thrombophilia and, 727, 728
of ETP, diet, simvastatin, and/or estrogen-progestogen therapy in hypercholesterolemic early postmenopausal women, 1465
plasma CE transfer and, 601
of sequential estrogen-progestin therapy, 1412, 1413
of tibolone and/or CEEs, 526
Triglyceride(s) (TG), as risk factor
for CAD, 1082, 1085
for CV disease, 1036, 1038, 1072, 1073
for MS in women, 1574
Triglyceride(s) (TG), SM
FXTN effects on, in pancreatectomized subjects, 41
synthesis of, 1198-1205
Triglyceride(s) (TG) in dyslipidemic NIDDM
atorvastatin effects on, 336
combined dyslipidemia, 1356-1358
Triglyceride(s) (TG) in FCHL
LPL gene polymorphism and, 1302, 1303
PPARγ, HSL, and C3 expression in AT and, 666-668
Triglyceride(s) (TG) in HIV infection
in HIV-infected men on antiretroviral therapy, lipolysis in, 1145
with lipodystrophy, 262
Triglyceride(s) in hyperlipidemia
in hypercholesterolemia, effects of dietary portfolio of vegetable proteins, fiber, and plant sterols on, 1599, 1601, 1602
in kindreds of FCHL subjects, 219-221
in subjects on HF diet, effects of exercise on, 159
see also Triglyceride(s) in FCHL
Triglyceride(s) (TG) in IDDM
atherogenic, extended-release niacin therapy effects on, 1123
Triglyceride(s) (TG) in IDDM (*Continued*)
with insulin resistance and atherosclerosis, 942
LEAD and, 250, 251
Triglyceride(s) (TG) in Japanese NIDDM subjects
carotid artery IMT and, 540, 541
see also Triglyceride(s) in non-obese insulin-resistant NIDDM Japanese subjects
Triglyceride(s) (TG) in NIDDM
apo E gene polymorphism-dependent effects of age, BMI, and fasting TGs on PP lipemia in NIDDM, 1089-1092
atherogenic, extended-release niacin therapy effects on, 1123
cilostazol effects on, 1350, 1351
CS-045 effects on, *see* Triglyceride(s) in NIDDM, CS-045 effects on
diet effects on, *see* Triglyceride(s) in NIDDM, diet effects on
with dyslipidemia, *see* Triglyceride(s) in dyslipidemic NIDDM
fasting, *see* Fasting triglycerides in NIDDM
glycemic control with alpha-glucosidase inhibitor and sulfonylurea drug and, 1549, 1550
with insulin resistance, *see* Triglyceride(s) in non-obese insulin-resistant Japanese NIDDM subjects; Serum triglycerides in NIDDM with insulin resistance
ischemic stroke and, 245
in Japanese subjects, *see* Triglyceride(s) in Japanese NIDDM subjects
with obesity, *see* Triglyceride(s) in NIDDM with obesity
with remnant-like Lp particles, 966
serum, *see* Serum triglycerides
Triglyceride(s) (TG) in NIDDM, CS-045 effects on
400 or 600 mg/d CS-045 effects on, 47, 48
and on insulin-mediated FA flux, 171
Triglyceride(s) (TG) in NIDDM, diet effects on
in NIDDM men, low-glycemic index breakfast with soluble fiber and, 820, 823
phytosterol-enriched margarine effects, 191
response of, to dietary protein intake, 1031
Triglyceride(s) (TG) in NIDDM with obesity
hypofibrinolysis and coagulation and, 472, 474
in Korean subjects, ADRB2 gene polymorphism and, 834-836
soluble serum E-selectin and, 933
Triglyceride(s) (TG) in non-obese insulin-resistant Japanese NIDDM subjects
CRP and, 1579
regional AT relationship to insulin resistance and, 545
Triglyceride(s) (TG) in non-obese subjects
with CAD, insulin secretion and, 185
in non-obese men, AT compartments and kinetics of apo B-100 and, 1207, 1208
young women, weight cycling effects on, 151
see also Triglyceride(s) in non-obese insulin-resistant Japanese NIDDM subjects
Triglyceride(s) (TG) in obesity
with CAD, insulin secretion and, 185
with insulin resistance, 717, 718, 722
with NIDDM, *see* Triglyceride(s) in NIDDM with obesity
in nondiabetic hyperinsulinemic obese women, 1263
polymorphism of exon 3 of POMC gene and, 643
Triglyceride(s) (TG) in postmenopausal women
in hyperinsulinemic women, 239, 241
see also Triglyceride(s), postmenopausal ERT effects on
Triglyceride lipase (TGL), hepatic, and PP TG response to fat-containing meal by obese and non-obese women, 211, 213-217

Triglyceride transfer protein, *see* Microsomal triglyceride transfer protein
Triiodothyronine (T_3)
in non-obese young women, weight cycling effects on, 151
response of, to CHO-restricted diet, 868
serum, in lung cancer associated with hypercalcemia, 872
supplementation with, in hypothalamic obesity, 1381-1383
total, in chronic AITD, 1490
in treadmill-exercising men, 1424
Triphosphatase, adenosine, *see* Na^+/K^+ ATPase
Troglitazone (CS-045; TGZ), effects of
on albuminuria in STZ-DM, 403-408
effects of inhibition of neointimal formation by, on blood flow after balloon injury, 998-1002
in hyperglycemia, berberine compared with, 1439-1443
on plasma Hcy, hepatic and RBC SAM and SAH, and CβS and MTHFR in Hcy metabolism, 783-786
see also Non–insulin-dependent diabetes mellitus, troglitazone effects on
Trp64Arg β_3-adrenoceptor gene polymorphism, effects of, on weight loss, body composition, or energy expenditure in obese postmenopausal women, 801-805
TSH (thyroid-stimulating hormone), *see* Thyrotropin
TT, *see* Total testosterone
Tumor necrosis factor (TNF)
effects of neutralization of, on age-induced impaired insulin responsiveness in skeletal muscle, 1061-1064
shift from nighttime to daytime secretion of IL-6 and, in chronic insomnia, 887-892
see also Tumor necrosis factor-α
Tumor necrosis factor-α (TNF-α)
in adipocytes, TCDD effects on, 65-68
effects of, on insulin-induced increase in eNOS and on IR content and phosphorylation in HAECs, 487-491
effects of hyperinsulinemia induced by, on circulating leptin during fasting, 1104-1110
high- and low-isoflavone soy diet effects on, 921
in obesity, level and relationship of soluble ICAM-1 to insulin resistance and activity of, 75-78
plasma level of, and effects of aerobic exercise on insulin sensitivity in older hypertensive women, 1402-1406
20 S proteasome preparations, lovastatin effects on activities of, 1153-1160
Two-compartment-labeled minimal model, insulin sensitivity and glucose effectiveness in late prepubertal children and early adolescents determined with, 1582-1586
Type I collagen-cross-linked N telopeptide, urinary levels of, correlated with results of bone scintigraphy in prostate cancer, 814-818
Type 1 diabetes mellitus, *see* Insulin-dependent diabetes mellitus
Type 1 hexokinase gene expression in INS-1 cells, effects of acute and/or chronic lipotoxicity on, 155-162
Type 2 diabetes mellitus, *see* Non–insulin-dependent diabetes mellitus
Tyrosine kinase, small bowel and colonic mucosal, effects of repetitive deformation and pressure on activity of, 1525-1527
Tyrosine phosphatase, *see* Protein tyrosine phosphatase
TZDs (thiazolidinediones), *see* Pioglitazone, effects of; Troglitazone, effects of

UAH (unilateral adrenal hyperplasia), unilateral hyperaldosteronemia compared with, 350-355
Ultrasound
of carotid artery IMT in Japanese NIDDM subjects, 539-543
Ultrasound (*Continued*)
intra-abdominal thickness measured by, predicting risk factors for CV disease, 1034-1040
Umbilical vascular endothelial cells, *see* Human umbilical vascular endothelial cells
Unilateral adrenal hyperplasia (UAH), unilateral hyperaldosteronemia compared with, 350-355
Unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, adrenal venous sampling in detection of, 350-355
Unilateral nephrectomy, plasma leptin concentrations after, 206-210
Unsaturated fatty acids (FAs)
insulin regulation of, 779-782
see also Monounsaturated fatty acids; Polyunsaturated fatty acids
Uracil, beer effects on, 1321
Urban population, Mexican, apo A-I and B distribution in, 560-568
Urea
in CRF, 1606
in endurance exercise, effects of high-fat and high-carbohydrate diets on, compared, 685
leucine oxidation and production of, in malnourished children with and without acute infection, 1418-1422
serum, in ESRD, 882
Urea nitrogen, blood in LPG, 202
Uric acid
angiotensin II effects on urinary excretion of, 893-895
anti-oxidized LDL antibody effects on, 430
beer effects on, 1321
in MCS, 424, 426
in NIDDM, insulin response to dietary protein intake and, 1030
in normotensive nondiabetic subjects, carotid artery IMT and, 256, 257
plasma, inosine effects on, 438-442
Pro12Ala polymorphism of PPARγ2 gene effects on, in Japanese subjects, 1408
and risk factors for CV disease, 1072, 1073
serum, *see* Serum uric acid
and thyroid function in elderly subjects, 106
Uric acid syndrome in subjects at risk for NIDDM, relationship between MS and, 372-375
Uridine
beer effects on, 1317-1323
inosine effects on, 438-442
Urinary excretion
of albumin, *see* Albuminuria
of ANP in CHF, 584-585
of Ca, P, PTH, CTX, OC, vitamin D_3, and ALP in SCI, 961
of cAMP, in lung cancer associated with hypercalcemia, 872
of collagen IV, effects of glycated albumin inhibition on, in DM, 901-906
of cortisol by normoponderal men, short-term therapy effects on, 533
in NIDDM, *see* Urinary excretion in NIDDM
of purine bases, *see* Hypoxanthine, urinary excretion of; Oxypurinol, urinary excretion of; Xanthine, urinary excretion of
of type I collagen-cross-linked N telopeptide, levels of, correlated with results of bone scintigraphy in prostate cancer, 814-818
of uric acid, *see* Urinary excretion, uric acid
of uridine, inosine effects on, 440
Urinary excretion, uric acid
angiotensin II effects on, 893-895
in NIDDM, 1031
Urinary excretion in NIDDM
of C-peptide, declining beta-cell function and, 144-148

Urinary excretion in NIDDM (*Continued*)
of nitrite and nitrate, chronic L-NAME effects on, 703-704
of urea, uric acid, Na, K, and glucose, 1031
Urine volume, angiotensin II effects on, 894
U73122, effects of PLC inhibition with, on insulin-stimulated glucose transport in SM, 271-273
Uvuloplasy, effects of laser-assisted, on sleep energy expenditure in OSAS, 622-627

Valproic acid, effects of, on PP serum insulin in epilepsy, 1274-1278
Vascular cell adhesion molecule-1 (VCAM-1)
angiographic assessment of circulating E-selectin, ICAM-1 and, in men with CAD and CHO metabolism disturbances, 733-736
in ECs, nuclear factor-κB–dependent linoleic acid-stimulated expression of, 327-333
in NIDDM with obesity, soluble serum E-selectin and, 933
Vascular endothelial cells, *see* Endothelial cells
Vascular functions in postmenopausal women on ERT, plasma CE transfer and, 602
Vascular relaxation induced by isoproterenol through PI3-K NO production, 380-386
Vascular smooth muscle cells (VSMCs), troglitazone effects on, 998-1002
Vasopressin, *see* Arginine-vasopressin; Arginine-vasopressin V_2
VAT, *see* Visceral adipose tissue
VCAM-1, *see* Vascular cell adhesion molecule-1
VDR (vitamin D receptor) polymorphism, and NIDDM or metabolic syndrome in older subjects, 356-359
Vegetable proteins
effects of fiber, phytosterols and, on hypercholesterolemia, 1596-1604
see also Low- and high-isoflavone soy diet; Soybean meal
Venous sampling, adrenal, in detection of unilateral hyperaldosteronemia due to adrenocortical micronodules, 350-355
Vertebral bone mass, effects of long-term therapy with strontium ranelate on, 906-911
Very-low-density lipoprotein (VLDL)
hepatic, in fructose-induced insulin resistance, atorvastatin effects on, 409-418
influence of particle distribution of, on hypoglycemic and nonhypoglycemic effects of 400 or 600 mg/d CS-045 in NIDDM, 44-51
Very-low-density lipoprotein-cholesterol (VLDL-C)
400 or 600 mg/d CS-045 effects on, 44-51
in normolipidemic obese women on energy-restricted diet, 1099
in parenchymal liver cirrhosis, 612
see also Very-low-density lipoprotein-cholesterol, postmenopausal ERT effects on
Very-low-density lipoprotein-cholesterol (VLDL-C), postmenopausal ERT effects on
of ETP, diet, simvastatin, and/or estrogen-progestogen therapy in hypercholesterolemic early postmenopausal women, 1465
of tibolone and/or CEE effects on, 526, 527
Vessel dilator in CHF, 582-588
Visceral adipose tissue (VAT)
in HIV-infected men on antiretroviral therapy, lipolysis and, 1146
in NIDDM, pioglitazone effects on, 316
see also Abdominal adipose tissue
Visceral obesity, kinetics of apo B-100 in, plasma apo C-III and, 1041-1046
Viscosity, plasma, phytosterol-enriched margarine effects on, 191
Viscous fiber, effects of vegetable proteins, phytosterols and, on hypercholesterolemia, 1596-1604
Vitamin(s)
in HF diet, 918
serum fat-soluble, effects of plant sterols on, 652-656
see also specific vitamins
Vitamin A (retinol)
in alcohol-containing diet, 1563
effects of, on serum thyrotropin concentrations, 691-694
serum, plant sterol effects on, 653, 654
see also Retinoic acid 4-hydroxylase; All-*Trans*-Retinoic acid
Vitamin B_1 (thiamine) in alcohol-containing diet, 1563
Vitamin B_2 (riboflavin) in alcohol-containing diet, 1563
Vitamin B_6 in alcohol-containing diet, 1563
Vitamin B_{12}
in alcohol-containing diet, 1563
Hcy, renal failure, and pharmacology of, 399-402
in methionine-induced hyperhomocysteinemia, 1237
serum, in ESRD, 882, 883
Vitamin C (ascorbic acid)
in alcohol-containing diet, 1563
effects of supplementation with, on insulin glycation and glucose homeostasis in obese hyperglycemic subjects, 514-517
Vitamin D (calciferol)
in alcohol-containing diet, 1563
serum, plant sterol effects on, 654
Vitamin D_3 [1-25 $(OH)_2$ VD_3]
in elderly male subjects, effects of Ca-deficient diet on, 1232
serum, in lung cancer associated with hypercalcemia, 872
Vitamin D receptor (VDR) polymorphism, and NIDDM or metabolic syndrome in older subjects, 356-359
Vitamin E (α-tocopherol; β-tocopherol; γ-tocopherol)
in alcohol-containing diet, 1563
in *Camelina sativa* oil, 1254
LPL activity-dependent mammary gland uptake of, around parturition and during lactation, 1444-1451
plant sterol effects on, 653, 654
plasma, psyllium effects on, sex and hormonal status and, 503
relationship of, to Lp composition, nutritional factors, and plasma oxidation in parenchymal liver cirrhosis, 609-615
Vitamin K, serum, plant sterol effects on, 654
Vitamin K1 (phylloquinone) alcohol-containing diet, 1563
VLDL, *see* Very-low-density lipoprotein
VLDL-C, *see* Very-low-density lipoprotein-cholesterol
$\dot{V}O_{2max}$
in cigarette-smoking young women, 1314
in exercise, *see* $\dot{V}O_{2max}$ in exercise
and FM increase in overfed young men, 452
in obese postmenopausal women, 855
$\dot{V}O_{2max}$ in endurance exercise
endurance exercise effects on, in sedentary subjects, 1056, 1058
high-fat or high-carbohydrate diet effects on, 683, 684
by obese NIDDM men, 1249, 1250
$\dot{V}O_{2max}$ in exercise
CETP genotype and changes in, 776
effects of high-fat and high-CHO diet on, 1292
in endurance exercise, *see* $\dot{V}O_{2max}$ in endurance exercise
in low-intensity exercise by weight-reduced obese men, 1005
MCFA and LCFA oxidation in skeletal muscle and, 461
older hypertensive women engaged in aerobic exercise, 1004
VSMCs (vascular smooth muscle cells), troglitazone effects on, 998-1002

Waist circumference (WC), metabolic risk factors and, in European and Chinese ancestry subjects, 1427-1432
Waist-to-hip ratio (WHR)
aging effects on, 106

Waist-to-hip ratio (WHR) (*Continued*)
and carotid atherosclerosis in women, 53
in FCHL, and PPARγ, HSL, and C3 expression in AT, 666-668
and high risk for NIDDM, 745-747
of HIV-infected subjects, *see* Waist-to-hip ratio of HIV-infected subjects
of IDDM subjects, LEAD and, 250, 251
and influence of hormonal status and metabolic syndrome on bone density, 268, 269
of MCS subjects, 424-426
of MS subjects, serum ceruloplasmin and, 839-841
of NIDDM subjects, *see* Waist-to-hip ratio of NIDDM subjects
of normotensive nondiabetic subjects, carotid artery IMT and, 256, 257
of obese subjects, *see* Waist-to-hip ratio of obese subjects
of older MS subjects, VDR polymorphism and, 357
of postmenopausal women, *see* Waist-to-hip ratio of postmenopausal women
Waist-to-hip ratio (WHR) of HIV-infected subjects
of HIV-infected men on antiretroviral therapy, 1145, 1146
lipodystrophy and, 262
Waist-to-hip ratio (WHR) of NIDDM subjects
obese NIDDM men engaged in endurance exercise, 1249, 1250
of older subjects, VDR polymorphism and, 357
Waist-to-hip ratio (WHR) of obese men
of obese NIDDM men engaged in endurance exercise, 1249, 1250
of obese nondiabetic men, 1480
Waist-to-hip ratio (WHR) of obese subjects
ICAM-1 levels and, 76, 77
polymorphism of exon 3 of POMC gene and, 643
with visceral obesity, 1043
see also Waist-to-hip ratio of obese men: Waist-to-hip ratio of obese women
Waist-to-hip ratio (WHR) of obese women
nondiabetic hyperinsulinemic women, 1263
normolipidemic women on energy-restricted diet, 1099
postmenopausal women, apo E genotype effects on diet-induced changes in HDL-C and, 855
Waist-to-hip ratio (WHR) of postmenopausal women
and ACTH and cortisol response to CRH, 139, 140
hyperinsulinemic women, 239, 241
obese, apo E genotype effects on diet-induced changes in HDL-C and, 855
WC (waist circumference), metabolic risk factors and, in subjects of European and/or Chinese ancestry, 1427-1432
Weight, *see* Body weight; Organ weight
Weight loss, *see* Men, obese, weight loss by; Women, obese, weight loss by
Wheat gluten in protein-free diets, 570
White adipose tissue (AT), vitamin E uptake by mammary gland but not by, dependent on LPL activity around parturition and during lactation, 1444-1451
White population, *see* Race and ethnicity
Whole-body insulin sensitivity (S_I), LDL particle size, and oxidized LDLs in obese nondiabetic men, 1478-1483
Whole body leucine, *see* Kinetics, whole body leucine
Whole body resistive exercise, energy intake of older men and women engaged in lower body resistive exercise versus, 989-997
WHR, *see* Waist-to-hip ratio
Women
aging effects on muscle mass of, 935-939
appendicular LTM_A and sarcopenia in, 69-74
exercising, *see* Women, exercising
Women (*Continued*)
hyperinsulinemic perimenopausal, androgens in, 238-243
IDDM, eGDR as predictor of LEAD in, 248-254; *see* Insulin-dependent diabetes mellitus
with impaired glucose homeostasis and preclinical carotid artery atherosclerosis, 52-56
middle-age, *see* Middle-age women
non-obese, *see* Women, non-obese
obese, *see* Obesity; Women, obese, race and; Women, obese, weight loss by; Women, obese postmenopausal
postmenopausal, *see* Women, postmenopausal
premenopausal, *see* Premenopausal women
psychological risk factors for metabolic syndrome in, 1573-1577
TBP in, 181-183
young, *see* Young women
see also Sex *and specific conditions*
Women, exercising
metabolic syndrome and, 1574
see also Women, older exercising
Women, non-obese
LPL in, *see* Lipoprotein lipase in non-obese women
young, weight cycling effects on, 149-154
Women, obese postmenopausal
apo E genotype effects on diet-induced changes in HDL-C in, 853-858
effects of Trp64Arg β_3-adrenoceptor gene polymorphism on EE, body composition, or weight loss in, race and, 801-805
Women, obese, race and
lipolytic function of AT and, 1514-1516
postmenopausal, effects of Trp64Arg β_3-adrenoceptor gene polymorphism on EE, body composition, or weight loss in, 801-805
PP TG response to fat-containing meal and LPL in, 211-217
Women, obese, weight loss by
fasting insulin levels and increased plasma pollutant levels in response to, 482-486
by nondiabetic hyperinsulinemic obese women, effects on composition of erythrocyte membrane PL in, 1261-1268
normolipidemic, kinetics of plasma chylomicron-like emulsion in, after short-period weight loss with energy-restricted diet, 1097-1103
by obese postmenopausal women, effects of Trp64Arg β_3-adrenoceptor gene polymorphism on, race and, 801-805
physiologic changes and, after restricted caloric intake and structured aerobic exercise or lifestyle activity, 1528-1533
Women, older exercising
engaged in lower versus whole body resistive exercise, energy intake of, 989-997
hypertensive, effects of aerobic exercise on insulin sensitivity independently of plasma TNF-α levels in, 1402-1406
see also Exercise; Older subjects
Women, postmenopausal
early, *see* Early postmenopausal women
hyperinsulinemic, androgen levels and, 238-243
obese, *see* Women, obese postmenopausal
psyllium effects on Lp remodeling and composition in, 500-507
TBP in, 180-183
see also Hormone replacement therapy
Wound healing in DM, effects of L-arginine supplementation on, 1269-1273

Xanthine
beer effects on, 1317-1323
inosine effects on, 438-442

Xanthine (*Continued*)
see also Xanthine, urinary excretion of
Xanthine, urinary excretion of
angiotensin effects on, 893-895
beer effects on, 1319, 1320, 1322
inosine effects on, 440
X-ray absorptiometry, dual-energy, bone loss evaluation in SCI with bone biochemical markers and, 958-963
Xylitol, dietary, effects of, on biomechanical properties of bone in elderly subjects, 92-96

Young men
plasma Hcy correlation with MDA in, 1434
skeletal muscle characteristics and increased FM in, in response to overfeeding, 451-456
Young subjects
hepatic gluconeogenesis in, 876-880
see also Young men; Young women
Young women
non-obese, weight cycling effects on, 149-154
smoking, HDL-C subfractions, and LCAT in, 1313-1316

Zeaxanthin, serum, plant sterol effects on, 653
Zinc (Zn)
effects of metabolism of, on apoptosis and proliferation of PBMC in chronic hemodialysis patients, 1392-1396
retinal and renal CuZn dismutase in DM, measurement of, 1279-1284